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SUMMARY 
Metallothioneins (MTs) are metal binding proteins which have been implicated 
in a variety of physiological roles, including heavy metal detoxification, metal 
homeostasis and free radical scavenging. In both the human and the sheep there are 
multiple MT isoforms which may provide functional diversity. In both species 
differential regulation and expression patterns of MT isoforms have been reported. 
The work presented here investigates the expression and gene structure of MTs in 
these two mammalian species; firstly investigating MT in the developing sheep brain, 
and secondly studying a novel human MT isogene, MTIL. The underlying theme is to 
correlate the structure and expression profiles of specific MT isoforms with their 
proposed physiological functions. 
Since the discovery of a novel MT in humans, MT-III, which is brain specific, 
much interest has centred on the expression and role of all MTs in the brain. In this 
thesis, the sheep was used as a model system in which to study the neural expression 
of MT at the RNA and protein level. MT-I and -II expression was found to be 
correlated with the development of glial cells, and limited solely to glial cells including 
foetal oligodendrocytes, which were previously not suspected to be involved in MT 
physiology. Distinctive shifts in the regional and cell-type expression of MT were 
observed during neural development, and these are discussed in terms of the 
functional role of MT. 
The expression of MT-III, the brain specific isoform, is of current interest. 
This thesis reports the cloning of the gene encoding this isoform from a sheep brain 
cDNA library. Although homologous to MT-III isoforms from other species, the 
predicted sheep MT-III protein sequence contains several unique features, including 
the deletion of a highly conserved 3 amino acid sequence, and thus may have altered 
metal binding properties. Sheep MT-III mRNA was shown to follow the same 
regional and developmental expression patterns as MT-I and -II mRNA. This unique 
MT-III isoform may be useful to resolve pending questions about the role of MT-III 
in the brain, and the apparent neurotrophic actions of this isoform. 
This work also investigates a novel human MT isogene, MTIL, which contains 
a TGA ("stop") codon midway through the transcribed region. By analogy to 
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previously characterised human MT genes, this codon interrupts the putative coding 
region ofMTIL, suggesting the isogene is either not functional, expresses a truncated 
protein or potentially, produces a novel selenoprotein. In previous work, the author 
has shown that the gene has biological activity since it can confer resistance to 
cadmium to a transfected cell line. In this thesis, MT1L was shown to produce a full 
length mRNA transcript when cloned into expression vectors, and furthermore 
expression ofMT1L rnRNA was detected in a range of endocrine tissues and 
lymphocytes by northern blotting and RT-PCR. These findings confirm that MT1L 
has the potential to contribute to the repertoire of MT expression in the human. 
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bp 	 base pairs 
BSA 	 bovine serum albumin 
cDNA 	 complementary DNA 
CuZnSOD 	 copper/zinc superoxidedismutase 
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DMF 	 N,N-dimethylformamide 
DNA 	 deoxynucleic acid 
DTT 	 dithiothreitol 
EDTA 	 ethylene diamine tetra-acetic acid 
FBS 	 foetal bovine serum 
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GSH 	 glutathione 
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O.D. 	 optical density 
PBS 	 phosphate bufered saline 
PCNA 	 proliferative cel nuclear antigen 
PEG 	 polyethylene glycol 
phi 	 plaque forming unit 
PVP 	 Polyvinylpyrolidone 
RNA 	 ribonucleic acid 
RNAase 	 ribonuclease 
RT-PCR 	 reverse transcriptase polymerase chain reaction 
ROS 	 reactive oxygen species 
SDS 	 sodium dodecyl sulphate 
TEMED 	 N,N,N',N',-t etramethylethylenediamine 
Tris 	 tris(hydroxymethyl)aminomethane 
X-gal 	 5-bromo-4-chloro-3-indoy1-13-D-galactopyranoside 
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NOMENCLATURE 
MT nomenclature is not yet standardised despite recommendations by the 
Committee on the Nomenclature of Metallothionein appointed at the General 
Discussion Session of the Second International Meeting on Metallothionein and Other 
Low Molecular weight Metal-binding Proteins (see Fowler et al., 1987). 
This thesis discusses primarily the genes and cognate proteins from mouse, 
sheep and human and these will be distinguished when necessary by the prefixes m, s 
and h, respectively. The various isometallothioneins are referred to as MT-I, MT-II, 
MT-III and MT-IV. 
Both the human and the sheep have complex isometallothionein families and 
therefore when specific subforms are referred to they are designated using the 
nomenclature established in the literature documenting these gene families. 
Therefore, the sheep MT subforms are designated in the style established by Peterson 
et al. (1988), i.e. the genes and cognate proteins are designated as MT-Ia, MT-lb etc. 
The human isogenes are designated following human gene nomenclature guidelines in 
the style established by Karin etal. (1984a) and West etal. (1990), i.e. hAlT1A, 
hAITIB etc and the cognate proteins as hMT1A, hMT1B etc. 
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CHAPTER 1: INTRODUCTION 
1.1 Discovery 
A metallothionein (MT) protein was first discovered in 1957 in equine kidney 
as a consequence of the search for components responsible for the natural 
accumulation of cadmium in mammalian tissues (Margoshes and Vallee, 1957). These 
proteins were subsequently found to bind both zinc and copper also (Pulido et al., 
1966; Kagi and Vallee, 1960). 
1.2 Occurrence 
MTs or MT-like proteins have been found throughout the animal kingdom, in 
plants, eukaryotic microorganisms and prokaryotes (Table 1.1, reviewed in Hamer, 
1986). MTs are cytoplasmic proteins (e.g. Cherian etal., 1981; Banerjee etal., 
1982). However, nuclear localisation of MT is well documented (e.g. Banerjee etal., 
1982) and polymeric copper containing MT has been shown to accumulate in 
lysosomes in the neonatal human liver also (Riordan and Richards, 1980). 
1.3 Definition 
MTs have been traditionally defined according to their structural features. 
They are characteristically low molecular weight proteins having a high content of 
heavy metals bound in thiolate clusters (Otvos and Armitage, 1980). The proteins 
have a high content of cysteine residues (22-33 mole %) and lack aromatic amino 
acids (Kagi et al., 1974). MTs have been defined as polypeptides which resemble 
many of the properties of equine MT (Fowler etal., 1987). There have been 3 classes 
of MT defined (Fowler etal., 1987). Class I are polypeptides containing cysteine 
residues in positions closely related to equine MT and includes all mammalian MTs. 
Class II are polypeptides with the cysteine residues in positions only distantly related 
to equine MT and includes yeast MTs. Class III MTs are atypical, metal thiolate 
polypeptides including the phytoMTs and will not be discussed here further. This 
review will mainly focus on class I mammalian MTs. 
human 	 frog 
monkey 	 sea urchin 
horse 	 crab 
cow 	 trout 
sheep 	 carp 
pig 	 oyster 
rabbit 	 mussel 
hamster 	 wheat germ 
rat 	 tobacco 
mouse 	 tomato 
seal 	 Drosophila melanogaster 
chicken 	 Caenorhabditis elegans 
pigeon 	 Saccharomyces cerevisia 
duck 	 Neurospora crassa 
dolphin 	 cyanobacteria 
Table 1.1 The occurrence of MT and MT-like proteins. 
This table lists some of the wide range of species which have be demonstrated to 
express MT or MT-like proteins. A more extensive list is presented in Hamer (1986). 
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1.4 Protein structure 
Mammalian MTs can bind 7 equivalents of bivalent metal ions, e.g. cadmium 
and zinc (Kojima etal., 1976), or 11-12 equivalents of univalent metal ions, e.g. 
copper (Nielson and Winge, 1984), exclusively through thiolate bonds to the cysteine 
residues. The binding is in a tetrahedral coordination for cadmium or zinc (Vagak et 
al., 1981; Furey etal., 1986) and a trigonal geometry for copper (Nielson etal., 
1985). The tertiary structure of the MT protein is dependent on metal binding, as the 
thionein exists as a random coil (Va§ak et al., 1980). The cysteine residues are 
distributed throughout the protein chain as cys-cys, cys-x-cys and cys-x-y-cys 
sequences, where x and y are any other amino acid (Kojima et al., 1976). All cysteine 
residues occur in reduced form, coordinated to metals through mercaptide bonds, the 
native proteins containing no disulphide bonds (Baler and Kagi, 1974; Kagi et al., 
1974). The proteins contain two distinct metal-thiolate clusters corresponding to two 
protein domains as demonstrated in Figure 1.1. Cluster A contains 11 cysteines, 4 
zinc or cadmium ions, or 5-6 copper (CuI) ions and is located in the carboxyl-terminal 
a-domain. Cluster B consists of 9 cysteine residues, 3 cadmium or zinc ions or 6 
copper (Cup ions and is located in the amino-terminal 0-domain (Winge and 
Miklossy, 1982; Boulanger etal., 1983, Nielson and Winge, 1984). The a- and 13 -
domains can be cleaved with subtisilin (Winge and Miklossy, 1982) and these domains 
are able to bind metals in the same stoichiometries as are found in the intact protein 
(Nielson and Winge, 1985). The three metals most commonly found bound to MTs 
are cadmium, copper and zinc, although MTs have been shown to bind at least 18 
different metals (Nielson etal., 1985). The metal composition of the protein is 
dependent of the species, tissue, stage of development and also the exposure of the 
organism to metals (reviewed in Vallee, 1979). Copper has the greatest binding 
affinity for MT, and the binding affinities for the most commonly bound metals are in 
the order copper>cadmium>zinc (see Nielson et al., 1985). The a- and 13- domains 
have differing stabilities and reactivities which are dependent on the metal species 
bound. For example cadmium and zinc can exchange within seconds in the 13-domain, 
but within minutes in the a- domain (reviewed in Kagi and Kojima, 1987). 
o. 
beta- ' 
domain 
alpha- 
domain 
Figure 1.1 Metallothionein protein structure 
A spatial structure model of rat MT-II derived from coordinates of its crystal 
structure is shown. It depicts a ribbon representation of the main chain fold with 
enclosed metal ion / cysteine (M/Cys) clusters (indicated by filled circles and thin 
lines, respectively). The alpha-domain enfolds the M 4Cys i1 cluster and the beta-
domain enfolds the M3Cys9 cluster (taken from Kagi, 1993). 
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1.5 Isoforms 
Mammalian MTs can be classified into 4 different subforms, which differ in 
their charge, size or amino acid composition. While two of the isoforms, MT-I and 
MT-II where characterised in many species relatively soon after the discovery of MTs 
(see Kagi and Kojima, 1987), the other two isoforms, MT-III and MT-IV were 
discovered only recently (Uchida etal., 1991; Palmiter etal., 1992; Quaife etal., 
1994). The genes which encode the various MT isoforms tend to be clustered on a 
single chromosome, the most well defined of the mammalian MT gene families being 
in the mouse. As shown in Figure 1.2A the 4 mouse MT isoforms (mMT-I, rnMT-II, 
mMT-III and inMT-IV) are encoded by four genes clustered on chromosome 8. 
1.5.1 MT-I and -II isoforms 
In all mammalian species investigated so far, there are at least two functional 
MT genes which encode two electrophoretically distinguishable isoforms, designated 
MT-I and MT-II. In many instances there are multiple MT-I isoforms and a single 
MT-II isoform encoded by multigene families. For example in humans there are 7 
functional MT-I genes; /WIT IA (Richards etal., 1984), hMT1B (Heguy et al., 1986), 
hIVIT1E (Schmidt etal., 1985), hMT1F (Schmidt etal., 1985), hMT1G (Foster et al., 
1988), hMT1H (Stennard etal., 1994) and hIVIT1X (Stennard etal., 1994) and a 
single functional MT-II gene; hMT2A (Karin and Richards, 1982). In sheep there are 
3 functional MT-I genes; sMT-Ia, sMT-Ib and sMT-Ic and a single functional MT-II 
gene; sMT-II (Peterson et al., 1988). In contrast, in mouse there is only a single 
functional MT-I gene; mMT-I (Durnam etal., 1980) and a single functional MT-II 
gene; mMT-II (Searle et al., 1984). Characteristically, the MT-II isoform contains an 
acidic amino acid in position 10 or 11, instead of the neutral amino acid found in MT-
I isoforms, as shown in Figure 1.2B. 
MT-I and -II isoforms are the most extensively studied of the mammalian MTs 
and their expression within an organism appears to be widespread (see Hamer, 1986). 
Highest levels of MT-I and -II isoforms are found in parenchymatous tissues, e.g., in 
the mouse, highest levels of MT-I and -II are induced by metals in the liver, kidney, 
intestine and pancreas (Durnam and Palmiter, 1981). Expression of MT-I and -II 
isoforms have been shown to be induced by an array of factors including metals, 
A 
• MT-IV 	 MT- II 	 MT- II 	 MT-I 
mouse MT-I 
MDPN-CSCSTGGSCTCTSSCACKNCKCTSCKKSCCSCCPVGCSKCAQGCVCKG 	 AADKCTCCA 
mouse MT-II 
MDPN-CSCASEGSCSCAGACKCKQCKCTSCKKSCCSCCPVGCSKCAQGCVCKG 	 AADKCTCCA 
mouse MT-III 
MDPETCPCPTGGSCTCSDKCKCKGCKCTNCKKSCCSCCPAGCEKCAKDCVCKGEEGAICAEAEKCSCCQ 
mouse MT-IV 
MDPGECTCMSGGICICGDNCKCTTCSCKTCRKSCCPCCPPGCAKCARGCICKG 	 GSDKCSCCP 
Figure 1.2 The mouse metalothionein isoforms 
The organisation of the functional metalothionein locus on chromosome 8 is shown 
(A). Adapted from Palmiter etal., 1993. Arows indicate the transcriptional 
orientations of the individual genes. The amino acid sequences of the 4 mouse 
isoforms encoded by these genes are shown (B). Amino acid diferences which 
characterise the MT isoforms are indicated (bold, underlined). 
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hormones and xenobiotics. In the mouse, MT-I and -II genes have been 
demonstrated to be induced coordinately by metals, glucocorticoids and 
lipopolysaccharide (LPS, Searle etal., 1984; Yagle and Pahniter, 1985), whereas in 
other species like the human (for example, Heguy etal., 1986; Jahroudi etal., 1990) 
and the sheep (Peterson and Mercer, 1988; Pitt etal., 1992) differential regulation of 
MT-I and -II genes has been documented. 
1.5.2 MT-III isoform 
MT-III was first purified and characterised as a 68 amino acid MT-like protein 
from the human brain (Uchida etal., 1991). Molecular cloning of the full length 
cDNA revealed remarkable homology to known MTs, including conservation of the 
number and position of cysteine residues, the conservation of lysine residues 
juxtaposed to cysteine residues, the absence of aromatic amino acids or histidine and 
the binding of 7 bivalent metal atoms per molecule (Tsuji etal., 1992). Human MT-
III however contains two unique insertions of 1 and 6 amino acids in the amino- and 
carboxyl-terminal regions respectively, as depicted in Figure 1.2B. Unlike previously 
characterised MTs, MT-III expression is largely restricted to the nervous system 
(Tsuji etal., 1992). 
The gene encoding the mouse homologue of human MT-III predicted a similar 
protein, containing inserts in the same positions and of the same size although the 
amino acid sequence of the carboxyl-terminal insert is not conserved. Mouse MT-III 
expression is also largely restricted to neural tissues (Palmiter etal., 1992). Highly 
homologous rat, bovine and equine MT-III proteins have now been identified 
(Kobayashi et al., 1993; Poutney etal., 1994). 
Although expression of MT-III isoforms appears to be mainly restricted to 
neural tissue (Tsuji etal., 1992; Palmiter etal., 1992; Kobayashi etal., 1993), very 
low levels have been detected in the pancreas of the mouse (Erickson et al., 1995). 
Masters etal. (1994b) showed that levels of MT-III mRNA in various regions of the 
mouse brain are approximately equivalent to levels of MT-I mRNA. However, unlike 
MT-I and -II isoforms, studies have failed to demonstrate upregulation of MT-III 
expression by metals or glucocorticoids (Palmiter et al., 1992, Masters et al., 1994b). 
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1.5.3 MT-IV isoform 
The gene encoding a further isoform, MT-IV, was discovered in both human 
and mouse (Quaife et al., 1994). The predicted protein has a single glutamine amino 
acid insertion at position 5 with respect to MT-I and -II isoforms, as shown in Figure 
1.2B. This insertion is in the same place as the N-terminal insertion in MT-III 
isoforms. MT-IV is mainly expressed in differentiating cells of stratified squamous 
epithelia, and furthermore appears restricted to the suprabasal cells in the stratum 
spinosum of the epithelia (Quaife eta!, 1994). 
As outlined above, MT-III and MT-IV isoforms display restricted expression 
patterns, while MT-I and -II isoforms are expressed more widely within an organism. 
However, in the mouse, all of the known MT isoforrns, mMT-I, -II, -III and -IV, have 
been localised in the maternal deciduum during embryonic development. All the MT 
genes were shown to be co-expressed in at least some cells by in situ hybridisation 
(Liang etal., 1996). 
1.6 Gene structure 
The functional mammalian MT genes are characterised by a tripartite structure 
consisting of 3 exons separated by 2 introns (Glanville etal., 1981). Whilst the exons 
are highly conserved, the 5' and 3' untranslated regions and the introns show little 
homology and vary in size (Hamer, 1986). In all cases the intron/exon boundaries 
conform to the GT...AC splicing rule (Breathnach and Chambon, 1981). 
1.7 Regulation 
The synthesis of MTs is induced by a wide variety of factors including heavy 
metals, glucocorticoids, cytokines, growth factors and hormones as outlined in Table 
1.2. The regulation of MT expression occurs largely at the level of transcription 
initiation, although small effects on MT mRNA stability have been suggested in some 
cases (Mayo and Palmiter, 1981). Studies investigating MT induction by zinc and 
copper, however, have suggested that MT gene expression is also modulated to some 
degree by factors at the post-transcriptional level (Sadhu and Gedamu, 1989; 
Vasconcelos etal., 1996). The increase in MT protein synthesis in response to 
Metals 	 Cytotoxic agents 
Cd, Zn, Cu, Hg, Au, Ag, Co, Ni, Bi 	 butyrate 
retinoate 
Hormones and cytokines 	 phorbol esters 
glucocorticoids 	 endotoxin 
progesterone 	 streptozotocin 
estrogen 	 2-propanol 
glucagon - 	 ethanol 
catecholamines 	 formaldehyde 
interleukin-1 	 alkylating agents 
interferon 	 chloroform 
carbon tetrachloride 
Pathophysiological conditions 
starvation 
infection 
inflammation 
physical stress 
X-irradiation 
high oxygen tension 
Table 1.2 Physiological factors and experimental conditions which have been 
demonstrated to result in induction of metalothionein synthesis in cultured cels or in 
vivo. This table lists some of the wide range of factors which are inducers of 
metalothionein synthesis (adapted from Kagi and Schafer, 1988) 
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inducers is accomplished through interactions between cis-acting elements (DNA 
sequence motifs) and trans-acting elements (cellular factors) (Karin etal., 1987). MT 
gene expression is also regulated at more complex levels by changes in gene structure, 
such as amplification (Beach and Palmiter, 1981; Crawford etal., 1985) and 
methylation (Compere and Palmiter, 1981). 
Functional analysis has revealed metal-induced transcription of MTs to be 
mediated by metal-responsive elements (MREs), multiple copy imperfect repeats 
(Carter etal., 1984; Stuart etal., 1984), since shown to contain an essential core 
heptanucleotide motif TGCA/GCXC flanked by less conserved GC rich sequences 
(Culotta and Hamer, 1989). Individual MREs vary in their metal-activated 
transcriptional responses (Stuart et al., 1985). 
Genomic footprinting experiments suggest that a positively acting 
transcription factor binds to the MREs, since factors were only found to bind to these 
sequences after induction by metals (Andersen et al., 1987; Mueller et al., 1988). 
However, several different factors have in fact been reported to bind to MREs 
(Sequin and Prevost, 1988; Imbert et al., 1989; Andersen etal., 1990; Koizumi et al., 
1992). One of these factors, MTF-1, appears to be a constitutively active 
transcription factor capable of interacting with MREs (Radtke etal., 1993). Palmiter 
(1994) demonstrated that a zinc-sensitive inhibitor, termed MT transcription inhibitor 
(MTI) was able to interact with MTF-1 and proposed a model in which the inhibitor 
and MTF-1 dissociate in the presence of zinc allowing MTF-1 to interact with the 
MREs of the MT promoter (see Figure 1.3). This model is supported by data which 
suggests that de 170V0 synthesis is not required for activation of MT genes by metals 
(Karin etal., 1980). However, it is still not known whether the zinc interacts directly 
or indirectly with the inhibitor. 
A number of different trans-acting factors are now thought to be involved in 
the control of MT transcription. Most of these are general transcription factors, 
however the putative metal regulatory transcription factors thought to mediate 
induction of MTs by heavy metals appear to be MT-gene-specific (Culotta and 
Hamer, 1989). All MT genes investigated thus far have MREs present in their 
promoter region, and such elements have not been detected in promoters of other 
genes. The presence of other regulatory elements along with MREs within the 5' 
MREs MT  MREs • 
+Zn 
	IMT 	 MREs 
MT 
Zn-MT 
MT  
Figure 1.3 Model of MT gene regulation by zinc 
The model depicted above proposes that the transcription factor MTF-I is complexed 
with metalothionein transcription inhibitor (MTI). This complex dissociates in the 
prescence of zinc alowing MTF-1 to interact with MREs of the MT promoter, 
activating MT transcription. The MT protein produced binds free zinc and the MTF-
1/MTI complex reforms (taken from Palmiter, 1994) 
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flanking promoter region raises the possibility that protein-protein interactions may be 
an important component of regulatory mechanisms for MT genes (Thiele, 1992). 
MT promoters contain binding sites for general transcription factors involved 
in the maintenance of basal level expression including the GC box sequence 
(GGGCGG) for the DNA binding protein Spl (Kadonaga et al., 1986), which appears 
important for the general function of many promoters. This is often found to overlap 
promoter elements implicated in the control of basal level expression termed basal 
level elements (BLEs). These element may have an important role in determining the 
efficiency of transcription (Karin etal., 1984). 
Some MT promoters also contain recognition sequences for the activator 
protein AP-1 (Activator protein 1) (Lee etal., 1987), and this is involved in the 
induction of the human gene lthilT2A by 12-0-tetradecanoyl-13-phorbol acetate 
(TPA) (Angel etal., 1986). The induction response involved is thought to utilize 
protein lcinase C (PKC). AP-2 (Imagawa etal., 1987) and AP-4 (Culotta and Hamer, 
1989) binding sites have also been detected. 
A glucocorticoid-responsive element (GRE) has been identified in the 
promoter of hMT2A and implicated as the major regulatory factor in induction of 
MTs by glucocorticoids (Karin et al., 1987). The sequence motif in hMT2A 
determined to be responsible for induction of this gene by glucocorticoids is 
GGTACACTGTGTCCT (Karin et al., 1984b), which is homologous to GREs 
identified in other promoters. 
A region of the mouse MT-I promoter has been implicated in the induction of 
this MT by hydrogen peroxide. This region contains a composite element which 
consists of a major late transcription factor (MLTF) binding site overlapping an 
antioxidant response element (ARE) and/or MIRE (Dalton et al., 1994). The ARE 
which has the core sequence (GTGACnnnGC) can be bound by a factor(s) which is 
suggested to be activated by reactive oxygen species (ROS) (Rushmore etal., 1991; 
Schroeder and Cousins, 1990) although the mechanism involved is unknown. 
Although most cells exhibit MT expression and respond to a variety of 
inducers, there are a few cell lines such as Chinese hamster ovary (CHO) cells, which 
do not express MT even though the genes are present (see Grady et al., 1987). 
Experiments have been conducted using the potent hypomethylating agent 5- 
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azacytidine and these studies have implicated DNA methylation as a regulatory 
mechanism in such cell-type specific expression of MT (Heguy eta!, 1986; Jahroudi 
et al, 1990). An inverse relationship between MT expression and the extent of 
methylation of cytosine residues has been postulated, and the methylation status of the 
5' region appears particularly important. The mechanisms involved are unknown, but 
interference with the binding of RNA polymerase or regulatory factors, changes to the 
nucleosome phasing or alterations to higher order chromatin packaging have been 
suggested (Hamer, 1986). Methylation may also be an important regulating factor 
then, in the developmental control of tissue-specific MT gene expression (Palmiter, 
1987). 
There may also be domain regulatory elements which regulate genes within the 
MT locus. Palmiter etal. (1993) may in fact have detected a locus control region 
flanking the mouse MT-I and -II genes, which is responsible for the coordinate 
expression of these MTs. The MT-III and -IV genes, which are regulated and 
expressed differently, appear to be outside this locus control region. MT-III isoforms 
have very restricted expression and in fact the mouse MT-III promoter has been 
found to contain a tripartite repeat (25 X CTG) which has repressive activity on MT-
III. This repeat also had repressive activity when joined to other promoters, in three 
different non-neural cell types (Imagawa etal., 1995). A similar repeat has not been 
found in the human MT-III promoter however. 
1.8 Physiological roles 
1.8.1 Heavy metal detoxification 
Several lines of evidence demonstrate that MTs are able to act in the 
detoxification of cadmium and other heavy metals. Such a role is suggested since 
MTs are transcriptionally activated by the heavy metals they bind (Durnam and 
Palmiter, 1981). Various studies have demonstrated the induction of MTs by heavy 
metals in both animal models (e.g. Shaik and Lucas, 1970; Nordberg etal., 1971) and 
in cultured cell systems (e.g. Karin etal., 1981). Cell lines which fail to produce MT 
due to methylation of the genes are sensitive to cadmium toxicity (Compere and 
Palmiter, 1981). Conversely, many cell lines which demonstrate resistance to 
cadmium toxicity, have been found to overexpress MT due to gene amplification 
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(Beach and Palmiter, 1981; Mayo and Palmiter, 1982; Gick and McCarty, 1982; 
Crawford et aL, 1985). Studies have also shown that transfection of MT genes on 
self replicating vectors causing overproduction of MT confers the transfected cells 
with cadmium resistance (Schmidt etal., 1985; Karin et al, 1983). Furthermore, 
Morton et a/. (1992) found that NTH/3T3 cells with increased MT levels due to 
transfection of the mouse MT-I gene, were at least 10 times more resistant to 
cadmium, at least in part due to a 4-fold reduced uptake of the metal into the cells. 
In the whole animal model the situation is more complicated, however various 
studies have demonstrated that low dose treatment with a heavy metal resulting in 
induction of MTs can confer protection against the toxicity of subsequent higher dose 
heavy metal treatments (e.g. Leber and Miya, 1976). Furthermore, transgenic mice 
with non-functional MT-I and -II genes are extremely sensitive to cadmium poisoning 
(Michalska and Choo, 1993; Masters etal., 1994a), while transgenic mice 
overexpressing MT-I are more resistant to cadmium toxicity (Liu et al., 1995). 
However, there is some suggestion that excessive accumulation of cadmium-MT may 
be a major cause of kidney damage seen in acute cadmium poisoning (Nordberg et al., 
1975, Dorian etal., 1992). 
Much evidence then suggests that MT has a role in the detoxification of heavy 
metals as outlined above, however most researchers believe that this is not the 
primary physiological role of MTs (Karin, 1985, Webb, 1987). It is likely that this 
perceived role of MTs is adventitious, reflecting the similarity of cadmium and zinc. 
transgenic mice which can not produce MT-I and -II proteins were crossed 
with mice which have disrupted copper effluxers due to mutation of the copper 
effluxing ATPase, producing mutant embryos which died due to copper toxicity 
(Kelly and Palmiter, 1996). This study demonstrated that MT provides a second line 
of defence against copper toxicity. Zinc transporters play an important role in 
homeostasis of this ion in cells (Palmiter and Findley, 1995) and it is likely that MTs 
provide a second line of defence against zinc toxicity also. 
1.8.2 Metal homeostasis and metabolism 
Roles for MT in hepatic storage, intestinal absorption, renal excretion and 
transport of copper and zinc have been suggested. Many of the characteristics of MT 
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suggest that they could be involved in such cellular metabolism. For example, MTs 
are usually found as copper and/or zinc-containing proteins, they have a conserved 
structure and are transcriptionally regulated by hormones and cytolcines. 
Furthermore, high levels of MT are found in organs such as liver, kidney, intestine and 
pancreas which play important roles in homeostasis of these metals. 
The transfer of metals from MT to apo enzymes has been demonstrated in 
vitro (Udom and Brady, 1980). For example, MT has been shown to donate zinc to 
carbonic anhydrase (Li etal., 1980), and copper to ceruloplasmin (Schechinger et al., 
1986). Furthermore, copper MT not only donates copper to bovine dopamine 13-  
monooxygenase resulting in activation of the enzyme, but also extracts copper from 
the enzyme resulting in inhibition of its enzymatic activity (Markossian et al., 1988). 
Expression of MT in many tissues is a direct reflection of dietary zinc intake 
(Blalock etal., 1988; Huber and Cousins, 1988; Cousins and Lee-Ambrose, 1992) 
and there is substantial evidence to suggest that MT is involved in the regulation of 
absorption of essential metals in the intestine. Zinc administration induces MT in the 
intestine (Cherian, 1977; Hall eta! 1979) and high levels of the protein correspond to 
reduced zinc absorption (Richards and Cousins, 1975). This inverse relationship 
between MT and zinc absorption has been well documented (Hempe and Cousins, 
1992; Hoadley et al., 1988) and has led to the suggestion that MT may function as an 
intracellular buffer limiting zinc absorption. Interestingly, MT induction and zinc 
absorption appear responsive to zinc but not other MT inducers such as 
dexamethasone and interleukin-1 (Hempe etal., 1991). Tissue specific induction of 
MT appears also to be associated with the redistribution of zinc in the body (Cousins 
and Leinart, 1988; Huber and Cousins, 1988). Also, MT turnover is regulated by 
intracellular zinc levels, i.e. when zinc levels are low, MT is degraded (Karin et al., 
1981). 
There is also evidence that metal containing MT can be secreted since it has 
been detected by radioimmunoassay in extracellular fluid such as urine, plasma and 
bile (reviewed in Bremner et al., 1987). This has led to speculation that MT may be 
involved in transport of copper and zinc from one organ to another, or the excretion 
of these ions from the body. 
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1.8.3 Development and differentiation 
A role for MT in development and differentiation has been suggested for a 
number of reasons. Firstly, high endogenous levels of MT have been reported in 
foetal and neonatal tissues (Bremner et al., 1977; Bremner etal., 1984; 
Panemangalore etal., 1983; Elmes etal., 1991) and MT appears to be subject to 
programmed regulation during both foetal and perinatal development (Nartey et al., 
1987a; Andrews etal., 1984; Baklca and Webb, 1981; Klein etal., 1991). Secondly, 
elevated levels of MT are seen in regenerating tissues such as the liver after partial 
hepatectomy (Ohtake etal., 1979; Tohyama etal., 1993) and the kidney after 
uninephrectomy (Zalups et al., 1995). High levels of MT are often seen in actively 
proliferating and differentiating tissues, such as the basal layer of the epithelium of the 
cornea (Nishimura etal., 1991). MT is also detected in hair follicles and the basal 
layer of hyperplastic epidermis, indicating it may be associated with the proliferation 
of keratinocytes (Karasawa etal., 1991). Thirdly, the expression of MT in many 
tumour cells (Nartey etal., 1987b; Bahnson etal., 1991; Chauvin etal., 1992) and 
particularly its association with the proliferative edge of tumourous tissue (Cherian, 
1994) also suggest that these proteins are associated with cellular proliferation. 
A study has found links between expression of MT and the cell cycle (Nagle 
and Vallee, 1995) and there is a suggestion that the protein is translocated to the 
nucleus during S-phase, where it may provide metals for nuclear factors or enzymes 
involved in the cell cycle (Tsujikawa etal., 1991; Tohyama et al., 1993). However, in 
in vitro studies, Imbra and Karin (1987), found no association between MT synthesis 
and the cell cycle. Furthermore, mouse embryo development in vitro was unaffected 
by microinjection of anti-MT antibodies (Ibariez etal., 1995), although Peters etal. 
(1995) demonstrated that MT antisense oligonucleotides inhibited the frequency of 
blastocyst formation in mouse preimplantation embryos. Finally, transgenic mice 
lacking MT-I and -II isoforms develop normally suggesting that MT can not play a 
critical role in development (Michalska and Choo, 1993; Masters etal., 1994a). 
1.8.4 Free radical scavenging 
Several lines of study have led to the suggestion that MT may function in the 
defence against oxidative stress. Firstly, MT is induced in cells (Fornace et al., 1988) 
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and tissues (Bauman et al., 1991) by oxidative stress. Secondly, spin trapping 
experiments have shown that MT is able to scavenge hydroxyl radicals at least in vitro 
(Thornalley and Vagalc, 1985; Renan and Dowman, 1989), and thirdly MT displays a 
protective effect against hydroxyl radical induced DNA damage in vitro that is 
concentration dependent (Abel and Ruiter, 1989). 
Several studies have investigated the effect of MT on the lethality of free 
radicals. Overexpression of MT by induction with heavy metals and cytolcines has 
been reported to result in resistance to oxidative stress caused by hydrogen peroxide 
(Mello-Filho etal., 1988), organic peroxides (Ochi., 1988), hyperoxia (Hart etal., 
1990) and carbon tetrachloride (Schroeder and Cousins., 1990). However heavy 
metals and cytokines induce factors other than MT. For example, cadmium induces 
both MT and glutathione (GSH), a known free radical scavenger (Seagrave et al., 
1983), and in fact induction of MT by zinc which does not alter GSH concentrations 
failed to confer protection from free radicals in one study (Chubatsu et al., 1992). 
This finding is supported by gene transfection studies in which overexpression of MT 
by transfection of the gene failed to confer resistance to ionizing radiation or 
bleomycin (Lohrer and Robson, 1989; Kaina et al., 1990). 
However, hydroxyl radicals may produce single strand scissions which are not 
necessarily lethal (Ward et al., 1985), but result in mutagenic base damages (Aruoma - 
et al., 1989). Cells overexpressing MT by gene transfection have in fact been shown 
to have decreased hydrogen peroxide-produced DNA strand scissions, and depletion 
of MT by the antisense mRNA approach resulted in increased scissions (Chubatsu and 
Meneghini, 1993). These experiments suggest that MT may have antimutagenic 
properties and this line of reasoning is supported by studies which have demonstrated 
that cells overexpressing MT have resistance to alkylating agents (Kaina et al., 1990). 
This has led to the suggestion that MT participates as a cofactor or regulatory 
element in repair or tolerance of toxic alkylation lesions. 
Further studies which support the notion of the involvement of MT in free 
radical protection include its ability to confer resistance to the cytotoxic effects of 
monochromatic 365 nm UVA radiation, which is known to generate reactive oxygen 
species (ROS) intracellularly (Dudek et al., 1993), the correlation of increased MT 
expression with decreased side effects of anti-cancer agents that produce oxidative 
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stress including cisplatin and adriamycin (Basu and Lazo, 1990) and also its ability to 
protect against carbon tetrachloride induced hepatotoxicity, following induction by 
zinc pretreatment (Cagen and Klaassen, 1979). It has also been suggested that MT 
may reduce lipid peroxidation possibly by releasing zinc to stabilize membranes 
(Thomas etal., 1986). 
Yeast and monkey MT proteins have also been shown to substitute for 
copper/zinc superoxide dismutase (CuZnSOD) in yeast. It was suggested therefore 
that MTs play a direct role in the defence against oxidative stress (Tamai etal., 1993), 
although this activity was shown to be a property of only copper-containing MT. 
Interestingly, recent data has shown that CuZnSOD can play a role in copper 
buffering which is distinct from its role as a free radical scavenger (Culotta etal., 
1995). This raises the possibility that in the previous study MT is substituting for the 
copper homeostasis rather than free radical scavenging function of CuZnSOD. 
Finally, the production of MT-I/I I-/- mice which fail to produce MT-I and -II 
isoforms has provided a useful tool for examining the function of MT isoforms 
(Michalska and Choo, 1993, Masters etal., 1994a). These mice were shown to have 
increased sensitivity to both tertbutylhydroperoxide and paraquat, indicating that basal 
MT may be involved in the regulation of the redox state of the cell (Lazo et al., 
1995). 
1.8.5 MT and the acute phase response 
MTs are induced by many chemical and physical stresses, and the effect is seen 
most prominently in the liver. MTs are induced early in the acute phase response, and 
their induction by various cytolcines including a-interferon (Friedman and Stark, 
1985), tumour necrosis factor (TNF) (De etal., 1990; Sato etal., 1992), interleulcin-1 
(IL-1) (Cousins and Leinart., 1988) and interleukin-6 (IL-6) (Schroeder and Cousins, 
1990) has been observed. In vitro studies on rat hepatocytes have also demonstrated 
induction of MT by interleukin-11 (IL-11), leukaemia inhibitory factor (LIT) and 
activated macrophages (Coyle et al., 1995). 
MTs then, have been suggested to play an important role in the acute phase 
response. Low plasma zinc levels have been observed during infection or 
inflammation corresponding to induction of MT in the liver and sequestration of zinc 
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in this tissue (Cousins, 1985; Bremner and Beattie, 1990). However, the induction of 
MT during infection is not mediated primarily by zinc, since MT induction in the liver 
precedes the accumulation of zinc in this tissue, in animals treated with endotoxin 
(Durnam etal., 1984). Similarly glucocorticoids are not the primary mediator since 
MT is induced by inflammatory agents in adrenalectomized rats (Sobocinslci et al., 
1981). Min etal. (1992) showed that MT induction by inflammation is in fact 
mediated by cytokines and evidence suggests that along with metal and glucocorticoid 
regulatory elements, MT genes contain DNA elements responsive to inflammatory 
stress (first suggested by, Durnam etal., 1984). EL-6 has been implicated as a 
primary mediator in the induction of MT by inflammatory agents (Rofe et al., 1992), 
and is capable of inducing MT synergistically with zinc and glucocorticoids 
(Schroeder and Cousins, 1990; Coyle et al., 1993a; Coyle et al; 1993b). Thus a 
complex system involving many factors regulates MT expression in inflammation 
(reviewed in Coyle et al., 1993c) and it seems likely that the induction of MT in the 
liver has the role of sequestering zinc in this tissue where it is required for the 
synthesis of DNA and proteins, including the acute phase proteins. In fact studies of 
MT-me- transgenic mice which fail to express MT-I and -II isoforms have 
demonstrated that MT is essential for the accumulation of zinc in the liver in 
endotoxin-induced inflammation (Philcox et al., 1995). 
It has also been suggested that MTs have an antioxidative role during the 
acute phase response, protecting tissues from injury by oxidative stress, since 
induction of MTs by oxidative stress appears partly to be mediated by cytokines (Sato 
etal., 1995). 
1.8.6 MT and anticancer drugs 
A major factor in the failure of cancer chemotherapy appears to be resistance 
to anticancer drugs and MT has been implicated in this resistance. There are presently 
however conflicting results regarding the role of MT in anti-cancer drug resistance. 
MT induction by cadmium has been shown to result in resistance to cisplatin (Baldca 
etal., 1981) and chlorambucil (Endresen eta! 1983) and MT overexpression has been 
correlated to resistance to electrophilic anticancer drugs (Andrews PA et al., 1987; 
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Kelley et al., 1988). Non-metal inducers of MT have also been found to result in 
cisplatin resistance (Kondo etal., 1994; Basu and Lazo, 1991). 
In further studies overexpression of MT by transfection of cells with the 
human gene hMT2A correlated with resistance to cisplatin, chlorambucil and 
melphalon , but not the functionally unrelated 5-fluorouracil and vincristine (Kelley et 
al., 1988). Resistance was also seen to alkylating agents such as mitomycin C, N-
methyl-N-nitrosourea and cisplatin but not y-irradiation or bleomycin (Kaina et al., 
1990). Other transfection studies however, found no cisplatin resistance (Morton et 
al., 1993; Schilder et al., 1990). It has been suggested that sensitivity to DNA 
alkylating agents following MT gene transfer may depend in part on the phenotype of 
cells (Lohrer and Robson, 1989; Lohrer etal., 1990; Robson et al., 1992) and 
examination of cisplatin resistant cells has revealed that although some have increased 
MT levels (Kelley etal., 1988; Yang etal., 1994; Kasahara etal., 1991; Eichholtz-
Wirth etal., 1993) others do not (Andrews PA etal., 1987; Kelley etal., 1988; 
Schilder etal., 1990; Shellard et al., 1993). Several studies have also demonstrated 
the protective effects of induced MT on cisplatin in vivo, particularly in the mouse 
(Naganuma etal., 1985; Satoh et al., 1993a,b; Naganuma etal., 1987; Satoh etal., 
1988). 
Tumour samples have also been examined to investigate the link between 
alkylating agent resistance and MT (Nartey etal., 1987b; Chin eta!, 1993; Bahnson 
et al., 1991; Haile-Meskel etal., 1993). However no direct correlation between MT 
levels and response to therapy, age, stage, histology or tumour cell differentiation 
state has yet been found (Bahnson etal., 1991; Wood etal., 1993; Murphy etal., 
1991). In fact, Haerslev et al. (1995) concluded that immunohistochemically 
detectable MT was not prognostically significant in primary breast carcinomas. 
Many of the anticancer drugs cause oxidative injury to cells, and also illicit an 
inflammatory response resulting in production of cytokines, IL-1, IL-6 and TNF. The 
involvement of MT in resistance to anticancer drugs is most likely related to the role 
of these proteins in the acute phase response and/or free radical scavenging. 
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1.8.7 Growth inhibitory function 
MT-III was initially isolated as a growth inhibitory factor that is deficient in 
Alzheimer's disease (AD) (Uchida etal., 1991), although a separate study did not find 
this down regulation to be statistically significant (Erickson et al., 1994). MT-III 
inhibits the neurotrophic activity of AD brain extracts on neonatal rat cortical neurons 
(Uchida eta!, 1991, Tsuji etal., 1992). It is however only inhibitory in the presence 
of brain extract (either control or AD). In fact in the absence of brain extract MT-III 
(and MT-I) stimulate neuron survival (Erickson etal., 1994). The inhibitory activity 
unique to MT-III is due to its N-terminal 13-domain (Uchida and Ihara, 1995) and is 
more precisely dependent on the 2 prolyl residues in this domain which are only found 
in the MT-III isoform (Sewell etal., 1995). 
In transgenic mice overexpressing human MT-III, the expression profile of the 
human MT-III mimics that of the endogenous mouse MT-III. Zinc but not other 
metal concentrations are increased 9 fold, which is entirely accounted for by binding 
to the increased MT-III protein. However, despite the putative growth inhibitory 
activity of MT-III in vitro, the transgenic mice display no overtly deleterious effects in 
the development or function of the nervous system (Erickson et al., 1995). The 
question remains, then, as to whether the growth inhibitory activity demonstrated for 
MT-III in vitro is physiologically relevant. 
1.9 Expression of MT in vivo 
MT expression has been detected in most organs and tissues examined. 
Highest levels of MT mRNA and endogenous protein are detected in parenchymatous 
tissues such as the liver, kidney, intestine and pancreas (Kagi and Kojima, 1987). 
Shaikh and Nolan (1987), reported MT levels in control rat of 7 j.tg/g in liver and 67 
nig in kidney, as measured by radioimmunoassay. However, the actual levels of MT 
in a tissue vary widely depending on a range of factors including age, developmental 
status, dietary factors and exposure to metals. For example, measurement of hepatic 
MT levels by a cadmium binding assay during postnatal development of the rat 
demonstrated that MT levels are about 40 times greater immediately after birth than 
30 days later (Cherian etal., 1987). Notably MT has been detected in tissues which 
are rich in zinc ions such as Paneth cells of the small intestine (Danielson et al., 1982; 
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Nishimura et al., 1989) and the dorsolateral lobes of the prostate (Umeyama et al., 
1987; Nishimura etal., 1990). 
MT has been generally thought of as an ubiquitous protein however the use of 
immunohistochemical and in situ hybridisation methods, and the examination of 
endogenous rather than induced levels of MT have shown that its expression within an 
organ is not necessarily ubiquitous, but can be restricted to certain cell types and areas 
of the tissue. For example in the mammalian brain several studies have demonstrated 
the expression of MT-I and -II isoforms in glial but not neuronal cells by 
immunohistochemistry (e.g. Nishimura etal., 1992; Blaauwgeers etal., 1993). 
Furthermore, immunocytochemical studies have demonstrated that MT protein levels 
may vary markedly in individual cells within a tissue. This is evident both in various 
human organs (e.g. Nartey etal., 1987a,b; Cherian, 1994) and in experimental animals 
(e.g. Nishimura etal., 1991; Karasawa etal., 1991; Elmes etal., 1991; Danielson et 
al., 1982). 
MT mRNA has been detected using northern analysis and in situ hybridisation. 
These techniques are able to differentiate between mRNA for the various MT 
isoforms (e.g. Pitt et al., 1992; Andrews etal., 1991) and have demonstrated 
differential expression and regulation patterns. Similarly, various methods have been 
used to detect MT protein including immunohistochemistry, radioimmunoassay, an 
ELISA assay, and a silver saturation method. However, because of the similarity of 
the MT isoforms, specialized techniques are generally required to distinguish between 
them at the protein level. Many commonly used antibodies against MT cross react 
with both MT-I and -II isoforms (e.g. Jasani and Elmes, 1991), although isoform 
specific antibodies have been produced (e.g. Mehra and Bremner, 1983). Techniques 
such as capillary electrophoresis and high performance liquid chromatography are 
used most successfully to separate the various MT isoforms (Hunziker and Kagi, 
1985; Richards and Beattie, 1993; Beattie etal., 1993). 
1.9.1 Nuclear localisation 
Distinct differences in the cellular localisation of endogenous MT as detected 
by immunohistochemistry have been reported in developing tissues. MT was 
traditionally thought of as a cytoplasmic protein but its localisation in the cell nucleus 
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is now well documented. Although predominantly cytoplasmic localisation is 
observed in adult liver, in the foetal human liver, and foetal and neonatal rat liver MT 
is also localised to nuclei (Panemangalore et a/., 1983; Templeton et a/., 1985; Nartey 
etal., 1987a; Andrews GK etal., 1987; Elmes et a/., 1991). Nuclear localisation of 
MT in hepatocytes therefore appears to decrease with age. Both cytoplasmic and 
nuclear localisation have also been detected in studies of various tumours (e.g. Nartey 
etal., 1987b; Schmid etal., 1994; Suzuki etal., 1991). 
Tsujikawa etal., (1991) investigated the subcellular localisation of MT in 
primary cultured adult rat hepatocytes stimulated by epidermal growth factor and 
insulin and found that MT localised in the cytoplasm of hepatocytes during G1 phase 
was translocated into the nucleus during early S-phase of the cell cycle. A further 
study using DNA flow cytometry demonstrated MT in the nucleus of diploid and 
aneuploid adenocarcenoma cells during S-phase but not Gl-phase (Haile-Meskel et 
al., 1993). Tohyama et al. (1993) also demonstrated that although MT is localised 
predominantly in the cytoplasm of normal adult rat liver, nuclear localisation was 
present in the regenerating liver after partial hepatectomy. The significance of MT in 
the nucleus is not yet known although one proposal is that it may be linked to the 
interactions of metal ions such as zinc with nuclear factors and enzymes involved in 
the cell cycle (Cherian, 1993). Chubatsu and Meneghini (1993) showed MT 
expression predominantly in the nucleus of V79 Chinese hamster lung fibroblasts both 
before and after chronic cadmium exposure. They proposed a link between the 
presence of MT in the nucleus and the ability of MT to protect DNA against free 
radical damage. 
1.10 Expression in the brain 
Various studies have documented the expression of MT in the mammalian 
brain. Expression of the MT-I and -II isoforms, as well as the brain specific isoform 
MT-III, have been recorded in the brain. Several studies have demonstrated that the 
relative levels of MT-III mRNA in regions of the brain closely follow the expression 
patterns of MT-I and -II mRNA (Masters et al., 1994b; F.A.Stennard, Ph.D. Thesis). 
Furthermore, MT-I and -MT-III mRNA levels in the brain appear to be approximately 
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equal (Masters et al., 1994b). However, there is currently debate as to whether MT-I 
and -II isoforms are expressed in the same cell type as the MT-III isoform. 
1.10.1 MT-I and -II isoforms 
MT-I and -II isoform expression in the brain has been studied in various 
species. In the mouse expression has been localised in glial cells, ependymal cells, 
arachnoid and pia mater (Nishimura etal., 1992). Similarly in the rat brain expression 
has been detected in astrocytes throughout the brain (Young etal., 1991; Young, 
1994), ependymal cells, pia mater and arachnoid as well as the choroid plexus and 
blood vessels (Nakajima et al., 1989; Nishimura et al., 1992). In the monkey 
expression was reported in astrocytes, ependymal cells and pia mater (Suzuki et al., 
1992a) and in the human, various studies have localised MT-I and -II mainly to 
astrocytes (Nakajima etal., 1991; Suzuki etal., 1992b; Blaauwgeers etal., 1993; 
1994). 
1.10.2 MT-III isoform 
MT-III expression appears to be restricted to neural tissue (Tsuji et al., 1992) 
however there is considerable debate regarding its cell-type expression. In the human 
brain expression of the protein detected with an antibody to a synthetic peptide has 
been reported to be restricted to actrocytes, primarily in the grey matter (Uchida et 
al., 1991). In the mouse however, neural but not glial expression of MT-III mRNA 
was detected in vivo, by in situ hybridisation (Masters et al., 1994b; Choudhuri et al., 
1995). Furthermore, transgenic mice generated by fusion of the MT-HI promoter to 
the E. coli lac z gene demonstrated 13-galactosidase activity localised to neurons 
(Masters et al., 1994b). Zheng et al. (1995) however, found MT-III mRNA to 
colocalise with MT-I mRNA in the glial cells on the Purkinje layer of the cerebellum, 
and Masters et al. (1994b) reported MT-III mRNA in the choroid plexus indicating 
that the expression is not exclusively neuronal. In the rat brain also, in situ 
hybridisation revealed MT-III mRNA mainly in the neurons of the cortex, but both 
neuronal and non neuronal cells increased MT-III expression after ablation (Yuguchi 
etal., 1995a). In a separate study, MT-III was colocalised to facial motorneurons 
and mainly neurons of the cortex (Yuguchi et al., 1995b). Masters et al. 1994 
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showed that mouse astrocytes were capable of expressing MT-III after several days in 
culture, while Kobayashi et al. (1993) detected MT-III in rat astrocyte cultures, but 
not cultured neurons, fibroblasts or microglia. 
1.11 MT-I and -II null mice 
Although studies have demonstrated the ability of MTs to fulfil several roles, 
the primary physiological function of MT remains unresolved. Recently, transgenic 
mice have been employed to answer questions regarding MT and have proved a useful 
tool. Transgenic mice with disrupted MT-I and -II genes (MT-I1II 4- mice) where 
found to be apparently physiologically normal and fertile (Michalska and Choo, 1992; 
Masters et al., 1994a), apart fromincreased sensitivity to cadmium. However, 
embryonic fibroblasts made from these mice were shown to have increased sensitivity 
to oxidative stress (Lazo et al., 1995) and increased sensitivity to anticancer drugs 
(Kondo et al., 1995). These mice have also been used to demonstrate the importance 
of MT in the sequestering of zinc in the liver during inflammation (Philcox et al., 
1995). Finally a study in which these mice were crossed with mice with disrupted 
copper effluxers demonstrated that MT is essential in providing a second line of 
defence against copper toxicity (Kelly and Palmiter, 1996). Thus, studies using MT-
I/114" transgenic mice have demonstrated that although MTs are not necessary for 
normal development and function, they may provide essential back up systems, and 
may be required in situations of physiological stress. 
1.12 Concluding Remarks 
Despite the large number of studies investigating MTs over the past 30 years 
many features of MT remain enigmatic, not least being their physiological role and the 
requirement for the expression of multiple isoforms in mammals. Although many 
studies have investigated MT expression in artificially induced states, recent studies 
suggest that much can be learnt about this protein by examining its expression and 
regulation in the basal state and under physiological conditions, e.g. during 
developmental stages or during conditions of inflammation. Investigation of MT 
expression under such conditions may provide insight into the factors which are most 
important in regulating the expression of these proteins in vivo, and may lead to a 
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better understanding of their function. Similarly, the requirement for multiple 
isoforms to be expressed in mammals remains puzzling. These multiple isoforms may 
enable rapid responses to inducers, may provide a mechanism for tissue specific 
expression or may provide diversity of function. Examination of the individual MT 
genes, the features which set them apart, and the manner in which they are 
differentially regulated and expressed may provide insight into their requirement and 
their contribution to the physiology of MTs. 
This thesis addresses the unresolved points outlined above. Although MT is 
known to be present in the mammalian brain, its expression during the complex 
process of neural development is uninvestigated. Therefore, this work will examine in 
detail the expression of MT during the development of the sheep brain, with particular 
emphasis on its localisation to specific regions and cell types. Furthermore, it is not 
known whether an MT-III isoform exists in this species, and thus whether it 
contributes to the repertoire of brain MT expression. Consequently, the existence of 
sheep MT-III will be investigated and if found, its expression profile compared to 
MT-I and -II isoforms. Finally, the reason for the expression of multiple isoforms of 
MT in all mammalian species remains. One approach to resolving the significance of 
multiple isoform expression is to determine whether each isoform has specific 
structural or regulatory properties. In this context a novel human gene, MTIL will be 
investigated to determine whether it is expressed in human tissues and therefore 
contributes to the repertoire of MT expression in the human. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Media and Buffers 
All general chemicals and reagents were of molecular biology or analytical grade. 
Suppliers of specialised materials, enzymes or kits are listed. All buffers were 
prepared with double distilled water (dd water) purified using the Milli-Q Ultrapure 
Water System (Millipore) or glass distilled water, as specified. 
Alkaline agarose 2 X Loading buffer 
200 IA glycerol 
750 p.1 dd water 
46 p.1 saturated bromophenol blue 
5 ptl 5M NaOH 
10 X Alkaline Buffer 
3 ml 5 M NaOH 
2 ml 0.5 M EDTA 
45 ml distilled water 
Alkaline agarose gel 
Agarose (0.8 g) was dissolved in 72 ml distilled water, cooled to 55°C, then 8 ml of 
10 X alkaline buffer added. A thin layer of gel was poured, and once set, loaded and 
electrophoresed at 100 mA. 
Antibiotics 
Antibiotics were added to media and agar at the following concentrations when 
required: 
Ampicillin (Boehringer-Mannheim), added to 50 pg/m1 
Tetracycline (Sigma), added to 12.5 pg/m1 
Kanamycin (Boehringer-Mannheim), added to 50 pg/m1 
Bouin's fixative 
75 ml saturated aqueous picric acid 
25 ml 40% formaldehyde 
5 ml glacial acetic acid 
• Buffered glycerol 
50m1 0.5 M NaHCO3 , pH 8.3 
0.6 ml 0.5 M Na2CO3, pH 11.5 
100 ml glycerol 
DNA Hybridisation Buffer 
6 g HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) dissolved in 
250 ml dd water 
5 ml 10% SDS 
1 g Ficoll 
1 g BSA (bovine serum albumin) 
1 g PVP (Polyvinylpyrrolidone) 
1 ml 0.5 M EDTA 
75 ml 20 X SSC 
dd water to 500 ml 
denatured salmon sperm DNA, added to 0.5 mg/ml before use 
5 X DNA loading buffer 
25% sucrose 
6.25 mM EDTA 
1.25% SDS 
0.25% bromophenol blue 
Hybridisation Buffer (50% formamide, for cDNA probes) 
50% formamide 
5 X SSt 
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0.5% milk powder 
1% SDS 
10% dextran sulphate 
50 mM phosphate buffer 
denatured salmon sperm DNA, added to 0.5 mg/m1 before use 
Hybridisation Buffer (40 % formamide, for in situ hybridisation) . 
As above, with 40% formamide and omission of dextran sulphate 
Hybridisation Buffer (20% formamide, for oligonucleotide probes) 
20% formamide 
5 X SSC 
50 mM phophate buffer, pH 6.8 
1 mM sodium pyrophosphate 
0.1% BSA (Bovine serum albumin) 
0.1% PVP (Polyvinylpyrrolidone) 
0.1% Ficoll 
2% SDS 
denatured salmon sperm DNA, added to 0.5 mg/ml before use 
LB broth 
10 g NaCI 
10 g tryptone 
5 g yeast extract, 
distilled water to IL, pH 7.0 
LB agar 
20 g agar in H. LB broth 
LB top agar 
0.7% w/v agarose in LB broth 
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10 X MOPS Buffer 
200 mM 3-[N-morpholino]propane-sulphonic acid (MOPS) 
50 mM sodium acetate 
10 mM EDTA 
Adjusted to pH 6.5-7.0 
NZY broth 
5 g NaC1 
2 g MgSO4 .7H20 
5 g yeast extract 
10 g NZ amine (casein hydrolysate) 
distilled water to 1 L, pH 7.5 
NZY agar 
15 g agar in 1 L NZY broth 
NZY top agar 
0.7% w/v agarose in NZY broth 
Paraformaldehyde fixative 
4% w/v paraformaldehyde dissolved in 500 ml distilled water at 60°C, 
cleared by addition of several drops of 10 M NaOH. 
500 ml 0.2 M phosphate buffer 
10 X PBS 
80 g NaC1 
13 g Na2HPO4 
2 g NaH2PO4 
in 1 L distilled water, pH 7.2 
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0.2 M Phosphate buffer 
3.59 g NaH2PO4.2H20 
10.93 g Na2HPO4, anhydrous 
dissolved in 500 ml distilled water, pH 7.25 
5 X RNA loading buffer 
50% glycerol 
1 mM EDTA, pH8.0 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
SM Buffer 
5.8 g NaC1 
2.0 g MgSO4.7H20 
50 ml 1 M Tris.HCI, pH 7.5 
5.0 ml 2% (w/v) gelatin 
dd water to 1 L 
Solution D 
250 g guanidinium thiocyanate in 293 ml distilled water 
17.6 ml 0.75 M sodium citrate, pH 7.0 
26.4 ml 10% sarcosyl 
heated to 65°C and filter sterilized 
20 X SSC Buffer 
175.3 g NaC1 
• 88.2 g sodium citrate 
distilled water to 1 L, pH 7.0 
1 X TAE Buffer 
40 mM Tris.acetate 
1 mM EDTA, pH 8.0 
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10 X TBE Buffer 
121 g Tris.base 
61.7 g boric acid 
7.44 g EDTA, pH 8.3 
TBS •
6 g Tris.base 
8.8 g NaC1 
in 1 L distilled water, pH 7.6 
TE 
10 mM Tris.HC1, pH 7.4 
1mM EDTA 
TES 
0.1 M NaC1 in TE 
2.2 Cloning techniques 
Unless otherwise specified the cloning techniques used were as outlined in 
Sambrook etal. (1989). 
2.2.1 Preparation of insert and vector DNA 
Plasmid DNA was cleaved with restriction endonucleases (Pharmacia), using 1 
unit of endonuclease per pig of DNA in reaction buffer supplemented with 0.1 mg/ml 
BSA. The DNA was electrophoresed through 0.75% agarose/1 X TBE, visualised by 
ethidium bromide staining, and the required DNA fragments excised from the gel. A 
hole was made in a 0.5 ml eppendorf tube with a 19 gauge needle and glass wool was 
placed in the bottom. The 0.5 ml eppendorf tube was placed inside a 1.5 ml 
eppendorf tube. The DNA was removed from the agarose by centrifugation at 7000 g 
for 3 min through the glass wool and collected in the 1.5 ml eppendorf tube. The 
DNA was then recovered from the elute by ethanol precipitation. DNA fragments 
28 
amplified by PCR were electrophoresed through 1.4% agarose/1 X TBE and purified 
similarly. 
Vector DNA was digested with appropriate restriction endonucleases, and the 
linearized vector treated with calf-intestinal alkaline phosphatase (Pharmacia) to 
remove the 5'-phosphate groups and prevent recircularisation of the vector. The 
DNA was incubated for 30 min at 37°C with 1 unit of alkaline phosphatase. The 
reaction was phenol/chloroform extracted and the vector DNA recovered by ethanol 
precipitation. 
2.2.2 Bluntending of DNA ends 
DNA fragments isolated for subcloning into vectors, and linearized vectors 
were bluntended when necessary using mung bean nuclease (Promega) or Pfu DNA 
polymerase (Stratagene). DNA was incubated for 1 hr with 4.5 units of mung bean 
nuclease at 37°C, phenol/chloroform extracted and the DNA recovered by ethanol 
precipitation. Alternatively, DNA was incubated with 2.5 units of Pfu DNA 
polymerase for 30 min at 72°C in reaction buffer containing 1 mM dNTPs (Promega), 
and the DNA used directly in ligation reactions. 
22.3 Ligation of insert DNA into vectors 
Insert DNA (typically at 3 molar excess) was ligated into linearized vector 
DNA (50 ng) using T4 DNA ligase (New England Biolabs). Reactions were 
incubated for 16 to 24 hr at 16°C with excess ligase (50 to 500 units). 
2.2.4 Preparation and transformation of competent cells 
L-broth (100 ml) was innoculated with 1 ml of overnight bacterial culture, and 
incubated with shaking at 37°C until an 0.D. 650 „„, of 0.4-0.5 was reached for MC1061 
bacterial cells, or 0.D.590. of 0.5-0.6 was reached for JM101 bacterial cells. The 
cells were centrifuged at 7000 g for 5 min at 2°C, the cell pellet resuspended in 20 ml 
of ice cold 50 mM CaCl2 and the cell suspension incubated on ice for 30 min. The 
cells were pelleted by centrifugation at 7000 g for 5 min, and resuspended in 3.33 mls 
ice cold 50 mM CaCl2. 
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Competent cells (200 pl) were incubated with DNA (half of a ligation reaction 
or typically 2 ng of plasmid DNA) for 40 min on ice. The cells were heat shocked by 
incubation at 42°C for 90 secs. Transformations (1/10 th and 9/10 th of the cells) 
were plated onto L-agar plates containing the appropriate antibiotics, and incubated 
for 16 hr at 37°C 
2.2.5 Detection of recombinant clones 
The method used to transfer bacterial colonies to nitrocellulose filters was 
based on that of Grunstein and Hogness (1975). Nitrocellulose filters (0.45 gm, 
Schleicher and Schuell) marked with ink were lowered onto bacterial colonies on agar 
plates for 2 min and the markings transferred to the bottom of the plates. The filters 
were placed on blotting paper soaked in 0.5 M Na0H/0.5 M NaC1 for 5 min to lyse 
the bacteria and fix the DNA, transferred to blotting paper soaked in 2 M NaC1/0.5 M 
Tris.HC1, pH 7.0 for 10 min, then rinsed in 2 X SSC. The filters were baked under 
vacuum for 2 hr at 80°C. 
The filters were prehybridised in DNA hybridisation buffer for 1 hr, then 
hybridised in the same buffer with the addition of a radioactive probe for 16 hr at 
55°C to 65°C depending on the specificity of the probe. The filters were washed in 
0.2 X SSC, 1% SDS at temperatures up to 55°C to remove background radioactivity. 
The filters were exposed to autoradiography film (Hyperfilm-MP, Amersham) and the 
developed autoradiograph aligned against the filters and agar plates to select 
recombinant clones. 
2.2.6 Isolation of plasmid DNA by alkaline lysis 
L-broth (100 ml) containing the appropriate antibiotics was innoculated with 
plasmid containing bacteria and incubated at 37°C overnight. The cultures were 
centrifuged for 15 min at 7000 g and the pellet suspended in 4 ml of lysis buffer 1 (50 
mM glucose, 25 inM Tris.HC1, 10 mM EDTA, 20 mg/ml lysozyme [Boehringer-
Mannheim]). After a 5 min incubation at room temperature, 8 ml of buffer 2 (0.2 M 
NaOH, 1% SDS) was added and incubated on ice for 10 min, followed by 6 ml of 
buffer 3 (5 M K-acetate, pH 4.8) and a further 10 min incubation on ice. After 
centrifugation at 17000 g for 20 min, the supernatant was removed and 
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phenol/chloroform extracted. The DNA was precipitated by addition of 0.6 volumes 
of isopropanol. The DNA was pelleted by centrifugation at 10000 g for 30 min, 
washed in 70% ethanol, and dissolved in 0.5 ml TE. The DNA was treated with 
RNAase (100 pg/ml, Boehringer-Mannheim) for 30 min at 37°C, then pronase (100 
pg/ml, Boehringer-Mannheim) for 30 min at 37°C, phenol/chloroform extracted and 
ethanol precipitated at -20°C overnight. The DNA was pelleted, washed with 70% 
ethanol, dried and dissolved in 200 gl of TE. 
2.2.7 Caesiunt chloride purification of DNA 
DNA was isolated by alkaline lysis from 500 ml cultures, and dissolved in 2.4 
ml TE, then purified with caesium chloride as follows. To the DNA solution was 
added 0.6 ml of 2.5 M NaC1/50% PEG (polyethylene glycol). This was mixed by 
inversion and incubated on ice for 2 hr. The DNA was pelleted by centrifugation at 
3000 g for 1.5 min, and dissolved in 5 ml TES. Caesium chloride (8 g) and ethidium 
bromide (0.6 ml, of 10 mg/ml) was added to the DNA and incubated on ice for 30 
min. The solution was centrifuged at 12000 g for 30 min to pellet the PEG precipitate. 
, The DNA solution was decanted, and 1.5 ml TES added. The solution was 
centrifuged at 100000 g for 40 hr at 18°C. The lower DNA band was removed with a 
syringe and extracted 4 times with n-butanol equilibrated against TE to remove the 
ethidium bromide. The DNA was dialysed against TE buffer. 
2.3 Genomic DNA and RNA isolation and analysis 
Unless otherwise specified the DNA and RNA analysis techniques used were 
as outlined in Sambrook et al. (1989). 
2.3.1 Isolation of genomic DNA from frozen tissue 
Frozen tissue (up to 1 g) was ground under liquid nitrogen, then homogenized 
in 10 ml of ice cold N.K.M buffer (150 mM NaCI, 5 mM KC1, 2 niM MgC12). The 
nuclei were pelleted by centrifugation at 600 g for 5 min. The nuclei were suspended 
in 1 ml of N.K.M buffer and added dropwise to 5 ml of P.K.B. buffer (10 mM NaCl, 
10 mM Tris.HC1, pH 8, 10 mM EDTA, 0.5% SDS) containing 100 pi of 20 mg/ml 
proteinase K (Boehringer-Mannheim). This was mixed gently and incubated at 37°C 
for 16 hr. The DNA solution was phenol/chloroform extracted twice, chloroform 
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extracted and the DNA was ethanol precipitated. The DNA was spooled, washed in 
70%, then 100% ethanol, dried and dissolved in 0.5 ml TE. RNAase (Boehringer-
Mannheim) was added to a final concentration of 100 pg/m1 and incubated for 1 hr at 
37°C. The DNA was recovered by phenol/chloroform extraction and ethanol 
precipitation. The DNA was then dialysed in TE and quantitiated by measuring the 
optical density at 260nm (1 0.D.= 50 pg/ml). 
2.3.2 Southern analysis of genomic DNA 
DNA (15 .t.g) was digested with appropriate restriction endonucleases 
(Pharmacia) and electrophoresed through a 1% agarose/1 X TBE gel at 25 volts, for 
24 hr. The DNA was visualised by ethidium bromide staining and transferred to a 
nylon membrane (Zeta-Probe GT, BioRad) by alkaline blotting (0.4 M NaOH) for 16 
hr. The membrane was rinsed in 2 X SSC, then baked for 30 min at 80°C. 
The membrane was sandwiched between hardened filter paper (Whatman, 
#54), sealed in a plastic bag in hybridisation buffer (50% formamide for cDNA probes 
or 20% formamide for oligonucleotide probes) and prehybridised for 1 hr at 37°C. A 
radioactive probe was added to the same buffer and incubated for 16 to 24 hr at 37°C 
to 42°C, depending on the specificity of the probe. 
The membrane was washed in SSC/SDS buffers generally to a stringency of 
37°C in 0.2 X SSC, 1% SDS, although temperatures up to 65°C were used to remove 
background radioactivity. The membrane was sealed in plastic wrap, and exposed to 
autoradiography film (Hyperfilm MP, Amersham) in a cassette containing intensifying 
screens at -80°C. 
2.3.3 Isolation of total RNA from frozen tissue 
RNA was isolated by the method of Chomczynski and Sacchi (1987) with 
some modifications. Frozen tissue (0.5 g) was ground under liquid nitrogen and 
homogenized in 10 ml of guanidinium buffer (Solution D). To this was added, 1 ml of 
2 M sodium acetate pH 4.5, 10 ml TE-saturated phenol, 2 ml chloroform, and 40 pl 
isoamyl alcohol, with mixing after each addition. After centrifugation (15000 g, 10 
min) the aqueous layer was collected and the RNA precipitated by addition of an 
equal volume of isopropanol, and incubation for 16 hr at -20°C. The RNA was 
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recovered by centrifugation (10000 g, 15 min), washed with 70% ethanol, and dried. 
The pellet was dissolved in either 0.5% SDS or in DEPC-treated water if to be used 
for reverse-transcription. The RNA was quantitated by measuring the optical density 
at 260 nm (1 0.D.= 40 pg/m1). In some instances "mock extractions" were carried 
out in parallel with RNA isolations from cells or tissues. In these instances the 
isolation procedure was carried out as above but no tissue or cells were added to the 
Solution D. These extractions were used to check for contamination in the isolation 
materials. 
2.3.4 Isolation of total RNA from cultured cells 
RNA was isolated as above with some modification. RNA was isolated from 
adherent cells by removing the media, washing the cells with PBS, and adding 5 ml of 
Solution D directly to the cells. Cells in suspension were pelleted (1000g, 5 min), 
washed with PBS, and then solubilized in 5 ml of Solution D. Extractions were then 
carried out as above, except that all quantities were halved. 
2.3.5 Northern analysis of RNA • 
RNA (typically 50 pg) was denatured by incubation at 65°C for 15 min in 
16% formaldehyde and 45% deionised formamide. Once cool, RNA loading buffer 
and ethidium bromide (0.04 mg/ml final concentration) were added and the RNA 
electrophoresed through a 1.2% agarose denaturing gel (2.2 M formaldehyde in 1 X 
MOPS buffer). RNA was transferred to a nylon membrane (Zeta-Probe GT, BioRad) 
by alkaline blotting (0.05 M NaOH) for 6 to 8 hr. The membrane was washed in 2 X 
SSC then baked for 30 min at 80°C. 
The membrane was sandwiched between pieces of hardened filter paper 
(Whatman, #54) and sealed into a plastic bag with hybridisation buffer and a 
radiolabelled probe. For cDNA probes a 50% formamide buffer was used, while for 
oligonucleotide probes a 20% formamide buffer was used. The membrane was 
hybridised for 16 to 24 hr at 37°C to 42°C depending on the specificity of the probe. 
The membrane was washed in SSC/SDS buffers generally to a stringency of 37°C in 
0.2 X SSC, 1%SDS, although temperatures up to 65°C were used to remove 
background radioactivity. 
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The membrane was sealed in plastic film (Gladwrap) and exposed to 
autoradiographic film (Hyperfilm MP, Amersham) in a cassete with intensifying 
screens (Amersham), at -80°C. The autoradiographic film was pre-flashed using the 
Sensitize 	unit (Amersham) before exposure to the membrane. 
2.3.6 Removing probes from nylon membranes 
Radioactive probes were stripped from nylon membranes (Zeta-Probe GT, Bio 
Rad) by incubation in 0.5% SDS, 0.1 X SSC for 2 X 20 min at 95°C. Membranes 
were rinsed in 0.2 X SSC and stored between sheets of bloting paper. 
2.3.7 cDNA probes 
•general MT probe: 
A 279 bp human MT2A RT-PCR transcript produced by RT-PCR of HeLa cel RNA 
and cloned into pSP64 (as described in F.A.Stennard, Ph.D. Thesis). 
•human MT1B gene-specific probe: 
The HindlUBamH1 5' flanking region of the human MT1B gene (as described in 
A.K.West, Ph.D. Thesis). 
•human 0-actin probe 
Approximately ful length cDNA for human fibroblast cytoplasmic I3-actin cloned into 
the Okayama-Berg cDNA cloning expression vector (Ponte etal., 1984). 
•Glial fibrilary acidic protein (GFAP) probe 
Mouse GFAP cDNA cloned into pBR322 (Lewis etal., 1984). 
2.3.8 Radiolabeling of cDNA probes 
Plasmids containing the required cDNA insert were digested with restriction 
endonucleases (Pharmacia). The released cDNA insert was purified as outlined in 
section 2.2.1. The DNA (25-50 ng) was denatured by boiling for 5 min and labeled 
with a-32PdCTP (Bresatec) in the folowing reaction using the T7QuickPrime Kit 
(Pharmacia): 
34 pl denatured DNA 
10 p.I reagent mix 
5 p.1 a-32PdCTP (3000 Ci/mmol) 
34 
1 Al T7 DNA Polymerase 
The reaction was incubated for 30 min at 37°C, and the unincorporated label 
removed by running the reaction through a G50 Sephadex column. The labeled 
cDNA was denatured by boiling for 5 min before addition to the hybridisation bufer. 
Hybridisation of cDNA probes was in hybridisation bufer containing 50% formarnide. 
2.3.9 Oligonucleotide probes 
The folowing oligonucleotides were used in northern analysis or in situ 
hybridisation. The oligonucleotides hybridise to the 3' or 5' flanking regions of the 
respective genes, and are designed such that there is no crossreactivity with the other 
human MT genes. The oligonucleotides were prepared by the Bresatec or Auspep 
companies. 
Gene 	 Oligonucleotide 
human MT2A (20mer) 	 5'-ATC CAG GTT TGT GGA AGT CG-3' 
human MT1A (20mer) 	 5'-ATG GGT CAG GOT TGT ATG GA-3' 
human MT1E (20mer) 	 5'-CAA AGG GGA TGC TGG AGC TC-3' 
human MT1F (20mer) 	 5'-GAG AGA CTG GAC ITT CCA AG-3' 
human MT1G (21mer) 	 5'-GGT CAC TCT ATT TGT ACT TGG-3' 
human MT1H (24mer) 	 5'-CGT GTC ATT CTG TTT TCA TCT GAC-3' 
human MT1L (18mer) 	 5'-AAA TGA CGG GAG AGG CGA-3' 
human MT1X(24mer) 	 5'-GCT CTA TTT ACA TCT GAG AGC ACA-3' 
human 13-actin (21mer) 	 5'-CAC ACT TCA TGA TGG AGT TGA-3' 
sheep MT-II (18mer) 	 5'-TTT CAC ACG GGA CAG TGG-3' 
conserved MT-I/II (19mer) 5'-GCA GCC CTG GGC ACA CTT 0-3' 
2.3.10 Radiolabeling of oligonucleotide probes 
Oligonucleotides were radiolabeled under the folowing conditions using 
reagents in a 5'-terminal kinasing kit (Bresatec) and y-32PATP (Bresatec): 
21AI 10 X TM bufer 
2 pl 100 mM DTT 
100-500 ng oligonucleotide 
10111y-32PATP (4000 Ci/mmol) 
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sterile water to 19 pl 
1 pl T4 polynucleotide lcinase 
The reaction was incubated for 20 min at 37°C, then the kinase was 
deactivated by heating to 65°C for 5 min. Unincorporated label was removed by 
loading the sample onto a G25 Sephadex column and centrifuging it at 800 g for 5 
min. The eluted labelled oligonucleotide was boiled for 5 min before addition to 
hybridisation buffer. Hybridisation of oligonucleotide probes was in 20% formamide 
hybridisation buffer. 
2.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
Unless otherwise specified the techniques used were as outlined in Sambrook 
etal. (1989) with some modification: 
2.4.1 Reverse Transcription 
Total RNA (1 jig) was reverse transcribed under the following conditions, using 
reagents supplied by Promega: 
4 p.1 5 X First Strand Buffer (250 mM Tris.HCI, pH 8.3, 375 mM KC1, 15 mM 
MgCl2) 
2 pl DTT (1 niM stock, 100 pM final concentration) 
4 pl dNTP ( 2.5 mM stock, 0.5 mM final concentration of each) 
1 pl oligonucleotide (random hexamers or oligo d(T)16, 10 pg/m1 final 
concentration) 
lpg RNA 
1 piRNasin 
1 p.1 M-MLV Reverse Transcriptase (200 units) 
DEPC-treated dd water to a final volume of 20 pl 
The reaction was incubated at room temperature for 10 min, then 1 hr at 37°C. The 
reverse transcriptase was deactivated at 99°C for 5 min. 
2.9.2 Polymerase Chain Reaction 
DNA or cDNA was amplified by polymerase chain reaction under the following 
conditions: 
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2.5 pl 10 X PCR bufer (100 mM Tris.HC1, 15 triM MgC12, 500 mM KC1, pH 
8.3) 
2.5 IAldNTPs (2.5 mM stock, 250 pM final concentration, Promega) 
1 pi forward primer (10 pM stock, 0.04 pM final concentration) 
1 pl reverse primer (10 1AM stock, 0.04 pM final concentration) 
0.5 pi Taq (2.5 Units, Boehringer-Mannheim) 
10 ng cDNA 
dd water to a final volume of 25 pl 
PCR was performed in a DNA thermocycler (Perkin Elmer Cetus), using the 
folowing cycle sequence: 
95°C, 2 min 
95°C, 1 mini 
60°C, 1 min (35 cycles) 
72°C, 1 mini 
72°C, 7 min 
In some circumstances an annealing temperature other than 60°C was used, 
and in these cases the annealing temperature is specificaly indicated where 
appropriate in the text. 
2.4.3 PCR primers 
The folowing PCR primers were designed to the 5' and 3' flanking regions of 
the human MT genes, such that they do not amplify other MT genes. Those PCR 
primer pairs taken from published reports are referenced appropriately. Primers were 
obtained from Bresatec or Auspep. 
Primer 	 Primer sequence  
•human MT2A primers (F.A.Stennard, Ph.D. Thesis) 
hMT2A sense (20mer) 	 5'-GCA ACC TGT CCC GAC TCT AG-3' 
hMT2A antisense (20mer) 5'-ATC CAG GTT TGT GGA AGT CG-3' 
•human MT1H primers (F.A.Stennard, Ph.D. Thesis) 
hMT1H sense (20mer) 	 5'-CGT GTT CCA CTG CCT CTT CT-3' 
hMT1H antisense (24mer) 5'-CGT GTC ATT CTG TTT TCA TCT GAC-3' 
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•human MT1L primers 
hMT1L sense (18mer) 	 5'-TGC CCT CTC CCG TCA TTT-3' 
hMT1L antisense (16mer) 5'-AGC AGG GCT GTC CCC A-3' 
•human MTIX primers (F.A.Stennard, Ph.D. Thesis) 
hMT1X sense (20mer) 	 5'-AAC TCC TGC TTC TCC TTG CC-3' 
hMT1X antisense (24mer) 5'-GCT CTA TTT ACA TCT GAG AGC ACA-3' 
•human MT-II primers (F.A.Stennard, Ph.D Thesis) 
human MT-II sense (19mer) 	 5'-CGA CAT GGA CCC TGA GAC C-3' 
human MT-II antisense (17mer) 	 5'-GCC TCA GCT GCC TCT CC-3' 
•human actin primers (F.A.Stennard, Ph.D. Thesis) 
human actin sense (20mer) 	 5'-CAT CCT CAC CCT GAA GTA CC-3' 
human actin antisense (21mer) 	 5'-CAC ACT TCA TGA TGG AGT TGA-3 
•mouse MT-II primers 
mouse MT-II sense (20mer) 	 5'-TGG ATA TGG ACC CTG AGA CC-3' 
mouse MT-III antisense #1 (16mer) 5'-CCT TGG CCC CCT CTT C-3' 
mouse MT-III antisense #2 (19mer) 5'-GTT GTG CCC CAC CAG GGA C-3' 
•the antisense #1 primer is designed to the 3'flanlcing region of the MT-II gene, the 
antisense #2 primer is designed to the third exon of the MT-II gene. 
•MT-II degenerate primers (Palmiter etal., 1992) 
MT-II degenerate sense (11mer) 	 5'-ATG GA(CT) CC(AGCT) GA(AG) AC-3' 
MT-II degenerate antisense (10mer) 5'-CA(CT) TT(CT) TC(AGCT) GC(CT) TC-3' 
2.5 DNA sequencing 
2.5.1 Sanger dideoxy sequencing 
The Sanger dideoxy sequencing method used was as outlined in Sambrook et 
al. (1989). Double stranded fragments cloned into pUC19 were purified using Magic 
Minipreps (Promega) and sequenced using Sequenase version 2 (USB). The pUC 
38 
forward or reverse primers were annealed to the template to act as a priming site. 
Fragments incorporating 35 SdATP (Bresatec) were electrophoresed through 
polyacrylamide gradient gels and detected by autoradiography. 
2.5.2 Automated sequencing 
The ABI PRISMTm Dye Primer Cycle Sequencing Reaction Kit (Perkin Elmer 
Cetus) and ABI PRISM Tm Dye Terminator Cycle Sequencing Reaction Kit (Perkin 
Elmer Cetus) were used for DNA sequencing. Double stranded plasmids in pUC19 or 
pBK-CMV were purified using the QIAGEN Plasmid mini kit (QIAGEN) and the 
Cycle Sequencing Reaction Kits were used according to the manufacturers 
instructions. 
PCR products were purified for sequencing as outlined in section 2.2.1, and 
the ABI PRISMTm Dye Terminator Cycle Sequencing Reaction Kit used according to 
the manufacturers instructions. Primers specific for the PCR product including those 
outlined in section 2.4.3 were used. An ABI Prism 377 DNA Sequencer (Perkin 
Elmer Cetus) was used for automated sequencing. 
2.6 Immunocytochemistry and In situ hybridisation 
2.6.1 Fixation of Tissues 
Tissues were fixed in Bouin's fixative for immunocytochemistry and in 
paraformaldehyde fixative for in situ hybridisation. 
Immediately after dissection tissues were immersed in Bouin's fixative for 9-16 
hr depending on the size of the tissue. Tissues were dehydrated through graded 
alcohols, cleared in chloroform and embedded in paraffin wax (MP 56°C). Sections 
were cut 5 pm thick and floated onto poly-L-lysine (Sigma) treated slides or silanized 
slides (DAKO). 
Immediately after dissection tissues were immersed in paraformaldehyde 
fixative for 12-24 hr depending on the size of the tissue. Tissues were rinsed in 0.1 M 
phosphate buffer for 3 X 10 min, rinsed briefly in distilled water and dehydrated 
through graded alcohols. Tissues were cleared in chloroform and embedded in 
paraffin wax (MP 56°C). Sections were cut 5 j.tm thick and floated onto silanized 
slides (DAKO). 
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2.6.2 Immunocytochemical staining 
The enzyme-labelled streptavidin technique was used for immunocytochemical 
staining (Giorno, 1984). 
Sections were dewaxed in xylene (2 X 10 min) and rehydrated in graded 
alcohols (absolute ethanol, 5 min; 95% ethanol, 5 min). Endogenous peroxidase 
activity was removed by incubating the sections in 0.3% H 202 in methanol for 30 min. 
Sections were further rehydrated (95% ethanol, 5 min; 70% ethanol, 5 min), then 
washed in phosphate buffered saline (PBS) containing 0.01% v/v nonidet P-40 (PBS-
NiP) for 3 X 10 min. Sections were incubated in blocker solution; 10% gelatin 
solution (Amersham) in PBS-NiP for 30 min in a humidified box. 
Primary antiserum, diluted in blocker solution was applied to the sections for 
16 hr at 4°C in a humidified box. After washing in PBS-NiP for 3 X 10 mm the 
sections were incubated in the blocker solution for 20 min. Secondary antibody, 
diluted in blocker solution was applied to the sections for 1 hr at 37°C. After washing 
and blocking the sections again, they were incubated for 1 hr at 37°C with 
peroxidase-conjugated streptavidin diluted in blocker solution. The sections were 
again washed in PBS-NiP for 3 X 10 min, then in PBS for 5 min and Tris buffered 
saline (TBS) for a further 5 min. Peroxidase activity was visualised with 0.02% 3,3'- 
diaminobenzidine (Sigma) and 0.003% H202 TBS. The sections were dehydrated in 
graded alcohols, cleared in xylene and mounted in D.P.X. (Koch-Light Laboratories, 
Ltd) 
2.6.3 Fluorescent immunocytochemical staining 
Tissue sections were double-labelled with 1: anti-MT and anti-GFAP, 2: anti-
MT and anti-S100 and 3: anti-MT and anti-Gal-C antibodies. Immunoreactivity was 
visualised with fluorescent secondary antibodies. The antibody staining was visualised 
with either Fluoroscein anti-mouse IgG or with anti-rabbit IgG - Texas Red Avidin D. 
The same method as above was used for fluorescent labelling but with several 
modifications as follows. The sections were incubated with the secondary antibodies 
(fluoroscein anti-mouse IgG or anti-rabbit IgG) for 2 hr at 37°C and the Texas Red 
Avidin D for 1 hr at 37°C. After incubation with Texas Red the sections were washed 
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in PBS-NiP for 3 X 10 mm, PBS for 5 mm, mounted in buffered glycerol and 
photographed. 
2.6.4 Controls for inununocytochemisny 
Control sections for immunocytochemistry were prepared by the procedures 
outlined above but with the omission of one of the antibodies. Control sections were 
prepared omitting all primary antibodies, all secondary antibodies and also the 
peroxidase conjugated streptavidin and Texas Red Avidin. 
Control sections were also prepared using anti-MT antibody which had been 
preadsorbed with horse kidney MT-I and -II protein (Sigma). An aliquot of anti-MT 
antibody was incubated with a 10:1 ratio of MT protein for 1 hr at 37°C, then 16 hr at 
4°C. Before use the antibody was centrifuged at 13000 g for 15 min. 
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2.6.5 Antibodies and dilutions 
The following antibodies were used in immunocytochemistry at the specified dilutions. 
Immunocytochemistrv 
Primary antibody Secondary antibody Tertiary antibody 
Monoclonal anti-MT (E9, 
Accurate Chemical and 
Scientific Corporation), 
1:50 
Biotinylated anti-mouse IgG 
(Biogenex), 1:50 
. 
Peroxidase conjugated 
streptavidin (Biogenex), 
1:100 
Monoclonal anti-GFAP 
(Boehringer Mannheim), 1:4 
Biotinylated anti-mouse IgG 
(Biogenex), 1:50 
Peroxidase conjugated 
streptavidin (Biogenex), 
1:100 
Rabbit anti-S100 (DAKO), 
1:50 
Biotinylated anti-rabbit IgG 
(Biogenex), 1:50 
Peroxidase conjugated 
streptavidin (Biogenex), 
1:100 
Monoclonal anti-PCNA 
(Zymed), 1:200 
Biotinylated anti-mouse IgG 
(Biogenex), 1:50 
Peroxidase conjugated 
streptavidin (Biogenex), 
1:100 
Fluorescent Immunocvtochemistrv 
Primary antibody Secondary antibody Tertiary antibody 
Monoclonal anti-MT (E9, 
Accurate Chemical and 
Scientific Corporation), 
1:25 
Fluoroscein anti-mouse IgG 
(Vector), 1:200 
- 
Rabbit anti-GFAP (DAKO), 
1:50 
Biotinylated anti-rabbit IgG 
(Vector), 1:200 
Texas Red Avidin D 
(Vector), 1:200 
Rabbit anti-S100 (DAKO), 
1:50 
BiOtinylated anti-rabbit IgG 
(Vector), 1:200 
Texas Red Avidin D 
(Vector), 1:200 
Rabbit anti-Gal-C (Sigma), 
1:25 
Biotinylated anti-rabbit IgG 
(Vector), 1:200 
Texas Red Avidin D 
(Vector), 1:200 
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2.6.6 In situ hybridisation 
In situ hybridisation was by the method described by Penschow and Coghlan 
(1994). Sections were dewaxed in xylene, rehydrated through alcohols and rinsed in 
distilled water. Sections were transferred to TE buffer (50 tnM Tris.HC1, pH 7.5, 5 
tnM EDTA). An aliquot of 625 ptl of frozen pro nase E stock (40 mg/ml) which had 
been predigested for 4 hr at 37°C was added to 200 ml of prewanned TE buffer. The 
sections were incubated in this buffer for 10 min at 37°C. The tissue sections were 
rinsed in 0.1 M phosphate buffer and post fixed in 4% paraformaldehyde for 10 min at 
room temperature. The slides were rinsed in 4 X SSC and transferred to 
prehybridisation buffer. Radiolabelled oligonucleotide probes were added to tissue 
sections at a concentration of 300 ng/ml in 40% formamide hybridisation buffer. 
Sections were covered with coverslips and groups of slides were covered with plastic 
film (Gladwrap) and hybridised in a humid chamber for 16 to 24 hr at 37°C for 
general probes and 42°C for specific probes. After hybridisation sections were 
washed briefly in 2 X SSC, 1 X SSC, followed by a 1 hr wash in 1 X SSC at 40°C 
and a 30 min wash in 1 X SSC at 60°C. Sections were washed in ethanol, dried, and 
exposed to autoradiography film (Hyperfilm MP, Amersham) and then to liquid 
emulsion (Amersham) according to the manufacturer's directions. 
2.7 Tissue Culture 
2.7.1 Media and Reagents 
All media and reagents were of tissue culture grade: 
• Dulbecco's modification of Eagle's Medium (DMEM, Commonwealth Serum 
Laboratories) 
• Solution PS (Penicillin G, 5000 U/ml, streptomycin sulphate, 5000 pg/ml, 
Commonwealth Serum Laboratories) 
• 200 mM glutamine solution (2.92%), (Commonwealth Serum Laboratories) 
• RPMI-1640 medium (Sigma) 
• Foetal bovine serum (FBS, Commonwealth Serum Laboratories) 
• 10 X Hanks' balanced salts solution (modified) (10 X HBS, ICN) 
• Dulbecco's phosphate buffered salts (modified, without calcium and magnesium) 
(PBS, ICN) 
43 
• calcium chloride (Sigma) 
• HEPES (N-2-Hydroxyethyl piperazine-N-2-ethane sulphonic acid) (BDH) 
• Trypsin-Versene (Commonwealth Serum Laboratories) 
• All tissue culture flasks and equipment were from Falcon 
• 2.7.2 Maintenance of cultured cell lines 
Unless specified tissue culture techniques were as oulined by Adams (1980). 
COS cells, HeLa cells and embryonic fibroblasts were maintained in 
Dulbecco's modification of Eagle's Medium (DMEM, CSL) supplemented with 10% 
FBS, 2% penicillin/streptomycin solution (solution PS, CSL) and 2% glutamine 
solution (200 mM glutamine solution, 2.92%, CSL). Cells were subcultured by 
removing the adherent cells from the bottom of the flask using trypsin versene. Cells 
were maintained in an atmosphere of 5% CO2 at 37°C. 
Lymphocyte cell lines (K562 and CEM) were maintained in RPMI-1640 
medium (Sigma), supplemented with 5% FBS, 2% penicillin/streptomycin solution 
(PS solution, CSL) and 2% glutamine solution (200mM glutamine solution, CSL). 
Cells were maintained in an atmosphere of 5% CO2 at 37°C. 
2.7.3 Calcium phosphate mediated transfections 
The calcium phosphate mediated transfection protocol was as described by 
Keown etal., (1990). Adherent cells were grown to 50-80% confluency in 25 cm 2 
tissue culture flasks. The media was replaced with 3.5 ml of fresh media 4 hours 
before transfection. Caesium chloride purified plasmid DNA (20 i..tg) was 
precipitated, washed with 70% ethanol and dissolved in sterile TE (220 p1). A 30 IA 
aliquot of 2 M CaC1 2 in 10 mM HEPES was added to the DNA solution and mixed 
well. The calcium/DNA solution was added slowly to 250 pi of 2 X FIBS, 40 mM 
HEPES, pH 6.95-7.05, with vigorous bubbling, and incubated for 30 min at room 
temperature. This solution was added to the cells and incubated overnight at 37°C in 
5% CO2 overnight. After incubation, the cells were washed twice with DMEM and 
the media replaced. 
44 
2.7.4 Preparation of embryonic fibroblasts 
Embryonic mouse fibroblasts were prepared by the method of Harvey et al. 
(1993), with some modification. Pregnant mice were sacrificed by carbon dioxide 
asphyxiation, and the E14 embryos removed into a sterile petri dish. In a laminar flow 
hood the embryos were placed in a clean petri dish and rinsed in PBS. The head, tail 
and liver of the embryos were removed and the remaining embryonic tissue (from 3-4 
embryos) was homogenised by forcing the tissue through a 19 gauge needle on a 
syringe with 0.1 ml DMEM. A further 5 ml of DMEM was added to the 
homogenised tissue and centrifuged for 5 min at 1000 g. The DMEM was removed, 
the cells resuspended in 10 ml of fresh DMEM and recentrifuged. The cell pellet was 
resuspended in 5 ml of fresh DMEM (supplemented with FBS, glutamine and 
penicillin/streptomycin solution) and incubated for 6 hr in an atmosphere of 5% CO2 
at 37°C in a 25 cm2 tissue culture flask. The medium was aspirated to remove clumps 
of tissues and cells which had not adhered to the bottom of the flask, and replaced 
with fresh medium. 
2.7.5 Radiolabelling cells 
Flasks of cells (25 cm2) were radiolabelled with 35 S-L-cysteine (1188Ci/mmol, 
10.09 mCi/m1; ICN). Media was removed from the cells and replaced with 1 ml of 
fresh media which is enough to cover the bottom of the tissue culture flask. 35 S-L-
cysteine (200 IACi) was added to the cells and incubated for 16 hours in 5% CO 2 at 
37°C. The media was removed from the cells, the cells were washed in PBS and 
harvested. 
2.8 Protein isolation and gel electrophoresis 
2.8.1 Isolation of protein from cultured cells 
Cells were scraped from the bottom of tissue culture flasks in 1 ml PBS with a 
rubber policeman, centrifuged for 1 min at 13000 g and resuspended in 25 of 
protein isolation buffer (10 mM Tris.HC1, pH 7.4 / 0.15 M NaCl). Cells were lysed 
by freeze/thawing which involved submerging the cells alternately in a dry ice/ethanol 
bath and 37°C water bath. The cell membranes were removed by centrifugation for 5 
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min at 13000 g. The supernatant was heat denatured at 95°C for 2 mm and the heat 
unstable proteins removed by centrifugation for 5 min at 13000 g. 
2.8.2 Carboxymethylation of metallothionein protein 
Carboxymethylation of proteins was by the method of Koizumi and Kimura, 
(1982). To 25 pi of protein solution was added 12.51A1 of Tris.HC1 
carboxymethylation buffer (0.2 M Tris.HC1, pH 8.8, 8% SDS, 50% glycerol) and 5 pi 
of 0.2 M dithiothreitol (Boehringer-Mannheim). This was boiled for 5 min and after 
cooling, 7.5 p.1 of 1 M recrystalized iodoacetic acid, pH 8 was added to the solution 
and heated to 50°C for 15 min. To the protein solution, 5 ptl of 0.1% bromophenol 
blue was added before electrophoresis on a 15% polyacrylamide protein gel with a 
4.5% stacking gel. 
2.8.3 SDS polyacrylamide gel electrophoresis 
SDSPAGE of proteins was carried out as outlined in Sambrook etal. (1989). 
A 15% polyacrylamide gel was prepared containing 11.25 ml of lower gel buffer (1.5 
M Tris, 0.4% SDS, pH 8.8), 22.5 ml of acrylamide stock (30% acrylamide, 0.8% 
bisacrylamide) and 11.25 ml of distilled water. This was degased, 150 p.1 of 10% 
ammonium persulphate and 30 p.1 of TEMED added, the gel poured and allowed to 
set overnight. A 4.5% stacking gel, containing 5 ml stacking gel buffer (0.5 M Tris, 
0.4% SDS, pH 6.8), 3 ml of acrylamide stock and 12 ml of distilled water was 
degased, 80 p.1 of 10% ammonium persulphate and 20 pi of TEMED added and 
poured above the 15% gel. 
The gel was prerun in SDS running buffer (0.025 M Tris, 0.192 M glycine, 
0.1% SDS) for 1 hr before the radioactive samples and protein markers were added 
and electrophoresed for 6 hr at 125 volts. Lanes containing the protein markers were 
cut off the gel, stained with coomassie blue R-250 (0.05% in 50% methanol, 10% 
acetic acid) and destained in 7% acetic acid/5% methanol. Lanes containing the 
radioactive protein samples were dried in a gel drier (Model 583, BioRad) for 2 hr at 
60°C then 4 hr at 80°C, and exposed to autoradiography film (Hyperfilm-MP, 
Amersham). 
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2.8.4 13-galactosidase assays 
Assays were as outlined in Sambrook et al. (1989) with some modification. 
Cell extract (30 pl) was incubated with 1 pti of Mg solution (0.1 M MgC1 2 ; 4.5 M 13- 
mercaptoethanol), 22 gl of 1 X ONPG solution (4 mg/ml 2-nitropheny1-13-D-
galactopyranoside) and 47 pl of 0.1 M NaHPO 4 . Reactions were incubated for 30 
min at 37°C and stopped by addition of 167 ml of 1 M Na2CO3. Absorbances were 
measured at 420 nm using mock transfected cell extracts as a standard. Values for 13- 
galactosidase activity were determined using a standard curve. 
2.9 cDNA library construction 
Poly(A)+ mRNA was purified from total RNA using the Dynabeads mRNA 
Purification Kit (Dynal). Poly(A) + mRNA was then used in the construction of a 
cDNA library using the ZAP ExpressTM cDNA synthesis kit from Stratagene. 
2.9.1 Preparation of poly(Ar tnRNA 
The Dynabeads mRNA Purification Kit (Dynal) was used to purify poly(A) + 
mRNA from total RNA according to the manufacturer's directions. Briefly, 100 pi of 
RNA (75 i_tg) was heated to 65°C for 2 min, then added to 1.0 mg of oligo(dT)25 
Dynabeads suspended in 2 X binding buffer (20 mM Tris.HCI, pH 7.5, 1.0 M LiC1, 2 
mM EDTA). The RNA was hybridized to the beads for 5 min at room temperature, 
placed in the magnetic particle concentrater (Dynal MPC ®-E1) for 30 sec and the 
supernatant removed. The beads were washed twice with 200 pl of washing buffer 
(10 mM Tris.HC1, pH 7.5, 0.15 M LiC1, 1 mM EDTA). The poly(A) + mRNA was 
eluted in 20 p.1 of elution solution (2 mM EDTA, pH 7.5) by heating at 65°C for 2 
min, then removing the solution from the beads immediately. The integrity of the 
poly(A)+ mRNA was checked by electrophoresis of a sample through 1% agarose/1 X 
TBE and visualisation by ethidium bromide staining. 
2.9.2 cDNA synthesis and addition of EcoRI adaptors 
All reagents were supplied in the ZAP ExpressTM cDNA synthesis kit from 
Stratagene unless otherwise specified. 
First strand synthesis was performed under the following conditions: 
5.0 pi 10 X first strand buffer 
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3.0 p.1 first strand methyl nucleotide mixture 
2.0 pl linker-primer (1.4 pg/p1) 
1.0 pl RNase Block Ribonuclease Inhibitor (40 U/p1) 
37.5 p,1 poly(A) + RNA (3 lig) isolated as outlined above. 
The template and primer were allowed to anneal for 10 min at room temperature, then 
1.5 gl MMLV-RT (50 U/pl) added. A sample (5 p,1) of the reaction was added to 0.5 
p.1 of a,-32PdATP (3000.Ci/mmol, Bresatec). Both the reaction and radioactive 
sample were incubated at 37°C for 1 hr. A control first strand synthesis was set up as 
above using 5 p.1 of test poly(A) + RNA (0.2 pg/pl) provided with the kit. After 
incubation the radioactive sample was stored at -20°C for later analysis. 
Second strand synthesis was performed under the following conditions: 
45.0 pl first strand synthesis reaction 
20.0 p.110 X second strand buffer 
6.0 pi second strand nucleotide mixture 
88.9 pl sterile distilled water 
2.0 pi a-32PdATP (3000 Ci/mmol, Bresatec) 
2.0 pl RNase H (1.5 U/p1) 
11.1 pl DNA polymerase I (9.0 U/p1) 
The reaction was incubated at 16°C for 2.5 hr. The cDNA termini was bluntended by 
adding 23 pl blunting dNTP mix and 2.0 pl cloned Pfii DNA polymerase (2.5 U/p1) to 
the second strand synthesis reaction. The reaction was incubated at 72°C for 30 min. 
After incubation the reaction was phenol/chloroform extracted, chloroform extracted 
then the cDNA precipitated overnight at -20°C by the addition of 20 pl 3 M sodium 
acetate and 400 p.1100% ethanol. 
The cDNA was pelleted by centrifugation at 13000g for 60 min at 4°C. The 
radioactive supernatant was discarded and the pellet was washed with 500 pl of 70% 
ethanol. The pellet was lypholized until dry, then resuspended in 9.0 pl of EcoR I 
adapters and incubated at 4°C for 30 min. A sample (1.0 p.1) of the second strand 
synthesis reaction was removed at this stage and loaded onto an alkaline agarose gel 
with the radioactive sample of first strand synthesis reaction. After electrophoresis 
the gel was dried and autoradiographed. 
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EcoRI adaptors were ligated to the cDNA by adding the following 
components to the cDNA dissolved in EcoRI adaptor solution: 
1.0 pi 10 X ligase buffer 
1.Ojil 10 mM rATP 
1.0 i_t1 14 DNA ligase (4 U/p1) 
The reaction was incubated overnight at 8°C, then the ligase was heat inactivated by 
incubation at 70°C for 30 min. 
The EcoRI ends were kinased by addition of the following components to the 
above reaction: 
1.0 p.110 X ligase buffer 
2.0 p.1 10 rnM rATP 
6.0 1.1.1 sterile water 
1.0 p.1 14 polynucleotide lcinase (10 U/p1) 
The reaction was incubated for 30 min at 37°C, then heat inactivated by incubation 
for 30 min at 70°C. 
Xhol digestion of the cDNA was performed by addition of 28.0 ill XhoI buffer 
supplement and 3.0 IA XhoI (40 U/p.1) to the reaction above. The reaction was 
incubated for 1.5 hr at 37°C. 
2.9.3 Size fractionation of cDNA 
All reagents other than those required for electrophoresis were supplied with 
the ZAP ExpressTM cDNA synthesis kit from Stratagene. 
Size fractionation of the cDNA was performed using a Sephacryl S-500 spin 
column. The spin column was prepared by pipetting the sephacryl into a 1 ml syringe 
with a cotton plug inserted in the bottom. The column was spun at 400 g for 2 min, 
refilled and spun again. The column was washed with 2 X 300 p.1 of 1 X STE. The 
cDNA was pipetted into the top of the column and centrifuged at 400 g for 2 min, and 
the first fraction was collected. More fractions were collected by adding 60 IA 1 X 
STE to the top of the column and centrifuging to collect the eluent. The size of the 
cDNA in each fraction was determined by running 10% of each fraction on a 5% 
(29:1) nondenaturing acrylamide gel. The cDNA fractions were phenol/chloroform 
extracted, chloroform extracted and ethanol precipitated by addition of 2 X volume of 
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100% ethanol. The cDNA was precipitated overnight at -20°C. The cDNA was 
pelleted by centrifugation at 13000 g for 1 hr at 4°C, washed with 200 pl of 70% 
ethanol and dried under vacuum. The cDNA pellets (fractions 1 to 5 combined) were 
resuspended in 10.5 1.1.1 sterile water. 
2.9.4 Cloning of cDNA into the ZAPrm Express vector 
All reagents were supplied with the ZAP ExpressTM cDNA synthesis kit from 
Stratagene. Ligation of the cDNA into the ZAP Express vector arms was performed 
under the following conditions: 
2.5 pl resuspended cDNA (-100 ng, as determined by the cDNA ethidium 
bromide plate assay, section 2.10.1) 
0.5 ill 10 X ligase buffer 
0.5 pl 10 mM rATP (pH 7.5) 
1.0 pl ZAP Express vector (1 1.1g/ill) 
0.5 IA T4 DNA ligase (4 U/p1) 
The reaction was incubated overnight at 12°C. A test ligation was set up as follows: 
1.0 pl ZAP Express vector (1.0 pg/p1) 
1.6 pi test insert (0.4 pg) 
0.5 p.110 X ligase buffer 
0.5 p.110 mM rATP (pH 7.5) 
0.9 pl sterile water 
0.5 pi T4 DNA ligase (4 U/p1) 
2.9.5 Packaging a library 
The cDNA library was packaged using the ZAP ExpressTm cDNA Gigapack® 
II Gold Cloning kit. Packaging of the cDNA library was carried out by adding 2.5 pl 
of ligation reaction to a tube (10 p.1) of freeze-thaw extract (supplied in the ZAP 
ExpressTM cDNA Gigapack® II Gold Cloning kit) and placing it on ice. A sample (15 
pi) of sonic extract (supplied in the ZAP ExpressTM cDNA Gigapacke II Gold 
Cloning kit) was added immediately with gentle mixing and the reaction incubated at 
22°C for 2 hr. To this was added 500 pl of SM buffer and 20 pl of chloroform. After 
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brief centrifugation to sediment the debris, the supernatant was transferred to a new 
tube and stored at 4°C. As a positive control, 1 pl of Xc1857 Sam7 wild-type lambda 
control DNA (0.2 pg, supplied in the ZAP ExpressTM cDNA Gigapack® II Gold 
Cloning kit) was packaged. 
Plating of the library was carried out by adding 200 pl of XL 1-Blue MRF' 
• cells (supplied with the ZAP Express Tm cDNA Gigapack® II Gold Cloning kit) at 
0.D.600 of 0.5 (see section 2.10.2) to 1 p.1 of the final packaged reaction and 1 pl of a 
1/10 dilution. The phage were allowed to attach to the cells by incubation at 37°C for 
15 mm. The following components were added to the phage: 
3 ml NZY top agar (48°C) 
15 pi 0.5 M IPTG 
50 p.1 X-gal (250 mg/ml in DMF) 
This was plated immediately onto NZY agar plates and incubated overnight at 37°C. 
The packaged wildtype lambda control DNA was plated out as for the packaged 
library however VCS257 host cells were used instead of XL1-Blue MRF' cells 
2.9.6 Amplification of the ZAP Express library 
The primary library was amplified by mixing aliquots of library suspension 
containing up to 50000 plaque-forming bacteria with 600 p.1 of XL1-Blue MRF' cells 
at 0.D.600 of 0.5 (see section 2.10.2), and incubating at 37°C for 15 min. Melted 
NZY top agar (6.5 ml) was added and the mixture poured onto fresh 150 mm NZY 
agar plates. The plates were incubated for 6-8 hr, so that the plaques were visible but 
less than 1 mm in size. The plates were overlayed with 10 ml of SM buffer and stored 
at 4°C overnight. The bacteriophage suspension was recovered from each plate and 
pooled. The plates were rinsed with 2 ml SM buffer, chloroform was added to the 
pooled suspension at 5% final concentration and incubated at room temperature for 
15 min. The cell debris was removed by centrifugation at 500 g for 10 min, and 0.3 
% final concentration of chloroform was added to the supernatant. Aliquots were 
stored at 4°C and in 7% DMSO at -80°C. 
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2.9.7 Screening the cDNA library 
The cDNA library was titred to determine its concentration and plated onto 
150 mm NZY agar plates at 15000 pfu/plate, by mixing an aliquot of the library with 
600 ul of XL1-Blue MRF' cells at ()Dm of 0.5 (see section 2.10.2). The phage were 
allowed to attach to the cells by incubation at 37°C for 15 min. NZY top agar (6.5 
• ml) was added and the mixture poured onto NZY agar plates. The plates were 
incubated for 8 hr at 37°C, then stored at 4°C overnight. The phage was transferred 
to a nitrocellulose membrane (0.45 JAM, Schleicher and Schuell) by placing the 
membrane on the agar plate for 2 min, and for 4 min for a duplicate membrane. The 
orientation of the membrane was marked by pushing a needle with ink through the 
membrane and into the agar. The nitrocellulose was submerged in denaturing solution 
(1.5 M NaC1/0.5 M Na0H) for 2 min, then neutrilized in 1.5 M NaC1/0.5 M Tris.HC1, 
pH 8.0 for 5 min. The membrane was rinsed in 2 X SSC/0.2 M Tris.HC1, pH 7.5 for 
30 sec, then baked under vacuum for 2 hr at 80°C. The membranes were 
prehybridised for 2 hr at 55°C in DNA hybridisation buffer then the radioactive cDNA 
probe added and the membranes hybridised overnight at 55°C. Membranes were 
washed in SDS/SSC to a stringency of 0.2 X SSC, 1% SDS at room temperature and 
exposed to autoradiography film (Hyperfilm MP, Amersham). 
Positive plaques were identified by orienting the membranes with the 
developed autoradiography film and the original agar plates. Positive plaques selected 
from the agar plates were removed in a plug of agar with a pipette tip. The agar plug 
was added to 1 ml of SM buffer and 20 pl of chloroform. Aliquots (1 pi and and 1 pi 
of a 1/10 dilution) were plated onto NZY agar as before and incubated at 37°C 
overnight. Plaques were lifted onto nitrocellulose as before and hybridized with the 
radioactive probe. Subsequent screenings were performed until a positive plaque was 
isolated to purity. 
2.9.8 Single-clone excision 
The single-clone excision protocol was used to excise the pBK-CMV 
phagemid vector from the ZAP Express vector, using the ExAssist helper phage 
(Stratagene). Single-clone excision was performed on phage from a purified plaque 
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which had been stored in 0.5 ml SM buffer/20 R1 chloroform at 4°C for 24 hours. 
The protocol involved combining the following: 
200 RI XL 1-Blue MRF' cells at 0D600 1.0 (see Preparation of host cells, 
section 2.10.2) 
250 R1 phage stock (containing > 1 X 10 5 phage particles) 
1 p.1 ExAssist helper phage (>1 X 10 6 pfu/R1) 
This was incubated at 37°C for 15 min, 3 ml NZY broth added and the incubation 
continued with shaking at 37°C for 3 hr. The culture was heated at 70°C for 20 min 
then centrifuged at 1000 g for 15 min. The supernatant was stored at 4°C. The 
phagemids were plated at two concentrations by combining the following 
200 R1 freshly grown XLOLR cells at 0D600 1.0 (see Preparation of host cells, 
section 2.10.2) 
100 pl phage supernatant or 10 pl phage supernatant 
This was incubated at 37°C for 15 min, 300 pl NZY broth added and the incubation 
continued for 45 min at 37°C. Aliquots (200 pl) were plated on LB-kanamycin plates 
and incubated overnight at 37°C. 
2.10 Miscellaneous Procedures 
2.10.1 Quantitation of cDNA-ethidium bromide plate assay 
100 ml of 0.8% (w/v) agarose in TAE buffer was prepared. Ethidium bromide 
(10 R1 of 10 mg/ml stock) was added to the cooled agarose, and poured into petri 
dishes. The plates were dried at 37°C, then spotted with 0.5 p.1 aliquots of DNA 
standard solutions (200 to 10 ng/pl solutions). A 0.5 ptl aliquot of the sample cDNA 
was immediately spotted onto the plate adjacent to the standards. The samples were 
allowed to absorb for 15 min, the plate inverted and photographed under UV light and 
the concentration of the sample cDNA estimated in comparison to the standards. 
2.10.2 Preparation of host bacteria 
Bacterial glycerol stocks were streaked onto appropriate agar plates and 
incubated overnight at 37°C. An isolated colony was innoculated into 50 ml of 
appropriate media, and grown overnight at 30°C with shaking at 200 rpm to an 0D600 
of less than 1. The bacteria was pelleted by centrifugation at 500 g for 10 min. The 
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cells were gently resuspended in half the volume of sterile 10 mM MgSO 4, and stored 
at 4°C to be used within 48 hr. The cells were diluted to an Moo of 0.5 in sterile 10 
mM MgSO 4 and used immediately. For the single-clone excision protocol the cells 
were prepared as above, however they were used at an 0D 600 of 1.0. 
The following table demonstrates the various host strains used in the 
preparation of the cDNA library and the conditions under which they were grown: 
Host strain Agar plates Medium for glycerol culture Medium for bacterial 
cultures 
XL1-Blue MRF' LB-tetracycline LB-tetracycline LB + 0.2% maltose-10mM 
MgSO4 
XLOLR LB-tetracycline LB-tetracycline LB 
VCS257 LB LB LB + 0.2% maltose-10mM 
MgSO4 
2.10.3 Preparation of TE-saturated phenol 
Phenol was melted at 65°C, then 40% v/v TE buffer added, and shaken 
vigorously for 5 min. The phases were allowed to separate overnight at 4°C, the 
aqueous layer removed and repeated with 25% v/v TE buffer. After the phases had 
separated, most of the aqueous layer was removed and 8-hydroxyquinoline added to a 
final concentration of 0.1%. 
2.10.4 Preparation of sephadex columns 
Sephadex G50 or G25 was added to sterile distilled water, washed several 
times then equilibrated in TES. The slurry was autoclaved for 10 min and stored at 
4°C. A G50 sephadex column was prepared by filling a 0.5 cm diameter glass column 
with sephadex to 1 cm in length. A G25 spin column was prepared by filling a 1 ml 
syringe with sephadex slurry and centrifuging in at 800 g for 5 min. 
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CHAPTER 3:EXPRESSION OF MT-I AND -II ISOFORMS IN THE 
DEVELOPING SHEEP BRAIN. 
3.1 Introduction 
3.1.1 Metallothionein in the brain 
In 1983 a low molecular weight zinc-binding and zinc-inducible protein was 
detected in rat brain (Itoh et al., 1983), and later determined to be a MT-like protein 
(Ebadi, 1986a). Since then MT has been identified in the brain of various species (e.g. 
Paliwal and Ebadi, 1989). More recently, the cellular localisation of MT in the brain 
has been examined by immunohistochemistry. In young rat brain, MT has been 
localised to ependyma, pia mater, arachnoid and also cells of the choroid plexus 
(Nishimura et al., 1992), while in adult rat MT was detected in ependymal cells, 
choroid plexus as well as blood vessel (Nakajima et al., 1989), and also in astrocytes 
throughout the brain (Young etal., 1991; Young, 1994). Similarly, in the mouse, MT 
has been localised to ependymal cells, glia, arachnoid and pia mater (Nishimura et al., 
1992). 
MT expression has also been examined in monkeys and humans. In the 
monkey brain, MT was detected in pia mater, ependymal cells and astrocytes (Suzuki 
etal., 1992a). In the human, several studies have localised MT mainly in astrocytes 
(Nakajima et al., 1991; Suzuki etal., 1992b). The expression was found to be in a 
subset of astrocytes mainly in the grey matter, and mutually exclusive to GFAP (glial 
fibrillary acid protein) immunoreactive astrocytes which were found mainly in the 
white matter. Some cells at the junction between white and grey matter, however, 
were both MT and GFAP immunoreactive (Blaauwgeers etal., 1993; 1994). 
Studies examining MT expression during development have shown that MT 
levels in the brain increase dramatically after birth (Ebadi., 1986b), in contrast to the 
liver which has higher levels of expression during foetal development (e.g. Paynter et 
al., 1990). However, no detailed studies have investigated the localisation of MT in 
the foetal brain. Suzuki etal. (1994) examined MT expression in human brain of 
several foetal ages. In the human brain, MT immunoreactivity was not detected at 21 
weeks gestation, but was detected in astrocytes in grey and white matter at 35 weeks 
and 40 weeks gestation. In infant brain MT was also expressed in the pia mater and 
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adventitia of blood vessels. In the adult brain MT was detected in the pia mater, 
ependymal cells, astrocytes and adventitia of blood vessels. Other than this brief 
study, the localisation of MT in the developing brain has not been described. 
Although the expression of MT in tissues such as the liver during development 
has been investigated in detail (Andersen et al., 1983; Andrews et al., 1984; Mercer 
and Grimes, 1986; Lehman-McKeeman et al., 1988; Paynter et al., 1990), less is 
known about MT regulation in the brain, and the factors important in its regulation in 
this tissue are still largely uninvestigated. Systemic factors are often excluded from 
the brain by the blood-brain barrier. For example, MT in the brain is induced by 
intracerebroventricular, but not peripheral administration of zinc (Ebadi, 1986a; 
Paliwal et al., 1990). MT in the brain is also induced by stress (Hidalgo et al., 1990; 
1991), dexamethasone and corticosterone (Gasull etal., 1994). Brain MT has also 
been shown to be induced by lipopolysaccharide (LPS) in both mouse (Searle et al., 
1984) and rat (Itano etal., 1991). 
3.1.2 Sheep metallothioneins 
In the sheep, metallothioneins are encoded by a multigene family (Peterson et 
al., 1988) and like in humans there are multiple MT-I isoforms (MT-Ia, MT-lb and 
MT-Ic) and a single MT-II isoform (MT-II). The sheep MT genes have been 
demonstrated to be differentially regulated (Peterson and Mercer, 1988) as have the 
human MT-I and -II genes (e.g. Heguy etal., 1986). In cultured fibroblasts only MT-
II is responsive to dexamethasone treatment, 'while all genes are responsive to metals, 
although to differing degrees (Peterson and Mercer, 1988). In contrast, the mouse 
MT-I and -II isoforms have been shown to be coordinately regulated (e.g. Searle et 
al., 1984). The sheep MT genes however have remained largely uninvestigated in 
vivo, although a study has documented expression of MT mRNA in the foetal lung 
(E120-132) in a study of late gestational lambs (Pitt etal., 1992). 
3.1.3 Development of the brain. 
An outline of mammalian neurodevelopment is presented here, highlighting 
particular aspects which put in context the results presented in this chapter. Further 
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information can be found in the following texts: Arey, 1965; Larsen, 1993; Sadler, 
1990; Jacobson, 1991. 
The central nervous system develops from an indentation in the neural plate, 
which originates from ectoderm of the embryo. The indentation along the midline of 
the plate forms the neural groove. Fusion of the edges of this groove forms the neural 
tube which gives rise to the brain and spinal chord (as depicted in Figure 3.1). The 
brain consists of 3 general classes of cells: neurons, glia and ependymal . cells, mainly 
originating from the neuroepithelial layer (as depicted in Figure 3.2). The ratio of 
neurons to neuroglia in the brain is in the range of 1:10-50. The neuroepithelial cells 
in the ventricular zones of the brain cycle through mitosis, the postmitotic cells 
moving outwards forming the subventricular and intermediate zones. The 
intermediate zone consists of differentiated neuroblasts and glioblasts. The remaining 
cells in the neuroepithelial layer differentiate into ependymal cells. Glial cells consist 
of several subclasses; astrocytes, oligodendrocytes, radial glial cells and microglia. 
Astrocytes develop from the gliablasts, whereas microglial cells develop from 
mesenchymal cells. The origin of oligodendrocytes is debatable, although evidence 
suggests that they originate from the same precursors as some astrocytes. 
Neuroblasts develop into neurons migrating into the intermediate zone where they 
settle and mature, losing their ability to divide. As more neuroblasts are formed they 
migrate through the settled neurons forming subsequent layers, and thus there is 
progressive expansion of the walls of the brain (as depicted in Figure 3.3). In this way 
the brain is said to develop from the "inside out". It is thought that the gliablasts and 
neuroblasts form at the same time, but the differentiation of glia is delayed and 
continues for some time after all the neurons are formed. Therefore migration of 
neurons is detected first, while glia migrate later in a second wave. The migration of 
neurons is thought to be guided by long thin cells, termed radial glial cells which 
stretch from the ventricular zone out to the marginal (outer) zone. Radial glial cells 
are only present in the foetal brain, and it is thought that some astroctyes develop 
from transformation of radial glial cells. 
At first the outer marginal zone consists only of processes of the 
neuroepithelial cells, but gradually becomes invaded by processes of the post-mitotic 
cells in the intermediate zone, and later mature glial cells. Astrocytes near the surface 
B Neural groove 
D Neural tube 
F Spinal Cord 
A Neural plate 
C Neural folds 
Neural 
crest 
Figure 3.1 Diagrammatic representation of the development of the mammalian 
brain and spinal chord. Taken from: Introduction to Histology (D.H.Cormack). 
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Figure 3.2 Diagrammatic representation of the cel types found in the brain and their origins 
The neuroblasts, astrocytes and ependymal cels are shown to originate from the neuroepithelial cels. The origin of oligodendroglia remains 
unclear. Taken from: Langman's Medical Embryology, 6th edition (J.W.Sadler). 
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Figure 3.3 Representation of the diferentiation of the cerebral neocortex 
This diagram ilustrates the expansion of the cerebrum from a single zone of cels to a multilayered structure containing diferentiated neural cels. 
Immature cels are depicted moving outwards from the proliferative ventricular zone causing expansion of the wals of the brain. VZ, ventricular 
zone; MZ, marginal zone; IZ, intermediate zone; CP, cortical plate; SZ, subventricular zone; SP, subplate; EL, ependymal layer; WM, white 
mater; NC, neocortex; ML, molecular layer. Taken from: Human Embryology (W.J.Larsen). 
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of the brain usually have one or more processes extending to the pial surface of the 
brain where they expand to form `endfeee forming the glia limitans. Other astrocytes 
have endfeet associated with blood vessel walls. Astrocytes are classified 
phenotypically as protoplasmic (predominantly in the white matter) or fibrillar 
(predominantly in the grey matter). Oligodendrocytes found in both the white and 
grey matter provide the myelin sheath of neurons and are therefore often found 
associated with neurons. 
Glial fibrillary acidic protein (GFAP), S100 and galactocerebroside (Gal-C) 
are frequently used as cell type markers in the brain. GFAP is a 51 kd protein of 10 
rim intermediate filaments of astrocytes, and is an astrocyte specific marker. S100 
proteins are a class of calcium binding proteins. They are dimers consisting of 2 
subunits, and are markers of ependymal cells and astrocytes. There is some evidence 
that S100 is also expressed in oligodendrocytes (Janeczko, 1994). Gal-C is the major 
galactosphingolipid of myelin. It is expressed in cell membranes of oligodendrocytes 
in the central nervous system, and in Schwann cells in peripheral nerves. 
The aim of this work was to examine the cell-type expression of MT-I and -II 
isoforms in the developing mammalian brain; to determine where and when MT is first 
expressed in the brain and whether the regional and cellular expression patterns 
change as the brain develops. Also, to determine whether the expression profiles of 
MT during development correlate with known changes in the physiology of brain 
development. The overall aim of these studies was to determine whether the 
expression profile of MT protein at the cellular level could provide insight into the 
function of MT in the brain in light of the roles played by the various cell-types in the 
adult brain and during development. 
3.2 Results 
Northern blotting and immunocytochemistry were used to examine the 
expression profile of MT-I and -II mRNA and protein in the developing sheep brain. 
Regional expression patterns of MT protein were compared with the astrocyte marker 
GFAP in the developing brain. Double-labeling fluorescent immunocytochemistry 
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with anti-MT antibodies and anti-GFAP, anti-S100 or anti-Gal-C antibodies was used 
to confirm cell type expression of MT. 
3.2.1 Selection of foetal ages. 
The cortical plate of the neocortex develops in the sheep brain between E30 and E35, 
and by E40 all regions of the neocortex have a cortical plate of 1-2 cell layers. By 
E80, most of the layers of the cortex are present, and all the adult layers are present 
by about E120. The period of gestation is 147 days. Foetal samples were obtained 
from the following ages: For northern blotting ages E40, E58, E64, E72, E86 and 
E115 were used and for immunocytochemistry ages E34, E40, E58, E73, E80 and 
E116 were used. Samples represent the pre-cortical plate stage (E34; n=2), the 
cortical plate proper stage (E40, E58, E64, E72, E73; n=5), the late-sub-plate stage 
(E80, E86; n=3) and the "mature foetal" stage in which all of the adult layers are 
present (E115, E116; n=4), as discussed in Dziegielewska et al. (1993). 
3.2.2 Expression of MT-I and -111 mRNA in the foetal and adult sheep brain. 
Southern blot analysis (section 2.3) of sheep genomic DNA was used to 
determine whether a human MT2A RT-PCR transcript hybridised to all sheep MT-I 
and -II genes, and was therefore a suitable probe to examine MT mRNA expression in 
the developing sheep brain. Genomic DNA from 2 sheep was digested with the 
restriction endonuclease, EcoRI, electrophoresed through 1.4% agarose and 
transferred to a nylon membrane by alkaline blotting. The membrane was hybridised 
with a radiolabelled probe for 16 hr at 37°C in 50% formamide hybridisation buffer, 
and washed to a stringency of 0.2 X SSC, 1% SDS at 37°C. The probe used was a 
279 bp human MT2A RT-PCR transcript produced by RT-PCR of HeLa cell RNA 
using the following primers: 5'-GCAACCTGTCCCGACTCTAG-3' (sense) and 5'- 
ATCCAGGTTTGTGGAAGTCG-3' (antisense), and cloned into pSP64 (as described 
in F.A.Stennard, Ph.D. Thesis). Southern blot analysis revealed 4 bands previously 
attributed to sheep MT-I and -II genes (Peterson et al., 1988) confirming that the 
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Figure 3.4 Southern blot analysis of the sheep genome with a human MT probe 
A:Genomic DNA from 2 sheep (lanes 1 and 2) was digested with EcoRI and 
subjected to Southern blot analysis with a human MT2A RT-PCR transcript as a 
probe. The genes which hybridised to the probe and the sizes of the restriction 
fragments.containing them are indicated. 
B:A restriction map of the sheep MT locus demonstrates the restriction fragments 
which hybridised to the human MT2A RT-PCR transcript and the sheep MT genes 
which they represent. Restriction sites for the folowing restriction endonucleases are 
indicated: E, EcoRl; H, HindII; B, Banal; C, Clal; K, Kpnl. Modified from 
Peterson etal., 1988. 
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probe used cross reacted with all known sheep MT genes (MT-Ia, -lb, -Ic and -II), as 
depicted in Figure 3.4. Some other fainter bands were observed on the 
autoradiograph. It is possible they represent additional MT isogenes, or processed 
pseudogenes outside of the mapped locus. However, no other MT genes have been 
reported in the sheep, and cross hybridisation with these bands was significantly less 
than with the known genes, and in fact these bands were undetectable on lesser 
exposures of the blot. 
RNA was isolated from the brains and livers of foetal and adult sheep and 
analysed by northern blotting (section 2.3) for the presence of metallothionein mRNA 
using the human MT2A RT-PCR transcript as a probe, under the conditions described 
above. As shown in Figure 3.5, high MT mRNA levels were observed at E115 and in 
the adult brain, but a very low signal was also detected at E72 and E86 which was 
more obvious following overexposure of the autoradiogram (not shown). In contrast, 
MT mRNA was observed in the liver at all foetal ages and in adults, and was most 
intense in the E40-E72 foetuses. 
For comparison the levels of GFAP mRNA were examined using a mouse 
GFAP cDNA, isolated from a clone supplied by N.J.Cowan (Lewis et al., 1984). This 
probe was hybridised at 37°C in 50% formamide hybridisation buffer for 16 hr and 
washed to a stringency of 0.2 X SSC, 1% SDS at 37°C. GFAP mRNA was present in 
the foetal sheep brain from E58. Like MT, highest levels were observed in the El 15 
and in the adult brain (Figure 3.5). As expected GFAP mRNA was not detected in 
the liver at any age. The northern blot was also hybridised to a human 13-actin cDNA, 
which is often used to demonstrate that equal amounts of RNA are present in each 
lane (Figure 3.5). This probe was hybridised for 16 hr at 37°C in 50% formamide 
hybridisation buffer and washed to a stringency of 0.2 X SSC, 1% SDS at 37°C. 
However, 13-actin can be subject to developmental regulation (e.g. Lazarini et al., 
1991) and therefore Figure 3.5 also shows the ethidium-bromide stained gel used for 
northern blotting, to demonstrate that equal levels of RNA were loaded in all tracks. 
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3.2.3 Expression of MT-I and 	 protein in the foetal and adult sheep brain. 
An anti-MT antibody was used to examine the expression of MT-I and -H 
proteins in the developing sheep brain. The anti-MT antibody used was a monoclonal 
antibody raised against horse MT, and has been shown to cross react with both MT-I 
and -I isoforms (Jasani and Elmes, 1991). Cross reactivity with MT-II and MT-IV 
was not examined since these isoforms have not been identified in the sheep, and in 
other species their expression in the foetal brain is very low (Kobayashi et al., 1993; 
Quaife et al., 1994). However, it has been shown that this antibody does not cross 
react with mouse MT-HI and MT-IV protein (West and Skabo, personal 
communication). The specificity of the immunostaining was confirmed by processing 
slides with the omission of primary antibody, secondary antibody or the peroxidase-
conjugated streptavidin. In addition, antibody preadsorbed with a mixture of horse 
kidney MT-I and MT-I (section 2.6.4) was used in some experiments. In each case, 
no specific immunoreactivity was observed (Figure 3.6). Immunocytochemical 
staining with an anti-GFAP antibody was examined on similar sections in order to 
compare MT and GFAP regional expression paterns. 
Pre-cortical plate and cortical plate proper stage (E34-E73) 
The first positive but weak immunostaining against MT was observed amongst 
the population of proliferating cels in the ventricular zone of the diencephalon at E73 
(data not shown). No staining of other cel types or in other regions of the brain were 
observed. At earlier ages, from E34 to E58, there was no MT immunostaining on 
sections of whole foetal brains, either of celular or non-celular regions. Similarly, no 
positive staining was observed with the astrocyte marker, GFAP. 
Late sub-plate stage (E80) 
In the E80 foetal brain MT staining was observed in radial glial cels, 
ventricular zone cels and astrocytes, as depicted in Figure 3.7. Litle staining of 
astrocytes was observed in the cerebral cortex, with the exception of the molecular 
B 
Figure 3.6: Controls for immunocytochemistry in the sheep brain. 
Sections were processed for immunocytochemistry as outlined  in materials and 
methods. Panels A and B show lack of specific staining resulting from the omission 
of primary antibody (A) and secondary antibody (B), respectively. Panel C 
demonstrates the lack of specific staining resulting from omission of the peroxidase-
conjugated streptavidin. Panel A shows an area of grey matter in the cerebral cortex 
of the E116 foetal sheep brain. Panels B and C show areas of the molecular layer of 
the cortex of the E116 foetal sheep brain. Panel D demonstrates  the lack of specific 
immunoreactivity for MT in the adult sheep brain cortex when the anti-MT antibody 
was preadsorbed with horse kidney MT-I and -II. Panels A to D, bars=50 Ii.M. 
Figure 3.7 MT and GFAP immunoreactivity in the E80 foetal sheep brain 
Sections were stained with anti-MT (A,C,E) or anti-GFAP (B,D,F) antibodies. 
Panels A and B show glial cells (arrowheads) and the glial limiting membrane 
(arrows) of the molecular layer immunostained for MT (A) and GFAP (B), 
respectively. Panels C and D show the proliferative ventricular zone immunostained 
for MT and GFAP, respectively. Progenitor cells in the ventricular zone are 
immunoreactive for MT (arrow in C), but not GFAP (arrowhead in D), while radial 
glial cells are immunoreactive for GFAP (arrow in D). Panels E and F show radial 
glial cells extending from the ventricular zone at the base of the diencephalon which 
are MT immunoreactive (arrow in E) but not GFAP immunoreactive (arrow in F). Bar 
=50 1.1,M (Panels A to F). 
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layer where glial cells (arrowhead) and also astrocyte end-feet (arrow) of the glial 
limiting membrane were MT positive (Figure 3.7A). GFAP staining was also 
observed in the molecular layer in astrocytes (arrowhead) and end-feet (arrow) of the 
glial limiting membrane (Figure 3.7B). MT staining of the glial limiting membrane 
was less complete and weaker than GFAP. Some iinmunoreactivity (both MT and 
GFAP) was also observed in astrocytic fibres in this region. 
Some progenitor cells in the ventricular zones were intensely MT stained (see 
arrow, Figure 3.7C). GFAP staining was also present in the ventricular zones 
however in radial glial cells (e.g. arrow) rather than progenitor cells (e.g. arrowhead) 
confined to the proliferative ventricular zone (Figure 3.7D). MT positive cells having 
the morphological appearance of radial glial cells (arrow) which extend out from the 
ventricular zone were observed at the base of the diencephalon (Figure 3.7E). GFAP 
immunoreactivity was not observed in this region (Figure 3.7F), although radial glial 
cells which were GFAP positive were found in other areas, as indicated above (e.g. 
Figure 3.7D). Overall, the GFAP staining was similar to that of MT, but not identical. 
Mature foetal stage (E116) 
In the E116 foetal sheep brain MT staining was observed in oligodendrocytes, 
astrocytes, fibre tracts, and astrocyte end feet in the molecular layer, as depicted in 
Figure 3.8. The limiting glial membrane, consisting of astrocyte end-feet was 
particularly intensely stained (see arrow, Figure 3.8A). Some morphologically distinct 
MT positive astrocytes were also observed in this region (see arrowhead, Figure 
3.8A). The limiting glial membrane was also intensely stained with GFAP (see arrow, 
Figure 3.8B), although the staining pattern was not identical to that of MT. The 
considerable punctate staining observed in the molecular layer is interpreted as being 
due to cross sections of processes from MT positive astrocytes. 
Compact astrocytic fibre tracts (arrow, Figure 3.8C) were observed in the 
white matter of the cortex which were MT positive. GFAP positive fibre tracts were 
also seen in this region (see arrow, Figure 3.8D). MT positive cells which 
Figure 3.8 MT and GFAP immunoreactivity in the E116 foetal sheep brain 
Sections were stained with anti-MT (A,C,E) or anti-GFAP (B,D,F) antibodies. 
Panels A and B show the glial limiting membrane (arrows) of the molecular layer 
immunostained for MT (A) and GFAP (B), respectively. MT positive cells 
resembling astrocytes are also seen in the molecular layer (arrowhead in A). 
Astrocytic fibre tracts in the white matter of the cerebrum are both MT (Panel C, 
arrow) and GFAP (Panel D, arrow) immunoreactive. Panel E shows MT 
imrnunoreactive cells morphologically resembling astrocytes (arrow) and 
oligodendrocytes (arrowhead). Glial cells associated with blood vessels are also 
indicated (white arrow). Panel F shows GFAP immunoreactive astrocytes (arrow) in 
the white matter of the cerebrum. Bar=50 1AM (Panels A to F). 
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morphologically resembled astrocytes were observed in the white matter of the 
cerebrum (see arrow Figure 3.8E). Smaller cells, morphologically resembling 
oligodendrocytes were also observed to be MT immunoreactive (see arrowhead, 
Figure 3.8E). GFAP positive astrocytes were also observed throughout the cerebrum 
(Figure 3.8F). MT positive cells were often found associated with blood vessels 
throughout the cortex (e.g. white arrow, Figure 3.8E). 
Adult 
In the adult sheep cortex MT immunoreactivity was observed in astrocytes (in 
the white matter of the cerebral cortex and outer molecular layer), in glial processes 
throughout the grey matter and in astrocyte end feet in the limiting glial membrane, as 
depicted in Figure 3.9. This figure depicts MT and GFAP expression in the adult 
brain, as detected by fluorescent immunocytochemistry. The same monoclonal 
antibodies were used as in the foetal brain, however the MT and GFAP 
immunoreactivities were visualised with the fluorescent secondary antibodies, FITC 
and Texas Red, respectively (as detailed in section 2.6.3). 
In the molecular layer MT and GFAP staining of astrocytes and astrocyte end-
feet (arrow) was similar although not identical (see Figure 3.9A,B). MT staining was 
confined to a narrower region of the molecular layer than GFAP. GFAP staining 
throughout the white matter was considerably more widespread than that for MT, 
although many MT immunoreactive astrocytes where present. There was widespread 
MT immunoreactivity throughout the grey matter probably due to the dense network 
of glial cell processes (Figure 3.9C,D), while GFAP staining was weaker in this region 
than in the white matter. A MT+/GFAP+ astrocyte in the grey matter is indicated 
(arrows, Figure 3.9C,D). No cells resembling oligodendrocytes were immunoreactive 
for MT in the adult brain. 
	g 	 g 	 '1 .6.• a. CO C:L. c Li C`D' tz 
C..) (Cr CD 0 0-t 0 „ 
el 61 S) r4 	4 cp cra 1-3 
-, CD ag 
CD X 	 • =. ..,c/1 Po 	 Po 
• .•)0 	 co- 
w q41 c A, CD 	 • 
v9 OC9 Po it tit 	 1, n  0 Po ■-• • 	 ■-• • S CD 	 1 
C7 E 4 E CL cr, 	 c  
-co 	 • -I 
A) 5- 	 CD r 
CD 	 ■••■ 	 , 
CD 	 0 
; 
6.9jpo wat7 ,:„ 	 .• 	 • 
a •T1 
6d CD ‘2,. 
- 	 CA 
" cp 
c) 	 o 
•CD Clt 0 eD c 	 5. 
+ 	 • 0.0 
r-t- ■-e 	 cD 
0 CD *-1 •rj2- 0 C A 0 ›. 
'"" 
63 
In summary, MT immunostaining was first observed in the foetal sheep brain 
at E73 at a similar time to when MT mRNA was initially observed by northern 
blotting (see Figure 3.5). MT immunoreactivity was detected in radial glial cells, 
astrocytes and oligodendrocytes, as outlined in Table 1. MT immunoreactivity was 
consistently observed in the molecular layer of the cerebral cortex, ventricular zones 
of the telencephalon and diencephalon, as well as throughout the white and grey 
matter of the cortex in the "mature" brain (E116 and adult). Shifts were observed in 
regional localisation and cell-type expression during development, for example, MT 
immunoreactivity was observed in oligodendrocytes in the foetal but not the adult 
brain. No MT immunoreactivity was observed in neurons at any stage of brain 
development. 
3.2.4 Expression of MT and cellular markers in the E116 foetal sheep brain. 
Double-labeling immunocytochemistry (section 2.6.3) was performed with 
anti-MT antisera and antisera to the cellular markers; GFAP, S100 and Gal-C to 
confirm correlations made earlier between MT immunoreactivity and cell type, based 
on cell morphology. MT was visualised using as a secondary antibody, anti-mouse 
IgG conjugated to FITC while the cellular markers GFAP, S100 and Gal-C were 
visualised using as a secondary antibody, anti-rabbit IgG conjugated to Texas Red. 
The specificity of the secondary antibodies was verified by processing sections as 
normal but either the anti-GFAP antibody (Figure 3.10A,B) or the anti-MT antibody 
(Figure 3.10C,D) was omitted. GFAP is a marker of astrocytes, S100 is a marker of 
astrocytes, ependymal cells and possibly oligodendrocytes, and Gal-C is a marker of 
oligodendrocytes (see section 3.1.3: Development of the brain) 
Comparison of the MT staining pattern with that of GFAP, particularly in the 
E116 foetal brain (Figures 3.11 and 3.12), showed that the regional distribution of 
these proteins was similar but their expression patterns were not identical. For 
example, MT+/GFAP+ cells (i.e. astrocytes, e.g. arrows) were observed in the white 
matter of the cortex, but were in close proximity to MT+/GFAP- cells (e.g. 
Age Cell type MT GFAP 
E73 •progenitor cells + - 
E80 •radial glial cells 
•progenitor cells 
•astrocytes 
•astrocyte end feet 
+
+
+
+
 
+
,
+
+
  
E116 •astrocytes 
•astrocyte end feet 
•oligodendrocytes 
•astrocytic fibre tracts 
+
+
+
+ 
+
+
,   +
  
Adult •astrocytes 
•astrocyte end feet 
+
+
 
+ 
+ 
Table 3.1 Cellular localisation of MT and GFAP immunoreactivity in foetal and 
adult sheep brain 
MT and GFAP proteins were localised by irnmunocytochemistry in foetal and adult 
• sheep brain. This table outlines the cell types in which unambiguous MT and GFAP 
immunoreactivity was detected, from E73 when staining was first observed to adult. 
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Figure 3.11 MT and GFAP fluorescent double-labelling in the E116 foetal sheep brain 
Panels A and B show immunostaining of a single section from the white matter of the cerebrum with anti-MT (A) and anti-GFAP (B) antibodies, 
respectively. Panel C is a double exposure photograph showing both MT (green) and GFAP (red) immunoreactivity. Cells expressing both 
proteins are therefore stained yellow. MT+/GFAP+ astrocytes (see arrows) can be seen in close proximity to MT+/GFAP- cells resembling 
oligodendrocytes (see arrowheads). Panels D and E show immunostaining of a single section of cortex immunostained with anti-MT (D) and anti-
GFAP (E) antibodies. Panel F is a double exposure photograph showing both MT (green) and GFAP (red) immunoreactivity. Both MT+/GFAP+ 
astrocytes (see arrows) and MT-/GFAP+ astrocytes (see arrowheads) are shown. Bar=50 1..tm (Panels A to F). 

Figure 3.12: MT and GFAP fluorescent double-labelling in the E116 foetal 
sheep brain. 
Panels A and B show a section of the molecular layer of the cerebral cortex double-
stained with anti-MT (A) and anti-GFAP (B) antibodies.The glial limiting membrane 
is immunoreactive for both MT and GFAP (arrows), as are many glial processes 
(arrowheads). Panels C and D show a section of the grey matter of the diencephalon 
double-stained with anti-MT (C) and anti-GFAP (D) antibodies. Small circular 
profiles morphologically resembling oligodendrocyte processes encircling axons are 
MT+/GFAP- (eg arrows). Bar=50 un (Panels A to D). 
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arrowheads) which morphologically resembled oligodendrocytes (see Figures 
3.11A,B,C). Furthermore, not all astrocytes within a region expressed MT. As 
demonstrated in Figures 3.11D,E,F, GFAP+/MT- (e.g. arrowhead) as well as 
GFAP+/MT+ (e.g. arrow) cells were evident by fluorescent double labeling. 
In the molecular layer both MT and GFAP staining was observed although 
again the staining was not identical. The staining of the glial limiting membrane with 
MT, appeared to be more limited than with GFAP. Astrocytic processes both within 
the glial limiting membrane (see arrows, Figure 3.12A and B) and in more internal 
regions of the molecular layer (see arrowheads, Figure 3.12A and B) were observed 
to be MT+/GFAP+. In areas characteristic of grey matter in the diencephalon, MT 
staining, which gave rise to small circular profiles surrounding non-staining cores was 
observed. These structures did not exhibit GFAP immunoreactivity, as demonstrated 
by double labeling immunocytochemistry (see arrows, Figure 3.12C and D, 
respectively) and it is proposed that they represent MT positive processes of 
oligodendrocytes encircling axons. 
Double labeled sections then, illustrated cells which were MT+/GFAP-, 
MT+/GFAP+ and MT-/GFAP+ indicating that there is no simple correlation between 
the expression of these two proteins. 
Staining with anti-S100 antibodies did not correlate well with the MT 
immunoreactivity. The S100 staining was much more widespread than MT and 
therefore did not help to clarify the identity of MT positive cells, although 
MT+/S100+ cells were observed (see Figure 3.13), and in fact MT staining appeared 
to be a subset of the S100+ cells. MT+/S100+ cells were observed, (see arrows, 
Figures 3.13A,B and C,D), in close proximity to morphologically similar cells which 
were MT-/S100+ (see arrowheads, Figures 3.13A,B and C,D). A MT+/S100+ glial 
cell with processes encircling a blood vessel is indicated (curved arrows, Figure 
3.13C,D). There appear to be no cells which are MT+/S100-. Similarly, in the 
molecular layer, the S100 staining is more widespread than MT, and all MT+ 
cells/processes appear to be S100+ (e.g. arrows/arrowheads in Figures 3.13E,F). 
Figure 3.13 MT and S100 fluorescent double-labelling in the E116 foetal sheep 
brain 
Sections were stained with anti-MT (A,C,E) and anti-S100 (B,D,F) antibodies. 
Panels A and B shows immunostaining of a single section containing a major blood 
vessel in the white matter of the cerebral cortex with MT and S100, respectively. 
MT+/S100+ glial cells (e.g. arrows) are in close proximity to MT-/S100+ glial cells 
(e.g. arrowheads). Panels C and D also show MT and S100 immunoreactivity, 
respectively in a region of the white matter of the cortex. A MT+/S100+ glial cell 
(arrow) and MT-/S100+ glial cell (arrowhead) are indicated. A MT+/S100+ glial cell 
with processes encircling a blood vessel is indicated (curved arrow). Panels E and F 
show MT and S100 inununoreactivity respectively, in the molecular layer of the 
cortex. MT+/S100+ processes (e.g. arrowhead) and cell bodies (e.g. arrow) are 
indicated. Bar=50 mm (Panels A to F). 
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Some MT+ cells had been assessed to be oligodendrocytes by their 
morphology and their failure to express GFAP. Double-labeling 
immunocytochemistry with anti-Gal-C and anti-MT antisera confirmed that some but 
not all oligodendrocytes are MT immunoreactive (see Figure 3.14). Both MT+/Gal-
C+ (e.g. arrowhead) and MT-/Gal-C+ (e.g. arrow) cells were observed. The small 
circular profiles previously proposed to be processes of oligodendrocytes encircling 
axons were observed to be Gal-C+ (arrow). 
The correlation between MT and PCNA expression was examined in the E116 
foetal brain. PCNA is a 36 lcDa protein which functions as a cofactor for DNA 
polymerase 8 in S-phase and also in DNA synthesis associated with DNA repair. It is 
often employed as a marker of proliferation (Hall etal., 1990). The expression of MT 
did not necessarily correlate with PCNA in the foetal sheep brain as demonstrated 
dramatically in Figure 3.15, which depicts expression of MT (A), GFAP (C), S100 
(D) and also PCNA (B) in areas surrounding fissures of the brain. Although MT, 
GFAP and S100 are all expressed in cells which form the glial limiting membrane of 
the sulcus (arrows, Figure 3.15A, C and D, respectively), PCNA is not expressed in 
these cells (see arrowhead, Figure 3.15B), but in cells further inward (arrow, Figure 
3.15B). Note that PCNA expression is exclusively nuclear (see arrow, Figure 3.15B), 
whereas MT expression was detected in both the nucleus (see arrow, Figure 3.15A) 
and cytoplasm (see arrowhead, Figure 3.15A). 
3.3 Discussion 
3.3.1 Localisation of NIT-I and -II in the developing sheep brain 
Northern analysis and immunocytochemistry were used to investigate the 
expression and distribution of MT-I and -II isoforms in the foetal and adult sheep 
brain. Both approaches indicate that MT expression begins at a timepoint around E70 
in the foetal brain since MT mRNA and protein were first detected at E72 and E73, 
respectively (see Figure 3.5). MT expression in the brain increased during further 
foetal development and immunoreactivity appeared most prominent in the E116 foetal 
Figure 3.14 MT and Gal-C fluorescent double-labelling in the E116 foetal sheep 
brain 
Sections were stained with anti-MT (A) and anti-Gal-C (B) antibodies. The 
immunostaining is of a single section from the white matter of the cortex with MT and 
Gal-C, respectively. A MT+/Gal-C+ oligodendrocyte is indicated (arrowhead). A 
MT-/Gal-C+ process of an oligodendrocyte is indicated (arrow). These small circular 
profiles are processes of oligodendrocytes encircling axons. Bar=20 gm. 
f 
Figure 3.15 Immunoeytochemical staining of fissures of the E116 foetal sheep 
brain. 
Panels A to D show immunostaining in the area surrounding fissures of the brain. 
Panel A shows MT immunoreactivity in glial cells with processes lining the sulcus and 
forming the glial limiting membrane. The MT immunoreactivity is in both the nucleus 
(arrow) and the cytoplasm/processes (arrowhead). Panel B shows PCNA 
immunoreactivity in the area surrounding a sulcus of the brain. The immunoreactivity 
is exclusively nuclear (eg arrow). The cells which form the glial limiting membrane 
are not PCNA immunoreactive (arrowhead). Panel C.shows GFAP immunoreactivity 
in cells forming the glial limiting membrane of a sulcus in the foetal brain (eg arrow). 
Panel D shows S100 immunoreactivity in the area surrounding a sulcus of the brain. 
Glial cells which form the limiting membrane are S100 immunoreactive (eg arrow). 
Panels A to D, bars=50 
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brain. Inununostaining appeared relatively less prominent in the adult brain, and the 
high MT mRNA levels possibly reflect the relatively low, but constant staining of 
fibres and glial processes throughout the entire adult cortex. Alternatively, not all the 
mRNA detected by northern blotting may have been translated into protein. Although 
regulation of MT genes is primarily at the level of transcription (see Palmiter, 1987), 
modulation of MT gene expression at the post-transcriptional level has been 
documented (Sadhu and Gedamu, 1989; Vasconcelos et al., 1996). 
In the development of the foetal brain, migration of neuroblasts precedes that 
of most glial cells; for example, in the sheep brain neuroblasts appear before E20 and 
their migration continues up to at least E65. The cortical layers contain only 
neuroblasts and their derivatives (apart from radiating fibres and rare epithelial cells) 
up to E58. Glial cells appear in increasing numbers after this (Astrom, 1967). It is 
apparent then from this study, that the appearance of MT immunoreactivity in the 
foetal sheep brain coincides with the development of glial cells and that MT-I and -II 
isoforms are present in neither neuroblasts nor developed neurons. Similarly, in 
studies in other species it has been demonstrated that MT-I and -II isoforms are not 
expressed in neurons (e.g. Nishimura et al., 1989; 1992; Blaauwgeers et al., 1993) 
It is clear that MT expression undergoes shifts in both regional and cellular 
localisation during the development of the sheep brain. For example, MT 
immunoreactivity was confined mainly to the ventricular zone and molecular layer in 
the E73-E80 foetal brain, but expression was considerably broader in the E116 and 
adult brain. In the E73 brain immunoreactive cells were in the still proliferating 
ventricular zone, but in the E80 and E116 brain radial glial cells and morphologically 
distinct astrocytes and oligodendrocytes exhibited MT immunoreactivity. These 
identifications were confirmed by double labeling experiments with anti-GFAP and 
anti-Gal-C antisera, and are significant because oligodendrocytes have not been 
previously recorded as expressing MT. Interestingly, no trace of MT 
immunoreactivity was observed in the adult oligodendrocytes suggesting that this is a 
phenomenon restricted to the foetal brain. Further work is necessary to determine if 
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ofigodendrocytes in the adult brain are able to express MT after induction with, for 
example, endotoxin. It has been shown in the rat optic nerve that oligodendrocytes 
and type-2 astrocytes develop from the same progenitor cells (Raff, 1989) and it is 
therefore possible that the MT positive progenitor cells observed in the ventricular 
zone give rise to MT positive astrocytes and oligodendrocytes. Interestingly, in a 
previous study low-level ovine GFAP immunoreactivity was detected as early as E60 
in radial glial cells (Hewicker-Trautwein and Trautwein, 1993), which may explain the 
early detection of GFAP mRNA in this study (Figure 3.5). 
We were able to show in the E116 and adult brain that MT and GFAP 
expression in astrocytes were not directly correlated, but there were overlaps in their 
expression profiles. Morphologically distinct astrocytes, which express all visible 
permutations of MT and GFAP, could be identified in single fields. This is of 
particular interest because previous studies in, for example, the adult human brain 
have shown the expression of these two proteins to be in different subsets of glial cells 
(Blaauwgeers et al., 1993). Furthermore, in contrast to the situation in the human 
brain where MT and GFAP are expressed in regionally separated sets of astrocytes 
(Blaauwgeers et al., 1993), in the sheep MT and GFAP were expressed in the same 
regions. In the sheep, MT immunoreactivity was observed in both white and grey 
matter regions of the El 16 and adult brains whilst in the adult human, MT 
immunoreactivity is associated mainly with the grey matter (Blaauwgeers et al., 
1993). Interestingly, Suzuki et al. (1994) showed that in the foetal and infant human 
brain astrocytes in both the grey matter and white matter were positive for MT. 
Clearly, in both the human and the sheep, there are changes in the expression profiles 
of MT during development. 
It has been suggested previously that MT may be associated with cell growth 
and proliferation (Nishimura et al., 1992; Wlostowski et al., 1993) This is supported 
by our study in that MT expression is detected in the proliferative ventricular zone in 
the E73 sheep brain and also in subsequent ages. However, we also noted high levels 
of expression in the molecular layer and the glial limiting membrane, regions not 
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associated with rapidly proliferating cells. Furthermore, in the E116 sheep brain it is 
apparent from the lack of correlation between MT and PCNA immunoreactivity that 
although MT is often expressed in proliferative regions, it is not intrinsic to dividing 
cells. A plausible explanation for the distribution observed is that MT expression is 
confined to a subset of glial cells and its expression is seen as they are formed in the 
ventricular zone, and then later in the subcortical layer and the molecular layer as 
these cells migrate outwards. MT may then be one of the earliest known markers of 
this class of cell. 
3.3.2 The role of MT in the brain 
MT has been most extensively studied in organs other than the brain, such as 
the liver and kidney, and much previous work has emphasised the ability of systemic 
factors such as blood-borne heavy metals, glucocorticoid hormones and interleukins 1 
and 6 to regulate expression of MT genes (Kagi and Kojima, 1987). The regional and 
cellular distribution of MT protein in the developing sheep brain suggests, however, 
that localised factors may be more important in the regulation of MT expression in 
neural cells under normal conditions. It is intriguing to observe adjacent cells with 
identical patterns of GFAP or S100 staining and morphological appearance, but which 
display MT immunoreactivity ranging from very intense to undetectable. Since each 
of these cells is presumably exposed to the same blood supply, it appears likely that 
cell-specific factors, such as intracellular zinc levels, redox state or proliferation 
status, may be determining MT expression in the brain under basal conditions. It is 
possible that at another timepoint, as the state of cells and the conditions of their 
microenvironment change, different populations of glial cells would be seen to express 
MT. It is well documented that under conditions of stress, MT levels increase, and it 
is most likely that in the brain this is due to an increase in the number of MT 
expressing cells, rather than simply an increase in MT levels in those cells already 
expressing the protein. This assertion could be tested by examining the expression of 
MT in the sheep brain before and after LPS treatment. Such a treatment would 
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possibly demonstrate the total population of cells which are capable of expressing MT 
protein when required. 
Clearly, in the mammalian brain, MT-I and -II isoforms are expressed in glial 
cells but not neurons, which would suggest that the function of MT-I and -II isoforms 
in the brain is related to the role played or circumstances encountered by glia but not 
neurons in the brain. Glial cells are the largest population of cells in the brain, and it is 
becoming evident that astrocytes have a number of varied roles in the brain. These 
include maintenance of the blood brain barrier, transport of factors from the blood to 
neurons, involvement in neuron migration and neurite outgrowth, regulation of water 
ions and amino acids in the brain, transfer of proteins and nutrients to neurons and 
also a protective role in the brain (Jacobson, 1991). 
Astrocytes have been suggested to play a role in the protection of neurons 
from free radicals (Juurlink, 1994; Makar etal., 1994). In vitro studies have 
demonstrated that pure cultures of neurons are highly susceptible to anoxic 
conditions, however when co-cultured with astrocytes, the degeneration of neurons 
under anoxic conditions is dramatically reduced (Vibulsreth et al., 1987). The manner 
in which astrocytes provide such protection to neurons is unclear. A role for MT in 
protection against free radicals has been suggested (Thornalley and Vagak, 1985; Abel 
and Ruiter, 1989; Chubatsu and Meneghini, 1993) and it is possible that MTs fulfill 
such a role in astrocytes. Not all astrocytes within a given area are likely to be subject 
to the same levels of oxidative stresses as the redox status of individual cells may 
differ depending on for example the physiological state of the cell, and this may 
explain the different intensities of MT staining seen in glial cells within a single region 
of the brain. Although the main role of oligodendrocytes is seen as providing the 
myelin sheath for neurons, evidence is surfacing that they have a much wider role in 
the brain also (Byravan et al., 1994; Caroni and Schwab, 1989). The possibility exists 
that MT expressed in astrocytes and oligodendrocytes acts as a free radical scavenger 
in the developing sheep brain. However, although evidence suggests MT may be able 
to scavenge free radicals within a cell, MTs are not generally thought to be secreted, 
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so a mechanism by which MTs expressed in glial cells would be able to protect 
associated neurons from free radical damage is unknown. 
The ability of MT proteins to protect against heavy metal toxicity has been 
well documented. The appearance of MT consistently in the glial limiting membrane 
and also consistently surrounding blood vessels supports a protective role for MT, 
and it may be an important component of the blood brain barrier. Neurons do not 
have contact directly with the blood supply and therefore a protein with such a 
protective role would not necessarily be required to be expressed in neurons. This 
may explain the failure of neurons to express MT-I and -II isoforms. A single 
astrocyte is often associated with blood vessels and neurons, and acts to transport 
some factors from the blood to neurons, while also preventing other factors from 
reaching neurons (Jacobson, 1991). MT protein expressed in astrocytes has been 
shown to protect against methylmercury cytotoxicity in vitro (Rising et al., 1995) and 
the role of MT in astrocytes may be to scavenge heavy metals and prevent them 
reaching neurons in the brain. However this protective role would not necessarily 
explain the expression patterns observed for MT in which a single cell near a blood 
vessel may express MT, while a neighbouring cell may not. 
Alternatively, MT has been proposed to have a role in zinc homeostasis and 
transport. High levels of zinc are found in the brain and it is essential for normal brain 
development. Zinc levels vary in different areas of the brain, as do MT levels, and 
although studies indicate that MT levels do not correlate completely with cytoplasmic 
zinc levels (Hidalgo et al., 1991; Gasull etal., 1994) it is possible that MT functions 
in astrocytes in the storage and transport of this metal. High levels of MT are in fact 
seen in zinc rich areas such as the pineal gland (F.A.Stennard, Ph.D. Thesis). A 
proportion of the zinc in the brain is found in vesicles concentrated in synaptic 
terminals of neurons (see Fredrickson, 1989). This zinc is released at glutamatergic 
synapses in response to depolarisation. It is possible that the role of MT-I and -II 
proteins in astrocytes is involved in the sequestration of this released zinc. This is 
possible since it is known that astrocytes are involved in scavenging excess potassium 
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ions released after excessive stimulation of neurons (see Jacobson, 1991). Under 
normal physiological conditions, MT may then be expressed only in those cells 
associated with glutamatergic synapses. 
It is also conceivable that MT expressing cells are responding to paracrine 
secretion of agents like interleukin 1 or 6, known inducers of MT (Bauer et al., 1993) 
since these are known to be produced by a number of cell types in the brain 
(Benveniste etal., 1990; Lee etal., 1993). Therefore, a productive line of future 
research will be to use available techniques to search for changes at the cellular level 
of agents such as zinc, interleukins or demonstrated free radical scavengers, and to 
correlate these with MT expression. Identification of the key factors which induce 
MT expression in neural cells may provide insight into the actual function of MT in 
the brain. 
Finally, it is unclear why MT-I and -II isoforms are not expressed in neurons 
and further studies are necessary to determine this. It is possible that MT-I and -II 
genes are methylated in neurons, and there is certainly evidence of regulation of MT 
genes in certain cell types by methylation (e.g. Compere and Palmiter, 1981). 
Alternatively, it is possible that factors involved in the regulation of MT, such as those 
that interact with the metal regulatory elements (MREs) are not expressed in this cell 
type. Another possibility is that those factors which regulate MT -I and -II isoform 
expression in the brain, have no effect on neurons, i.e. neurons do not express 
receptors that interact with these factors, or else they are excluded from contact with 
neuronal cells by the surrounding glia. 
The physiological basis for the exclusively glial expression of MT-I and -II in 
the brain is no doubt linked to the function of MT in this tissue. MT expression may 
not be required by neurons since they rely on glial cells for many protective 
mechanisms, or alternatively neurons may be unable to tolerate the accumulation of 
metals such as copper and zinc within the cell. Alternatively, there is some evidence, 
at least in the mouse, that the brain specific MT isoform, MT-III, is expressed in 
neurons (Masters et al., 1994b) and it is possible that this isoform has a compensatory 
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role in neurons. It should be noted, however, that in the rat, MT-I protein has been 
detected in neurons both in culture and in vivo (Hidalgo etal., 1994). However, the 
levels of MT-I protein in cultured neurons determined by RIA were 10 times lower 
than in glial cells. 
The investigation of MT in the sheep brain has revealed shifts in both regional 
and cellular expression during development. Although MT appears to be expressed in • 
many of the same cell types in various species there are often subtleties which 
distinguish expression of MT in different species. The sheep however, may prove to 
be a useful model to examine the factors which are most important in regulating MT 
expression in the brain, thus providing insight into the role of MT in this tissue. 
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CHAPTER 4: CLONING OF THE SHEEP 	 CDNA 
4.1 Introduction 
A protein was isolated from human brain extract and termed growth inhibitory 
factor (GIF) because of its ability to inhibit neurite sprouting in vitro (Uchida etal., 
1991). GIF was originaly isolated as a factor deficient in the Alzheimer's disease 
brain, although a further study failed to confirm this deficiency (Erickson et al., 1994): 
The protein was a novel MT isoform, containing 2 structural insertions with respect 
to MT-I and -I isoforms, (Tsuji etal., 1992), and thus termed MT-III. Genes 
encoding highly homologous MT-II isoforms have since been identified in mouse 
(Palmiter et al., 1992) and rat (Kobayashi et al., 1993), and MT-II proteins have 
been isolated from bovine and equine brain (Poutney et al., 1994). 
In al species examined, MT-II expression is restricted almost exclusively to 
neural tissue, although a very low level of MT-Il mRNA has been detected in the 
pancreas and smal intestine of the mouse (Erickson etal., 1995), and also in the 
deciduum during early embryonic development (Liang et al., 1996). However, the 
cel type expression of MT-II in the brain remains controversial. In the human brain, 
MT-II protein was detected using an antibody to a synthetic peptide, and its 
expression was found to be restricted to astrocytes (Uchida et al., 1991). In a further 
study, both MT-II tnRNA and protein were detected in astrocytes in layers 2-6 of 
grey and white mater of the human cerebrum, and were found to co-localise with 
MT-I (Nakajima and Suzuki, 1995). In contrast, in the mouse, MT-III mRNA 
expression was primarily detected in neurons (Choudhuri etal., 1995), and Masters et 
al. (1994b) reported a corelation between MT-II expression and neurons that 
sequester zinc in terminal vesicles. However, the expression of MT-II in the mouse 
does not appear to be exclusively neuronal as MT-II mRNA was found to co-localise 
with MT-I in glial cels of the purkinje layer of the cerebelum (Zheng et al., 1995), 
and was also detected in the choroid plexus (Masters et al., 1994b). Interestingly, in 
transgenic mice in which the human MT-II promoter was fused to the E.coli lac Z 
gene, expression of13-galactosidase was detected in neurons (Masters et al., 1994b). 
Furthermore, transgenic mice containing the human MT-II gene expressed a high 
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level of human MT-HI mRNA in the brain in a pattern which generally reflected the 
neuronal expression of endogenous mouse MT-III mRNA (Erickson et al., 1995). 
MT-III mRNA expression has also been examined in neural cells in culture. 
MT-III mRNA was detected in rat astrocyte primary cultures, but not cultures 
enriched for neurons, fibroblasts or microglial cells (Kobayashi etal., 1993). 
Similarly, Masters etal. (1994b) found that although MT-HI mRNA was not 
expressed in mouse astrocytes in vivo, astrocytes maintained in culture began to 
express MT-III after 1 week, suggesting that MT-III expression can be induced by 
culture conditions. However, MT-HI was not detected in 5 transformed human 
astrocyte cell lines (Masters etal., 1994b). 
Low levels of MT-III mRNA have been detected in the embryonic rat (E18), 
increasing dramatically postnatally (Kobayashi et al., 1993). In the mouse, MT-III 
mRNA was detectable in the foetal head at E13.5, enriched in the foetal brain at 
E16.5 and reached maximum levels at day 13 after birth (Masters etal., 1994b). 
However, significant levels of MT-III mRNA were not detected in the foetal human 
brain (Tsuji et al., 1992). In the mouse, MT-III mRNA has also been detected in 
early development in cells of the deciduum, co-expressed with MT-I and -II mRNA 
(Liang et al., 1996). The expression of MT-III in this instance appeared to be highly 
regulated, both temporally and spatially, and appeared to be co-regulated with other 
MT isoforms. In the various regions of the adult mouse brain MT-I mRNA and MT-
III mRNA have also been shown to be expressed at approximately equal levels, 
except in the hippocampus in which MT-III InRNA was enriched (Masters et al., 
1994b), suggesting a degree of co-regulation of MT isoforms in the adult mouse 
brain. 
However, MT-III regulation appears to differ from that of other MT genes in 
many respects. In the mouse MT-III is unaffected by cadmium chloride, 
dexamethasone, ethanol, kainic acid, lipopolysaccharide (LPS) or zinc chloride, while 
both LPS and zinc chloride increase MT-I mRNA levels in the brain (Zheng et al., 
1995; Palmiter et al., 1992). Furthermore, in cultured mouse astrocytes the MT 
inducers phorbol 12-myristate 13-acetate, dibutyryl cAMP, dexamethasone and zinc 
sulphate failed to affect MT-III expression. However, removal of serum from 
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astrocytes in culture, resulted in growth arest and increased MT-II mRNA 
expression (Masters et al., 1994b). 
Examination of the promoters of both the human and mouse MT-II genes 
revealed regulatory elements often found in MT promoters, including AP-2 like 
binding sites, Spl binding sites and also metal regulatory elements (MREs, Naruse et 
al., 1994). Despite the presence of three MREs in the promoters of both human and 
mouse MT-II genes, metal regulation of neither MT-II gene has been demonstrated. 
Interestingly, the human MT-II gene also contains an element similar to the sequence 
detected in the gene which encodes glial fibrilary acidic protein (GFAP) thought to be 
responsible for the astrocyte-specific expression of GFAP, and it was proposed that 
this element may be responsible for the astrocyte-specific expression which has been 
documented for human MT-II (Naruse et al., 1994). The mouse MT-III promoter 
has been shown to contain a CTG triplet repeat which is capable of acting as a 
repressor. However, binding proteins for this sequence have not been detected, and 
its activity in brain cels is yet to be examined (Imagawa etal., 1995). 
The growth inhibitory activity of human MT-II in vitro was first reported by 
Uchida et al. (1991), and has since been demonstrated for MT-II proteins from 
mouse (Erickson etal., 1994), horse and cow (Poutney et al., 1994). The growth 
inhibitory activity of the MT-II protein demonstrated in vitro, is entirely due to the 
N-terminal portion of the protein (Uchida and Ihara, 1995), and more particularly has 
been mapped to the CPCP sequence in the N-terminal domain, which is unique to the 
MT-II isoform (Sewel etal., 1995). Several studies have demonstrated changes in 
MT-II expression in vivo after neural damage, leading to the suggestion of a growth 
inhibitory role for MT-II in vivo also. For example, MT-II appears to be 
upregulated in rat brain after stab wound injury. Both MT-II mRNA and protein 
levels increased 4 days after injury and the response was sustained for 28 days 
(Hozumi et al., 1995). The increase 	 was suggested to be a result of 
upregulation of the gene due to the acute phase response after injury, and an 
indication that MT-II may be involved in repair after brain injury. Similarly, MT-II 
mRNA levels increased transiently in both neuronal and non-neuronal cels after 
ablation (Yuguchi et al., 1995a). - It was proposed that MT-II was involved in 
maintaining the neuronal network and controling the outgrowth of injured neurites. 
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In a further study, MT-III expression was dramatically suppressed after transection of 
peripheral facial nerves, and this response lasted for 5 weeks (Yuguchi et al., 1995b). 
In this instance it was suggested, that suppression of MT-III would reduce inhibition 
of neurite outgrowth which is necessary for regeneration of axons. In contrast, 
overexpression of human MT-III in transgenic mice did not result in any obvious 
• deleterious effects in the development or physiology of the brain, raising questions as 
to whether MT-III does have a growth inhibitory role in vivo.. These mice however 
accumulated increased levels of zinc (but not other metals) in the brain entirely 
accounted for by zinc bound to the human MT-III protein, raising the possibility that 
MT-III is involved in some aspect of zinc regulation (Erickson et al., 1995). 
The sheep MT gene family consists of 4 well characterised functional MT 
genes (MT-Ia, MT-Ib, MT-Ic and MT-II). However a MT-III isoform has not been 
documented in the sheep. The purpose of this study was to clone the MT-III cDNA 
from sheep, investigate its homology to MT-III genes from other species, and 
examine whether its expression patterns are consistent with those found in other 
species. Investigation of MT-III in a species with a complex MT locus (like humans), 
and in which MT isoforms have been well studied in the brain, may shed light on the 
function of MT-III in vivo and its relationship to other MT isoforms. Questions still 
remain as to whether the MT-III isoform does in fact have a function distinct from 
MT-I and -II isoforms and whether the growth inhibitory activity of MT-III 
demonstrated in vitro is physiologically relevant. Investigation of the cell type 
expression of MT-III in a further species will also be useful as studies to date on 
mouse, rat and human are contradictory and suggest that cell type expression of MT-
III may in fact be species specific. 
4.2 Results: 
4.2.1. Cloning of mouse MT-HI cDNA and its suitability as a sheep MT-HI 
probe 
Mouse MT-III cDNA (274 base pairs including the entire coding region) was 
amplified from mouse brain RNA by RT-PCR using mouse MT-III sense (5'- 
TGGATATGGACCCTGAGACC-3") and antisense (5'-CCTTGGCCCCCTCTTC-
3') PCR primers. The RT-PCR protocol was as outlined in section 2.4, using an 
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annealing temperature of 60°C, and 35 cycles. The amplified product was blunt 
ended using Pfu DNA polymerase and ligated into the pUC-19 vector at the Smal 
endonuclease restriction site. The RT-PCR product was sequenced by the dideoxy 
sequencing method (section 2.5.1) and confirmed to be identical to that reported 
previously for mouse MT-III (Palmiter et al., 1992). The hybridisation of this RT-
PCR product to sheep and mouse DNA and RNA was then examined, as outlined 
below. 
Genomic DNA was isolated from mouse and sheep tissue, digested with the 
restriction endonucleases EcoR1 and HindIII, electrophoresed through 1.4% agarose 
and transferred to a nylon membrane (ZetaProbe GT, BioRad) as outlined in section 
2.3. The Southern blot was hybridised at 37°C in 50% formamide hybridisation 
buffer for 16 hr with the radiolabelled mouse MT-III RT-PCR probe, and washed to a 
stringency of 0.2 X SSC, 1% SDS at 37°C. Southern analysis of sheep and mouse 
DNA under these conditions demonstrated that the probe hybridised to mouse as well 
as sheep sequences (Figure 4.1). The probe hybridised to an EcoRI fragment of 
mouse DNA of 4.5 kb as expected, as well as an EcoRI fragment of sheep DNA of 
4.4 kb, which did not correspond to any of the known sheep MT genes (Peterson et 
al., 1988, see Chapter 3). 
Total RNA was isolated from various tissues of both foetal (E72, E86, E116) 
and adult sheep. Northern analysis of the RNA (section 2.3) using the radiolabelled 
mouse MT-III RT-PCR product as a probe, under the conditions outlined above, 
demonstrated that the mouse MT-III probe hybridised to RNA from sheep brain 
(E116 and adult), but not RNA from other tissues (Figure 4.2). In contrast, the 
human MT2A RT-PCR product used as a general MT-Jill probe since it hybridises to 
all known sheep MT-I and MT-II isogenes (see Chapter 3), hybridised to RNA from 
sheep brain (E116 and adult) as well as liver (E72, E86, E116 and adult), kidney 
(E 116 and adult), and weakly to RNA from lung (adult), and heart (adult). 
4.2.2 Cloning sheep MT-HI cDNA 
Attempts were made to amplify sheep MT-III cDNA by low stringency RT-
PCR using PCR primers designed to the coding regions of the human and the mouse 
MT-III gene sequences and low annealing temperatures. Degenerate MT-III primers 
Mouse Sheep 
HE HE 
— 4.5 kb 
— 4.4 kb 
Figure 4.1 Analysis of mouse and sheep DNA with a mouse MT-DI probe 
Mouse and sheep genomic DNA was digested with the restriction endonucleases EcoRI 
(E) and HindIII (H), and subjected to Southern blot analysis with a mouse MT-III cDNA 
probe. The probe hybridised strongly to a 4.5 kb EcoRI fragment of mouse DNA and a 
4.4 kb EcoRI fragment of sheep DNA as indicated. 
MT-1/11 
MT-Il 
EtBr 
(1 2 3 4 ) (1 2 3 4) (1 2 3 4) (1 2 3 4) (1 2 3 4) (1 2 3 4) 
Liver 	 Kidney 	 Brain 	 Lung 	 Heart 	 Gut 
Figure 4.2 Expression of MT mRNA in foetal and adult sheep tissues 
Total RNA was isolated from foetal and adult sheep tissues and after electrophoresis subjected to northern bloting. Tissues were from 
sheep of the folowing ages; 1: E72, 2: E80, 3: E116 and 4: Adult. The RNA was hybridised to a mouse MT-II cDNA probe (MT-
II), and a human MT2A cDNA probe (MT-I/I) which hybridises to al sheep MT-I and -I genes. The ethidium bromide stained gel is 
shown to demonstrated that approximately equal amounts of RNA were loaded in each lane. 
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used to clone the mouse MT-III cDNA in a previous study (Palmiter et al., 1992), 
were also used. A product of approximately 150 bp was amplified from sheep brain 
RNA but not liver RNA, using primers designed to the coding region of the mouse 
MT-III gene (sense: 5'-TGGATATGGACCCTGAGACC-3' and antisense: 5'- 
GTTGTGCCCCACCAGGGAC-3') at an annealing temperature of 32°C. This 
transcript was shown to hybridise to the mouse MT-III RT-PCR product probe under 
the conditions outlined above. However, due to the low stringency of the PCR many 
transcripts were amplified, and despite numerous attempts an MT-like product could 
not be cloned. 
A sheep choroid plexus cDNA library in Xgt10 (Tu et al., 1989) was screened 
(see section 2.9.7) using the mouse MT-III RT-PCR product as a probe. 
Approximately 120,000 plaques were lifted onto nitrocellulose filters, hybridised with 
the radiolabelled probe at 55°C in DNA hybridisation buffer, and washed to a 
stringency of 0.2 X SSC, 1% SDS at room temperature. However, no positive 
plaques were detected from this library. 
Therefore it was decided to construct a sheep cortex cDNA library. Total 
RNA was isolated from brain cortex of 2 adult sheep. Poly(A) ÷ RNA was isolated 
from the total RNA using magnetic Dynabeads from Dynal, which have oligo(dT) 
residues covalently coupled to the surface (section 2.9.1). The poly(A) + mRNA (3 
lig) was used to construct a cDNA library with the ZAP express vector system from 
Stratagene (section 2.9). First strand cDNA was synthesized with MMLV-RT 
(Figure 4.3A). Rnase H was used to nick the RNA and DNA polymerase was then 
used in synthesis of the second strand of the cDNA (Figure 4.3A). The prepared 
cDNA was size fractionated with Sephacryl and the first 5 fractions (Figure 4.3B) 
were combined and ligated into the ZAP Express vector. After packaging and 
amplification the sheep brain cortex cDNA library consisting of 52,000 recombinants 
and with a titre of 1.2 X 10 10 pfu/ml was screened with the mouse MT-III RT-PCR 
product (section 2.9.7). Approximately 60,000 plaques were lifted onto nitrocellulose 
filters, hybridised with the radiolabelled mouse MT-III probe for 16 hr at 55°C in 
DNA hybridisation buffer, and washed to a stringency of 0.2 X SSC, 1% SDS at 
room temperature. Twelve plaques which hybridised to the mouse MT-III RT-PCR 
product were selected and purified after 3 rounds of screening. The required inserts 
1 2 3 4 5 6 7 8 	 1 	 2 	 3 	 4 5 	 6 	 7 
ale ER 00 "°1° 
Figure 4.3 Construction of a sheep brain cDNA library 
Poly(A)+ RNA (3p.g) was isolated from sheep brain cortex and used to construct a cDNA 
library using the Statagene ZAP Express vector system. 
A:First and second strand synthesis of the cDNA was monitored  by electrophoresis of an 
aliquot of the reactions through an alkaline agarose gel. The dried gel was exposed to 
autoradiography film. Test poly(A)+ RNA provided by Stratagene was used as a control 
of first and second strand synthesis. Lanes 1-3: test poly(A) + RNA, first strand synthesis 
(4%, 2% and 1% of reaction, respectively), Lane 4: test poly(A) + RNA, second strand 
synthesis (10% of reaction), Lanes 5-7: sheep brain cortex poly(A)4 RNA, first strand 
synthesis (4%, 2%, and 1% of reaction, respectively), Lane 8: sheep brain cortex 
poly(A)÷ RNA, second strand synthesis (10% of reaction). 
B:The cDNA was size fractionated through a S-500 sephadex  spin column. Aliquots 
(10%) of the 7 colected fractions were electrophoresed through a 5% (29:1) 
nondenaturing acrylarnide gel and exposed to autoradiography film. Inclusion of DNA 
markers on the gel alowed the size of the cDNA fractions to be determined, and a size of 
500 bp is indicated (arow). 
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were excised out of the phage in the kanamycin-resistant pBK-CMV phagemid vector 
(section 2.9.8). Clones were sequenced in both directions using the ABI PRISMTm 
Dye Primer Cycle Sequencing Ready Reaction Kit (section 2.5.2). Sequence analysis 
of the clones revealed 2 full length independent clones of a novel MT cDNA (Figure 
4.4). 
4.2.3 Analysis of a novel MT cDNA, sheep MT-111 
The protein predicted by the novel sheep cDNA is a 65 amino acid MT-like 
protein containing 17 cysteine residues, appearing in conserved positions when 
compared with the known sheep MTs (Figure 4.5), and devoid of aromatic amino 
acids. Insertions of a single amino acid in the N terminal domain and a 6 amino acid 
insertion in the C terminal domain identify the protein as a MT-III isoform. The 
putative sheep MT-III protein is clearly homologous to the known MT-III proteins 
from human, mouse, rat, cow and horse (Figure 4.5) with 87% and 85% amino acid 
conservation to the bovine and equine proteins, respectively. In fact, the putative 
sheep MT-III amino acid sequence is identical to the MT-III protein isolated from 
bovine brain at 61 out of 68 positions. Slightly less conservation is seen with the 
human, mouse and rat protein with 84%, 79% and 75% amino acid identity, 
respectively. The most significant difference in the putative sheep MT-III protein is a 
3 amino acid deletion of the amino acid sequence SCC, normally conserved at 
positions 33-35 of MT-III proteins. Furthermore, a serine residue at position 30 
replaces a cysteine residue which is conserved in all other MT-III proteins. The 6 
amino acid insertion in the C-terminal domain of the sheep MT-III protein is identical 
to that found in the corresponding bovine protein, although the single amino acid 
insertion at position 5 which is a threonine residue in all known MT-III proteins is an 
alanine residue in the putative sheep protein. The 3' untranslated region of the sheep 
MT-III cDNA has little similarity to those reported for the mouse and human 
(Palmiter et al., 1992) which are themselves unrelated, although the position of the 
AATAAA polyadenylation site is relatively conserved. 
The putative sheep MT-III protein is identical to all 4 known sheep MT-I and 
-II isoforms (Ia, Ib, Ic and II) at 32 positions, and contains unique residues at 18 
positions (not including the 2 insertions and the 3 amino acid deletion). At the 
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Figure 4.4: Nucleotide sequence of sheep MT-111 cDNA 
The sequence of sheep MT-II cDNA was obtained from 2 independent clones from a 
sheep brain cortex cDNA library. The start of the 2 clones are indicated (asterisks). 
The polymorphism identified by RT-PCR is indicated in bold (at position 108). 
Recognition sites for the HaeII restriction endonuclease are indicated. Binding sites 
for PCR primers are indicated (double underlined). The polyadenylation site is 
indicated (bold). 
A: 
Sheep MT-Ia 
MDPN-CSCPTGGSCSCAGSCTCKACRCPSCKIKSCCSCCPVGCARCAQGCVCKG 	 ASDKCSCCA 
Sheep MT-lb 
MDPN-CSCPTSGSCSCAGSCTCKACRCPSCKKSCCSCCPVGCAKCAQGCVCKG 	 ASDKCSCCA 
Sheep MT-Ic 
MDPN-CSCSTGSSCSCAGSCTCKACRCPSCKKSCCSCCPVGCARCAQGCICKG 	 ASDKCSCCA 
Sheep MT-II 
MDPN-CSCTAGESCTCAGSCKCIDCKCASCKRSCCSCCPVGCAKCAQGCVCKG 	 ASDKCSCCA 
Sheep MT-DI 
MDPEACPCPTGGSCTCSDSCKCEGCTCASSKK---SCCPAECEKCAKDCVCRGGEGAEAEEKKCGCCQ 
*** * * 	 **2* * *2* ** 	 **** * *** *;t*** 	 ** ** 
B: 
Human MT-III 
MDPETCPCPSGGSCTCADSCKCEGCKCTSCKKSCCSCCPAECEKCAKDCVCKGGEAAEAEAEKCSCCQ 
Mouse MT-III 
MDPETCPCPTGGSCTCSDKCKCKGCKCTNCKKSCCSCCPAGCEKCAKDCVCKGEEGAKAE,AEKCSCCQ 
Rat MT-III 
MDPETCPCPTGGSCTCSDKCKCKGCKCTNCKFCSCCSCCPAGCEKCAKIJCVCKGEEGAK-AEKCSCCQ 
Cow MT-III 
MDPETCPCPTGGSCTCSDPCKCEGCTCASCKRSCCSCCPAECEKCAKDCVCKGGEGAEAEEKKCSCCQ 
Horse MT-III 
MDPETCPCPTGGSCTCSGECKCEGCKCTSCKRSCCSCCPAECEKCAKDCVCKGGEGAEAEAEKCSCCQ 
Sheep MT-111 
MDPEACPCPTGGSCTCSDSCKCEGCTCASSKK- - -SCCPAECEKCARDCVCKGGEGAEAEEKKCGCCQ *  *** 	  
Figure 4.5 Comparison of the putative sheep MT-III protein with known MT 
proteins 
A:Comparison of the predicted sheep MT-II amino acid sequence with sheep MT-I 
and -I amino acid sequences (from Peterson et al., 1988). Amino acids common to 
al proteins are indicated with asterisks, those in MT-II also found in MT-I (1) or 
MT-I (2) isoforms are indicated, and the amino acids in the MT-Il sequence found 
in some MT-I and -I sequences are indicated (1/2). 
B:Comparison of the predicted sheep MT-II amino acid sequence with MT-II 
proteins from human (Uchida etal., 1991), rat (Kobayashi et aL, 1993), mouse 
(Palmiter etal., 1992) and cow and horse (Poutney et al., 1994). Substitutions 
unique to the sheep MT-II protein are indicated (asterisks). 
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remaining 8 positions it has identity to one or more of the known sheep MTs (see 
Figure 4.5). The sheep MT-III protein has 37 positions identical to MT-Ia and MT-
II, 36 positions identical to MT-lb and 34 positions identical to MT-Ic. 
The sequence of the sheep MT-III cDNA was confirmed from 4 more 
individuals to verify the sequence. The following PCR primers were designed to the 
sheep MT-III cDNA in the 5' and 3' non-coding regions: 
sheep MT-III sense: 5'-CGGTGGTCGCTCCTCT-3' 
sheep MT-III antisense: 5'-TTTCACACGGGACAGTGG-3'. 
The binding sites for the primers in the cDNA nucleotide sequence are indicated in 
Figure 4.4. RNA was isolated from 4 additional sheep brains and RT-PCR used to 
amplify the sheep cDNA. The RT-PCR protocol was as outlined in section 2.4, using 
an annealing temperature of 60°C and 35 cycles. Transcripts were electrophoresed 
through an agarose gel, purified through a spin column (section 2.2.1) and subjected 
to a second round of amplification. Purified transcripts were sequenced using the 
ABI PRISMTm Dye Terminator Cycle Sequencing Ready Reaction Kit and the sheep 
MT-III antisense oligonucleotide described above. Analysis of the 4 PCR products 
determined that they were identical to the sequences obtained from the cDNA library, 
except for a single polymorphism where the cysteine at position 22 was either 
encoded by a TGT or TGC codon (as indicated in Figure 4.4). 
4.2.4 Expression of sheep MT-III mRNA 
A 147 bp HaeIII fragment of the sheep MT-III cDNA (bases 56 to 202, 
Figure 4.4) was subcloned into pUC-19 at the Sinal endonuclease restriction site, 
creating a partial clone of sheep MT-III cDNA minus the poly (A)+ tail. The clone 
contains 77% of the coding region of the cDNA. This HaeIII fragment of the sheep 
MT-III cDNA was used as a probe in Southern and northern analysis of sheep DNA 
and RNA, as outlined below. 
Genomic DNA from 2 sheep was digested with the restriction endonuclease 
EcoRI and subjected to Southern analysis (section 2.3). The Southern blot was 
hybridised with the radiolabelled sheep MT-III cDNA probe described above for 16 hr 
at 42°C in 50% formamide hybridisation buffer, and washed to a stringency of 0.2 X 
SSC, 1% SDS at 37°C. Under these conditions the sheep MT-III cDNA probe 
2 
Figure 4.6 Southern blot analysis of sheep DNA with a sheep MT-III probe 
Genomic DNA from 2 sheep (lanes 1 and 2) was digested with the restriction 
endonuclease EcoRI and subjected to Southern blot analysis with a sheep MT-III 
cDNA probe. The probe hybridised to a 4.4 kb EcoRI fragment of sheep DNA as 
indicated. 
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hybridised to a 4.4 kb EcoRI fragment of sheep DNA (Figure 4.6), confirming earlier 
results using the mouse MT-III RT-PCR product as a probe. The sheep MT-III 
cDNA probe did not hybridise to fragments of DNA containing sheep MT-I and -II 
genes, confirming that the probe was specific for the MT-HI isogene (see Chapter 3). 
The Haell1 fragment of sheep MT-III cDNA was used as a probe in northern 
analysis (section 2.3) of RNA from sheep brain and liver of different developmental 
ages. RNA was isolated from liver and brain of foetal and adult sheep, 
electrophoresed through agarose, and transferred to a nylon membrane by alkaline 
blotting. The northern membrane was hybridised under the conditions outlined above 
with the radiolabelled HaeIII fragment of sheep MT-III cDNA. Expression of MT-HI 
mRNA was detected in the E116 foetal and adult brain but not at earlier time points 
(Figure 4.7) or in the foetal or adult liver. MT-I and -II isoforms were detected in the 
E116 and adult brain using as a probe the human MT2A RT-PCR product (i.e. MT-
1/II general probe) which hybridises to these isoforms. Low levels were also detected 
in the E72 and E86 brain, as detailed previously (see Chapter 3). 
Northern analysis was also used to examine the expression of sheep MT-III 
mRNA in different regions of the adult sheep brain (Figure 4.8). Using the HaeIII 
fragment of sheep MT-III cDNA and the conditions outlined above, expression was 
detected in all regions examined with highest levels of expression detected in the 
pineal gland, relatively high levels in the basal ganglia and midbrain and lowest levels 
in the brain stem and thalamus. MT-III mRNA again was not detected in the adult 
liver. Expression of mRNA for MT-I and -II isoforms was also examined using the 
human MT2A RT-PCR product as a probe. The northern blot was hybridised at 37°C 
for 16 hr in 50% formamide hybridisation buffer, and washed to a stringency of 0.2 X 
SSC, 1% SDS at 37°C; conditions under which the probe hybridises to all MT-I and - 
II isoforms, as outlined in Chapter 3. Expression of MT-I and -II mRNA was similar 
to that of MT-III mRNA, with highest levels of expression detected in the pineal 
gland (Figure 4.8). Unlike MT-III, MT-I and -II isoforms were detected in the adult 
liver, as expected. Hybridisation of the northern blot with a human 13-actin probe 
demonstrated that approximately equal amounts of RNA were loaded in each lane. 
Hybridisation was at 37°C in 50% formamide hybridisation buffer, and the blot was 
washed to a stringency of 0.2 X SSC, 1% SDS at 37°C. 
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Figure 4.7 Expression of MT mRNA in the foetal sheep brain and liver 
Total RNA was isolated from foetal (E40, E58, E64, E72, E86 and E115) and adult (A*) sheep brain and liver. After electrophoresis and 
northern bloting, the RNA was hybridised to a human MT2A RT-PCR product (MT-I/I) which hybridises to al sheep MT-I and -I genes and a 
sheep MT-II cDNA. The ethidium bromide stained gel is shown to demonstrate that approximately equal amounts of RNA were loaded in each 
lane. 
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Figure 4.8 Regional expression of MT mRNA in the adult sheep brain 
Total RNA was isolated from dissected regions of the adult sheep brain and from the 
adult liver. After electrophoresis and northern bloting, the RNA was hybridised to a 
human MT2A RT-PCR product (MT-I/I) which hybridises to al sheep MT-I and -I 
genes and a sheep MT-II cDNA. Hybridisation to a human 13-actin cDNA 
demonstrated that approximately equal amounts of RNA were loaded in each lane. 
RNA was from the folowing tissues regions: 1: frontal cortex, 2: occipital cortex, 3: 
midbrain, 4: brain stem, 5: pineal gland, 6: basal ganglia, 7: hypothalamus, 8: 
thalamus, 9: hippocampus, 10: choroid plexus, 11: liver. 
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4.2.5. Cellular localisation of sheep MT-Ill 
Preliminary studies were conducted to investigate whether the cellular 
localisation of MT-III tnRNA could be determined by in situ hybridisation. Adult 
sheep brain was dissected into anatomical regions, fixed in paraformaldehyde, sections 
5 i_tm thick cut and floated onto silanized slides. An oligonucleotide probe designed 
specifically to the sheep MT-III sequence, and a conserved oligonucleotide designed 
to MT-I and -H isoforms were radiolabelled with y- 32PATP. The oligonucleotide 
sequences used were: 
sheep MT-III antisense: 5'-TTTCACACGGGACAGTGG-3' 
conserved MT-I/II antisense: 5'-GCAGCCCTGGGCACACTTG-3' 
In situ hybridisation studies using these probes were conducted as outlined in 
section 2.6.6. Sections were hybridised for 16 hr with the radiolabelled 
oligonucleotide probes. A hybridisation temperature of 37°C was used for the 
conserved MT-I/II oligonucleotide and a hybridisation temperature of 42°C was used 
for the MT-III specific oligonucleotide. The sections were washed up to 60°C in 1 X 
SSC and exposed to autoradiography film. Figure 4.9 shows autoradiography of 
sheep brain cortex, basal ganglia and pineal gland as well as mouse kidney sections 
hybridised with the radiolabelled probes. These brain sections were chosen for 
preliminary studies as northern analysis demonstrated that these regions of the brain 
express widely varying levels of MT-III mRNA (see Figure 4.8). As demonstrated in 
Figure 4.9A, highest level of MT-III mRNA detected by in situ hybridisation were in 
the pineal gland, followed by the basal ganglia and the brain cortex. This is as 
expected from earlier northern analysis (Figure 4.8). However, although differential 
expression could be detected between sections taken from different regions of the 
brain, within a region there was little variation in the intensity of signal and at a 
microscopic level, the hybridisation signal could not be assigned to individual cells or 
a particular cell type. This is because the large amount of scatter from 32P 
radionucleotides means that signal from an individual cell is observed over many of 
the surrounding cells. Figure 4.9B demonstrates that while MT-III mRNA was 
detected in pineal gland and basal ganglia, no signal was detected in the mouse kidney 
sections, as expected, and therefore the probe was specific for the MT-III isoform the 
2 
4 
Figure 4.9 In situ hybridisation of MT in sheep brain regions 
Tissue sections were hybridised in situ to radiolabelled oligonucleotide probes as 
described in the text. The probes used were a sheep MT-III oligonucleotide probe (A 
and B) and conserved MT-I/II oligonucleotide probe (C). The hybridised sections 
were exposed to autoradiography film (Hyperfilm -MP, Amersham). Tissue sections 
were from: 1 sheep pineal gland, 2 sheep basal ganglia, 3 sheep  brain cortex, 4 mouse 
kidney. 
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probe was specific for the MT-III isoform. As demonstrated in Figure 4.9C the 
highest level of MT-Jill nilINA detected by in situ hybridisation was in the pineal 
gland, with lower levels in the basal ganglia and cortex as expected from previous 
northern analysis (Figure 4.8). Unlike the MT-III probe the conserved probe detected 
MT-I and -II mRNA in the mouse kidney, as expected. Again, the signal could not be 
assigned to any cell type at the microscopic level. However, the preliminary results 
presented here suggest that these oligonucleotides may be useful in examining the 
cellular localisation of MT-III in the sheep brain but more informative studies would 
necessitate using large areas of the sheep brain, containing various anatomical regions 
so that glial or neuronal rich areas of the brain can be correlated with the intensity of 
the MT-III signal. Also, a different radioisotope may be required which produces less 
scatter. 
4.3 Discussion 
4.3.1 Sheep MT-111 structure and homology 
A novel MT cDNA was cloned from a sheep brain cortex cDNA library. The 
cDNA encodes a putative sheep MT-III protein of 65 amino acids, containing 26% 
cysteine residues appearing in conserved positions throughout the protein chain. The 
predicted amino acid sequence is consistent with other MT proteins, containing no 
aromatic amino acids or histidine. The putative sheep MT-III protein shows a high 
degree of conservation to MT-III isoforms from other species, and in fact shares 87% 
and 85% identity to the bovine and equine MT-III proteins characterised by Poutney 
etal. (1994). Palmiter etal. (1992), suggested that the MT-I, -II and -III isoforms 
arose from the triplication of an ancestral MT gene. The mouse MT-III protein 
appears more similar to the mouse MT-I protein, while the human MT-III protein 
appears more similar to the human MT-II protein. At the protein level, sheep MT-III 
appears equally divergent from the MT-I and -II isoforms, having 37 amino acids 
identical to the sheep MT-Ia protein and 37 amino acids identical to the sheep MT-II 
protein. 
The most striking feature of the putative sheep MT-III protein in comparison 
to any mammalian MT is a deletion of 3 amino acids (SCC) at positions 33-35. This 
is a deletion in the SCCSCC sequence that occurs directly after the 2 lysine residues 
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which form the bridge between the a- and 13- domains of the protein. This sequence 
forms the start of the a-domain of the protein, and is conserved among all mammalian 
MT proteins sequences documented thus far (see Kagi, 1993). This deletion is likely 
to affect the structure of the protein and its metal binding properties and is unlikely to 
be an artifact since it was observed from a total of 5 individual sheep. In fact 3 
conserved cysteine residues are missing from the sheep MT-III protein, those 
normally found at positions 34 and 35 which are deleted, as well as the cysteine 
residue usually conserved at position 30 which is a serine residue in sheep MT-III. 
The absence of 3 cysteine residues is likely to diminish the metal binding properties of 
the sheep MT-III protein, since cysteine residues are critical in metal binding. 
The metal binding stoichiometries of MT-I and -II isoforms are well 
documented and appear to be identical for all MTs, as the metal complexing is 
dependent on the conserved cysteine residues alone, although other amino acids may 
contribute to the stability of the complex (see Kagi and Kojima, 1987). These 
conserved cysteine sulfhydryls can be classified as either terminal (liganded to one 
metal atom) or bridging (liganded to two metal atoms). Human and mouse MT-III 
proteins have been shown to exhibit the same metal binding stoichiometries with zinc, 
cadmium and copper as are documented for MT-I and -II isoforms (Sewell et al., 
1995), i.e. the MT-HI proteins bind 7 mole equivalents of the divalent metals 
cadmium and zinc, or 12 copper ions. MT-III isoforms, like MT-I and -II isoforms, 
consist of 2 domains enfolding separate polymetallic clusters (Sewell etal., 1995), i.e. 
MT-III proteins contain a Me,Cys, cluster (0-domain containing 3 divalent metals via 
3 bridging and 6 terminal cysteines) and a Me4Cys11 cluster (a-domain containing 4 
divalent metals via 5 bridging and 6 terminal cysteines). The zinc complexes of MT-
III proteins also exhibit similar cluster reactivities as have been established for MT-I 
and -II isoforms (Sewell et al., 1995). The putative sheep MT-III protein is missing 
one terminal cysteine residue from the 13-domain and two cysteine residues (one 
bridging, one terminal) from the a-domain. These cysteine residues are normally 
involved in the binding of 3 of the 7 divalent metal ions in the MT-metal clusters 
(represented in Figures 4.10 and 4.11). 
A number of studies have looked at the effect of mutations of the various 
conserved cysteine residues on the metal binding properties of MT mutants, and also 
Figure4.10Disruptions in metal binding of the putative sheep 	 protein. 
The metal thiolate clusters as determined for rat liver MT are shown. The f3-domain 
cluster (Metal3cysteine9) and a-domain cluster (Metalacysteinen) are shown. The sulfur 
atoms of the.cysteine residues are represented as S. where n indicates the position in the 
sheep MT-Il amino acid sequence. Those cysteine residues either deleted or mutated in 
the sheep MT-III protein are indicated (black) and those metal atoms normaly involved 
in binding to these residues are indicated (black). The numbering of the metals 
correspond to n.m.r spectral assignments. Adapted from Robbins etal., (1991). 
rat liver MT 
MDPN-CSCATDGSCSCAGSCKCKQCKCTSCKKSCCSCCPVGCAKCSQGCICKE ASDKCSCCA 
CdIV CdIII CdII 	 CdV 	 CdVII CcIVI 	 CdI 
mouse MT-111 
MDPETCPCPTGGSCTCSDKCKCKGCKCTNCKKSCCSCCPAGCEKCA1CDCVCKGEEGAKAEAEKCSCCQ 
cdrv CdIII CdII 	 CdV 	 CdVII CdVI 	 CdI 
sheep MT-III 
MDPEACPCPTGGSCTCSDSCKCEGCTCASSKK--SCCPAECEKCAlcDCVCKGGEGAEAEEKKCGCCQ 
C IV C III C II 
 
        
Figure 4.11 Cadmium-thiolate bonds which are disrupted in the putative sheep MT-III protein 
Cadmium-cysteine connectivities of rat liver ltdrthionein established by 2-dimensional n.m.r spectroscopy are shown (adapted from Kagi and 
Schafer, 1988). These connectivities are extrapolated to mouse MT-II, since identical conformations have been demonstrated for this isoform 
(Sewel etal., 1995). The putative sheep MT-II amino acid sequence is shown, and those cadmium-cysteine ligands which are disrupted due to 
mutation or deletion of cysteine residues are indicated as doted lines. Those cadmium atoms which are afected are underlined. 
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the ability of these mutants to protect against cadmium toxicity. In general, such MT 
mutants do not have major structural disruptions of the cadmium-thiolate binding 
geometry. For example, chinese hamster MT mutants C13Y, C50Y and C13,50Y (in 
which cysteine 13, cysteine 50 or both cysteine 13 and 50 are mutated to tyrosine 
residues) all retained a tetrahedral geometry of metal binding. They also retained the 
2 independent domain structure characteristic of MT proteins, although the mutations 
created domains which tended to be folded less tightly. All three mutants bound 6 
rather than 7 mole equivalents of cadmium (Cismowsid and Huang, 1991). The 
C13Y mutant (with altered fl-domain) was found to retain its ability to protect against 
cadmium toxicity, whereas the C50Y and C13,50Y mutants with altered a-domains 
did not. A second study determined the effect of mutation of terminal and bridging 
cysteine residues on detoxification capacity of the protein. While the mutation of all 
bridging cysteines examined resulted in decreased detoxification fimction, the 
mutation of some terminal cysteines resulted in decreased detoxification function 
while the mutation of other terminal cysteines was inconsequential (Chernaik and 
Huang, 1991). 
Since the putative sheep MT-III protein retains the lysine bridge which links 
the 2 domains and is the only interaction between them, the structural alterations in 
the two domains may be considered separately. The I3-domain of the sheep MT-III 
protein has a terminal cysteine residue mutated to a serine residue (C30S, position 30 
corresponding to position 29 of MT-I and -II isoforms) as represented in Figures 4.10 
and 4.11. Like the C13Y mutant with a mutated terminal cysteine residue in its 13 -
domain, this domain of the sheep MT-III protein may still coordinate metals in a 
geometry similar to that of normal MT complexes (Cismowski and Huang, 1991). 
However, the analogous MT-II mutant C29S was found to have decreased ability to 
protect against cadmium toxicity (Chernaik and Huang, 1991). 
The a-domain of the putative sheep MT-III protein is missing a terminal 
cysteine (C33) and a bridging cysteine residue (C34), as represented in Figure 4.10 
and 4.11. The mutation of the analogous terminal cysteine residue in Chinese hamster 
MT incidentally, had no effect on the ability of the protein to confer protection against 
cadmium toxicity (Chernaik and Huang, 1991). In contrast, mutation of any bridging 
cysteine residue appears to result in decreased ability to protect against metal toxicity 
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(Chemaik and Huang, 1991). Therefore, the loss of the C34 bridging cysteine residue 
in the sheep MT-III protein would be expected to result in a decreased ability to 
protect against heavy metal toxicity. In a 'normal' mammalian MT protein the 
Me3cys9 13-domain has a cysteine to metal ratio of 3:1 whereas the Me4cys 11 a-domain 
has a cysteine to metal ratio of 2.75:1. It may be possible that the a-domain of the 
sheep MT-HI protein which contains 9 rather than the usual 11 cysteine residues, may 
be able to form a I3-domain-like conformation, binding 3 divalent metal atoms. 
Studies of MT proteins with mutated cysteine residues like those outlined 
above, have demonstrated the plasticity of the metal-cysteine complexing, i.e. the 
ability of mutant MT proteins to bind a reduced number of metal atoms, but still in a 
structure resembling that found in the wildtype MT. Other studies have demonstrated 
the flexibility of the MT protein in accommodating divalent ions of vastly differing 
sizes, and the ability of MT proteins to accommodate univalent as well as divalent 
ions has been well documented (see Kagi and Kojima, 1987). There seems little 
doubt then that the putative sheep MT-III protein could bind metal ions, but the 
structure of the complex formed, the number of metals bound and how closely it 
resembles the mammalian MT-metal complexes documented to date remains to be 
determined. The studies outlined above have demonstrated that mutant MT proteins, 
although able to bind metals in a structure resembling that found in wildtype MT, may 
have impaired ability to protect against heavy metal toxicity. The ability of MT to 
protect against cadmium toxicity is often used to determine whether a MT protein is 
functional, however the role of MTs in vivo is still unclear and such an assay does not 
necessarily assess the ability of MT to function in the various other physiological roles 
proposed for MT, such as metal metabolism, homeostasis and transport, free radical 
scavenging or most importantly for MT-III isoforms, growth inhibition. 
All MT-III proteins contain 2 insertions, a single amino acid insertion at 
position 5 in the N-terminal domain, and a larger insertion (usually of 6 amino acids) 
in the C terminal domain. In all MT-III isoforms examined to date, the single amino 
acid insertion at position 5 is a threonine residue, whereas the novel sheep MT-III 
protein contains an alanine residue at this position (see Figure 4.5B). However, the 
substitution of an alanine for a threonine residue would not be expected to 
significantly affect the structure of the protein as the amino acids are similar in size 
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and charge. Notably, no specific fimction or involvement directly in metal binding has 
been assigned to this single amino acid insertion, and it is interesting to note that 
rabbit MT-2a and MT-2c contain a single insertion of an alanine residue in their 13- 
domain also, although the insertion is at position 9 (see Kagi, 1993). The 6 amino acid 
insertion in the C terminal domain of the MT-III proteins appears in the only extended 
loop of the MT-I and -II structure (Robbins etal., 1991), and is a generally less 
conserved, although predominantly acidic, sequence. The insertion GEGAEA in the 
sheep MT-III protein is in fact identical to that identified in the bovine protein (see 
Figure 4.5B). 
The actual positioning of the C-terminal insertion with respect to the MT-I or 
-II protein structure is debatable. This insertion found in the various MT-III proteins 
has been designated in the literature as occurring between residues 52 and 53 of the 
corresponding MT-I and -II isoforms for mouse and human (Palmiter et al., 1992), 
between residues 52 and 53 for rat and human (Kobayashi et al., 1993; Tsuji etal., 
1992 ) or between residues 51 and 52 for the bovine and equine MT-III proteins 
(Poutney et al., 1994). MT-I and -II isoforms have conserved lysine residues at 
positions 51 and 56 which correspond to conserved lysine residues in the MT-III 
amino acid sequence at positions 52 and 63. The amino acid residues between these 
lysines are divergent between MT-I, -II proteins and MT-III proteins which has led to 
difficulties in assigning the exact position of the insertion in MT-III simply from the 
amino acid sequence of the proteins. In positioning the insertion found in the putative 
sheep MT-III protein I have followed Palmiter et al. (1992), in designating the 
insertion between residues 52 and 53 with respect to the sheep MT-I and -II protein 
(see Figure 4.5A). 
Apart from those differences discussed above the only other amino acid in the 
sheep MT-III protein which is found to differ from those of the known MT-III 
isoforms is that the serine residue at position 65 in all other MT-III proteins is 
substituted by a glycine residue in the putative sheep MT-III. The serine residues 
throughout the MT protein chain are relatively conserved and although they are not 
directly involved in metal binding may have some effect on the stability of metal 
binding (see Kagi and Kojima, 1987). 
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Future work will involve confirming the predicted sheep MT-III structure at 
the protein level, either by purification of the protein and amino acid sequencing or by 
isolation of this isoform from sheep brain by chromatography and analysis by mass 
spectrometry to confirm its molecular weight. 
4.3.2 Sheep MT-ill expression in vivo 
The sheep MT-III cDNA (and mouse MT-III RT-PCR product) hybridised to 
a single restriction fragment after Southern analysis of sheep genomic DNA, but not 
those previously attributed to the sheep MT-I and -II isoforms (Peterson et al., 1988). 
Northern analysis with these MT-III probes indicated that sheep MT-III mRNA 
expression is restricted to the brain, in contrast to the more widespread expression of 
MT-I and -II isoforms. This is in keeping with the expression profiles seen in other 
species (Palmiter etal., 1992; Tsuji et al., 1992; Kobayashi et al., 1993). MT-III 
mRNA was detected in the foetal (E 1 16) and adult brain but not in the liver, kidney, 
gut, lung or heart of foetal or adult sheep (Figure 4.2). MT-III mRNA was not 
detected in the foetal liver at any time, or in the early foetal brain (before E116). It is 
interesting to note that the MT-III mRNA levels in the foetal E116 brain are 
approximately equal to those in the adult brain, whereas in other species a dramatic 
increase in MT-III mRNA has been reported after birth (e.g. Kobayashi etal., 1993). 
However, it should be noted that the E116 foetal sheep brain is relatively mature, 
since cortical development relative to gestation period proceeds more quickly in sheep 
than in other mammals (Astrom, 1967). Interestingly, MT-III was detected in the 
El 16 foetal brain, at the same time as significant levels of MT-I and -II tuRNA were 
detected suggesting similar controls may be involved in the regulation of MT-I, -II 
and -III isoforms during development. 
Furthermore, the expression profile of MT-III mRNA in different regions of 
the adult sheep brain appeared to mimic to some degree that of MT-I and -II (Figure 
4.8). For example, the highest level of MT-III mRNA was observed in the pineal 
gland, as was observed for MT-I and -II. Similarly, in the mouse (Masters et al., 
1994b) and in the human (see Figure 4.12), MT-III mRNA expression has been 
shown to have similar regional expression patterns to other MT isoforms. This 
seemingly concurrent expression of MT-III mRNA with MT-I and -II mRNA in the 
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Figure 4.12 Regional expression of MT-I, -Hand -1111 mRNA in the human brain 
Graphical representation of the relative proportions of MT- 1/1I and MT-III mRNA 
in various regions of 2 human brains, as determined by northern analysis, is shown. 
Levels of the rnRNA are arbitrary, and comparisons can not be made between 
diferent isoforms or between the 2 brains. Taken from F.A.Stennard, Ph.D thesis, 
1995. 
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brain, at least under basal conditions, suggests that they may be subject to similar 
regulatory controls. However, studies have failed to show induction of MT-III by 
factors such as LPS and dexamethasone which are well documented regulators of 
MT-I and -II expression in the brain (Palmiter et al., 1992). Another explanation may 
be that all MT isoforms are expressed in the same cell types, and the regional 
expression patterns reflect the relative proportion of MT expressing cells within each 
region of the brain. Similarly, the concurrent appearance of the MT isoforms during 
development may be due to the development/maturation of the MT expressing cells. 
The cell-type expression of MT-III is in fact controversial. MT-III mRNA and 
protein has been demonstrated to be co-expressed with other MT isoforms in glial 
cells in the human (e.g. Uchida etal., 1991), but MT-III mRNA has been shown to be 
expressed in neurons in the mouse brain (Masters etal., 1994b). This difference may 
be species specific, and investigation of cell type expression of the novel sheep MT-III 
isoform may shed light on this phenomenon. Preliminary in situ hybridisation 
experiments demonstrated varying intensities of hybridisation signal for MT-III in 
different regions of the sheep brain. However, the more elegant in situ hybridisation 
experiments have been in rat and mouse, where large regions of the brain have been 
investigated and comparison of the regional expression patterns has allowed MT-III 
expression to be correlated to glial rich or neuronal rich areas of the brain (e.g. 
Masters et al., 1994b; Yuguchi et al., 1995a). Such experiments in the sheep brain 
would require a large and detailed study and would require the perfusion of the sheep 
brain to successfully fix such large pieces of tissue. The preliminary experiments 
detailed in this study have however identified oligonucleotide probes which could be 
employed in such a study. 
Antibodies have been made to both human and rat MT-III. Synthetic peptides 
covering the C-terminal inserts in the MT-III isoforms were used in both cases to 
generate antibodies (Uchida etal., 1991; Hozumi etal., 1995), however, Masters et 
al. (1994b), were unable to produce antisera to either these peptides or a maltose-
binding protein-MT-III fusion protein. Due to the conservation of MTs difficulties 
have been encountered in generating isoform specific antibodies. Studies on the 
antibodies which cross react with MT-I and -II isoforms have revealed the antigenic 
region of the protein to be the first 7 amino acids (Winge and Garvey, 1983; Kay et 
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al., 1991). Since the sheep MT-III protein has a unique amino acid sequence in this 
region it may be an ideal candidate for the production of a specific MT-III antibody, 
and immunocytochemical techniques could then be employed to examine the cell type 
expression of sheep MT-HI. 
MT-III proteins are the only MTs for which a functional assay exists, in that 
they inhibit neurite sprouting in vitro (Uchida etal., 1991; Erickson et al., 1994; 
Poutney etal., 1994). This, and its discovery as a factor deficient in Alzheimer's 
disease has led to MT-III being implicated as a growth inhibitory factor in vivo. 
Interestingly, despite the amino acid substitutions and deletions in the ovine MT-III 
protein, which may alter its metal binding properties, it retains the CPCP sequence in 
the N-terminal domain (positions 6-9) to which the growth inhibitory function of MT-
III proteins has been attributed (Sewell et al., 1995). The role of MT-III in vivo 
however, remains to be determined and the similarity of MT-I, -II and -III mRNA 
expression profiles raises the possibility that the function of MT-III may not be 
entirely dissimilar to that of MT-I and -II. This is supported by studies which 
demonstrate that transgenic mice overexpressing human MT-III protein are 
apparently physically and physiologically normal, apart from increased sequestration 
of zinc in the brain, which is completely accounted for by the overexpression of 
human MT-III (Erickson et al., 1995). Much the same effect would be expected from 
overexpression of MT-I or -II isoforms. It is therefore possible that the in vitro assay 
in which MT-III exhibits growth inhibitory activity and is thus distinguishable from 
other MT isoforms may not be physiologically relevant, and may not represent the 
role of MT-III in vivo. 
The structurally distinct sheep MT-III isoform may be very useful in 
understanding the function of MT-III in vivo, and its relationship to other MT 
isoforms. Analysis of its metal binding properties, its ability to provide protection 
against heavy metal toxicity, and its growth inhibitory activity, may provide insight 
into which of the properties of MT-III are physiologically relevant and whether it has 
a role in the brain distinct from MT-I and -II isoforms. 
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CHAPTER 5: EXPRESSION OF THE HUMAN MT1L GENE 
5.1 Introduction 
5.1.1 Human metallothionein genes 
As is found in the sheep, humans have a large multigene MT family which 
encodes a single MT-II isoform and multiple MT-I isoforms. MT-II isoforms are 
distinguished from MT-I isoforms by the presence of an acidic amino acid at position 
10 or 11 rather than a neutral amino acid in these positions. In the human all 
functional MT genes appear to be restricted to human chromosome 16 (Karin et al. 
1984a) with all MT-I and -II genes linked in a cluster of 14 genes in a single locus, 
16q13 as indicated in Figure 5.1. Genes encoding MT-III and MT-IV isoforms have 
also been identified in the human (Pahniter etal., 1992; Quaife etal., 1994) and these 
genes have been shown to be located in close proximity to the functional locus on 
chromosome 16 (Palmiter etal., 1993), although linkage has not yet been 
demonstrated. 
The human MT-I and -II genes have been characterised to varying degrees, 
and 8 of these genes (indicated in Figure 5.1) have been shown to be expressed at the 
protein or the mRNA level in vivo. A single MT-II isoform (MT2A) and multiple 
MT-I isoforms have been isolated from human liver (Hunziker and Kagi, 1987; Kagi, 
1993). MT2A is the best characterised of the human MT genes and MT2A mRNA is 
expressed at high levels in most tissues (Richards etal., 1984). MTIA is also 
expressed in most tissues at the RNA level, but at lower levels than MT2A (Richards 
etal., 1984). MTIF and MTIG have also been investigated at the mRNA level, and 
appear to be expressed in a tissue specific manner (Varshney et al., 1986; Jahroudi et 
al., 1990). Similarly, expression ofMT1B has been shown to be cell-type-specific 
(Heguy etal., 1986) and studies using cell lines derived from human embryonic 
tissues suggest that the expression ofMTIE and MTIF are developmentally regulated 
(Schmidt and Hamer, 1986). MTIH and MT1X mRNA have both been detected in 
HeLa cells after cadmium treatment (Stennard et al., 1994) and their expression in 
vivo has also been demonstrated (F.A.Stennard, Ph.D. Thesis). Although the 
expression of multiple human isoforms has been demonstrated in the human liver by 
HPLC (Hunziker and Kagi, 1985; 1987), the technical difficulties associated with 
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Figure 5.1 The MT-I/II functional locus on human chromosome 16 
The location of the MT genes in the locus on chromosome 16 and their transcriptional orientations (arow) are shown. Those genes which have 
been previously shown to be functional are indicated (asterix). Recognition sites for the restriction endonucleases Bam1-11, Hind!!, Sad and 
EcoRI (E) are indicated. The cosmid clones chMT-51, chMT-5 and chMT-10 which encompass the entire functional MT-I/I locus are shown 
below. 
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investigating individual MT isoforms has meant that most of the human MT genes are 
only characterised ai the RNA level. 
The most recently discovered genes which encode the MT-III and MT-IV 
isoforms have restricted expression patterns in vivo. Human MT-III expression 
appears largely restricted to the brain (Tsuji etal., 1992), while MT-IV expression 
appears to be restricted to squamous epithelial tissue, such as the nasal epithelia in the 
mouse (Quaife etal., 1994). 
The reason for multiple MT isogenes in the human is unclear. It is possible 
that their role is simply to allow the rapid accumulation of MT protein in cells, and 
certainly activation of multiple genes could theoretically result in the immediate 
expression of much larger amounts of protein than could be achieved by activation of 
a single gene. Such a system would be of value in situations of stress or physiological 
insults, conditions under which MT is often upregulated. However, the 
demonstration of differential expression patterns for various human MT isogenes has 
led to the suggestion that the multiple MT genes provide diversity of function. This is 
supported by studies which have demonstrated that the different isoforms can be 
induced by a variety of factors and to different extents. However, it remains to be 
seen whether the various MT isoforms have slightly different functions or whether 
they have identical roles, but in different cells or under different circumstances. 
Investigation of the individual MT genes, their expression in various tissues and their 
regulation may provide insight into the function of the various MT genes, and what 
part they play in the overall action of MTs in vivo. 
5.1.2 The human metallothionein gene, MT1L 
The sequence of the human MT gene MT IL has been obtained previously and 
is shown in Figure 5.2 (A.F.Holloway, B.Sc. Honours Thesis). The amino acid 
sequence encoded by MT IL is consistent with other human MT-I proteins (Figure 
5.3), except for the presence of an in-frame TGA codon in exon 2 which is usually a 
signal for the termination of protein translation. Otherwise the MT1L amino acid 
sequence contains no atypical amino acids, and all of the 20 conserved cysteine 
residues are present apart from that replaced by the termination codon at position 26. 
However, the presence of a TGA ("stop") codon at position 26 of the predicted 
1 . 	 100 ACAAGAAATGGGAATATGGGAAGTTCGCGCGGACGGCACGGCACCGCGGGACGACCGGGCGCACAGGCCTGAGCGAGCGAGCGAGTGAGCGGGTGCCAAG 
1 0 1  •  2 0 0  
CAAGAGACCCGCGGTGCACACCTTGCGCCCGGCCCGCCTGCTGCTCACAGTCCCTCCACGTACCCACAGGAGGCCCAGACTCAGCGGGGCGGGTGCAAGC 
2 0 1  .  .  .  .  P v u I I . . P v u I I . 300 
GCGGGGCGGGGCCTCTGCGTCCGGTCCCATCTCCGCCTocAAAAGGAGCAGCTGGCTCCAGGCTCCAACCGTGCCTTCCAGCTGccTGAcTGCcrCTTca 
3 0 1  .  .  .  .  .  .  .  .  .  4 0 0  
CCTcTccCGTCArrTCTTGGCTCGAAATGGACcccAAcTGCTCCTGCGCCACTGGTAAGGGAACCCCGGC1rTGCGCCTGGGAATGCCCAATTCCCAGCC 
MetAspProAsnCysSe rCysAl aTh rG 
401 	 . 	 . 	 . 	 Sad I 	 . 	 . 	 . 	 . 	 . 	 500 
ACAGTACAGTGTCCCTGCGTTTGAGGAGGTCGCATTTTGAGCTCTGAGCAGAAGGGAACCCTTTACTTCGTCCAGTACTTTCTTCTTGGAATAGCTCCTG 
5 0 1  .  .  .  .  .  .  .  .  .  6 0 0  
AGAGCATTGCCCTCCTCACTGTGCCTCTATGTCAGAGTTGAGTGTCCTGAGGCTCAAGGCTGTCCTGTTTCACATCACCTGGTTGATCAGGGGGcTGCTG 
6 0 1  .  .  .  .  .  .  .  .  .  7 0 0  
GCCAAGCCCCAATGCTCTGTCTAGGCTCTAAGCAAGCAGGGTGGGTGGGAGGCAGGGAACACTGTCTTTGAGATTCAGGACAGGAGGTTTTGGCCCCCAA 
7 0 1  .  .  .  .  .  .  .  .  .  8 0 0  
TCCCAGTCCTCCTGTGTTGTGTGTGTATCTGGGACCTTCCTGGTGGGGTGAAATAGGAGGGTGCTTGCCCTTCCCAGCACGAGTGGAGAGGACATGGGGC 
8 0 1  .  .  Sad I  .  .  .  .  .  .  900 
TTGTCTTTCTCTGCTCTAAGTGGGAAAGGAGCTCTGAGGGCTGGCCCTGCACAGAGGATGGCGCACACTGGAGACTCATTGACCCACTGCTGTACCTTCT 
9 0 1  .  .  .  .  .  .  .  .  .  1  0 0 0  
TCCTCTCACTCACTTGCCCACTGCGTTTTTCTCTTCCTTGCAGGGGGCTCCTGCTCCTGTGCCAGCTCCTGCAAGTGCAAAGAGTGCAAATGAACCTCCT 
lyGlySerCysSerCysAlaSerSerCysLysCysLysGluCysLys . ThrSerC 
1 0 0 1  .  .  .  .  .  .  .  .  .  1 1 0 0  
GCAAGAAGAGTGAGTGCGGGGCCATCTCCAGGAATCTGGGGCTGTGGCTAAGGTTGGGAGGGAACTCAAGGCTGGCCTGGAGTGCATGCTCTGGGGAACG 
ys Lys LysS 
1101 	 . Sad I 	 . 	 1200 
CTTTCTTTGCCCCTGTTGGCCATGTCATTCCCTCTCCAGGCTTTCTGCTCTGAGCTCGAATGTGGCAGGGCAGCCTTTTTCTTTTGAGACACAAACTCCA 
1201 	 . 	 . 	 . 	 . 	 . 	 . 	 . Sad I 	 . 	 . 	 1300 
AAGGTACCACCTGCGGTCTTAGAACAGAGCTGTACTAACCTAAAAAATCATCCTCTGGGTCTGGAGTCTGAGCTCGAACCAGGCCTGCTGTTGGGCCAGG 
1301 	 . 	 . 	 . 	 . 	 . 	 . 	 Picot 	 . 	 . 	 1400 
GAAGTGCCTGATTGAGTCCGCTCTGACCTCTCACTCTCCCTTTTCCCCCAGGCTGCTGCTCCTGCTGCCCCATGGGCTGTGCCAAGTGTGCCCAGGGCTG 
erCysCysSerCysCysProMetGlyCysAlaLysCysAlaGlnG1 yCy 
1401 	 . 	 . 	 PvuII 	 . 	 . 	 . 	 . 	 . 	 . 	 1500 
CGICTGCAAAGGGGCGTCGGAGAAGTGCAGCTGCTGTGCCTGATGTGGGOACAGCCCTGCTCCCAGATGTAAACAGAGCAACCTGCACAAACCTGGATTT 
sValCysLysGlyAlaSerGluLysCysSerCysCysAlaTer 
1501 	 . 	 . 	 . 	 . 	 . 	 . 	 . 	 . 	 . 	 1600 
TTTTTTCATACAACCCTGAGCGTTTGCTACATTCCTTTTTCTATTAAATATGTAAACGACAATAAAACAGTTTTGACTTGATTCGGACCCTCCTTTCCTT 
1601 	 1700 
TGTGTGGCTTTGAATTAATGGACCAGGGTTAGGGATTGAACCTGGAGTTTAGAGACCCAGGCTCTGGATGGACATGTGAGTCGCTAACAATCTGAGCGCC 
1701 	 1800 
TCCTGACAAGCCAGGTTACCTCACTGAGCTTCATCTTCTATAAAAGGGAATTGCACTGTGCCAGGTCATAATGGGGGGACATCTATGATCACCTCTGGTC 
1801 	 1900 
ATATCAATTGTGGCACAGAAACTTCTCCATCTCTCGTTTTTATTTTCTGATTTCCCTGCCCAATTTCAGTTTCCTCTTCAGATTTTAGGCTTCAAAGAGA 
1901 	 PvuI / 
TGACAGGGGTGGAATCCAATTCCTCAGCTG  
Figure 5.2 Nucleotide sequence of the human MTH, gene 
The nucleotide sequence of the MT1L gene was determined by dideoxy sequencing 
(A.F.Holoway, B.Sc. Honours Thesis). The putative amino acid sequence is 
indicated below the coding regions. Recognition sites for the restriction 
endonucleases Ncol, Sad and Pvul are indicated (underlined). The putative 
transcription start site and polyadenylation site are indicated (bold, underlined). 
Binding sites for oligonucleotides designed to amplify the gene or cDNA by PCR are 
shown (bold, double underlined). 
. .... C.0 ..... C.C...C.C..C.C..C...CC.CC...C..C...C.0 ............ C.CC. 
MDPN . CSCATGGSCSCASSCKCKECK* TSCKKSCCSCCPMGCAKCAQGCVCKG 	 ASEKCSCCA MT1L 
MDPN . CSCATGGSCTCTGSCKCICECKCNSCKKSCCSCCPMSCAKCAQGC I CKG 	 ASEKCSCCA MT1A 
MDPN. CSCTTGGSCACAGSCKCKECKCTSCKKCCCSCCPVGCAKCAQGCVCKG 	 SSEKCRCCA MT1B 
MD PN CSCATGGSC TCAG S CKCKE CKC T S CKKS CC S CC PVGCAKCAQGCVCKG 	 ASEKCSCCA MT1E 
MDPN. CSCAAGVSCTCAGSCKCKECKCTSCKKSCCSCCPVGCSKCAQGCVCKG 	 ASEKCSCCD MT 1 F 
MDPN. CSCAAGVSCTCASSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKG 	 ASEKCSCCA MT1G 
MDPN. CSCEAGGSCACCGSCKCKKCKCTSCKKSCCSCCPLGCAKCAEGCICKG 	 ASEKCSCCA MT1H 
MD PN . CSCSPVGSCACAGSCKCKECKCTSCICKSCCSCCPVGCAKCAQGC I CKG 	 TSDKCSCCA MT1X 
MDPN. CSCAAGDSCTCAGSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKG 	 ASDKCSCCA MT2A 
MDPETCPCPSGGSCTCADSCKCEGCKCTSCKKSCCSCCPAECEKCAKDCVCKGEAAEAEGAEKCSCCQ MT3 
MD PRE CVCMS GG I CMC GDNCKC T TCNCKTCRKS C C PC C P PGCAKCARGC I CKG 	 GSDKCSCCP MT4 
Figure 5.3 Comparison of the putative human MT1L protein sequence with known human MT proteins 
The putative amino acid sequence encoded by the human MTIL gene is shown. For comparison the amino acid sequences of the other MT-I and -I 
proteins encoded by genes of the functional locus on chromosome 16 are shown. Amino acid sequences of the human MT-II and -IV proteins are also 
shown. The features which define the MT-I, MT-II and MT-IV isoforms are demonstrated (underlined) and those features unique to MT1L are 
indicated (underlined). The conserved cysteine residues (C) are shown above the sequences. Conventional single leter abbreviations are used for the 
amino acids and an asterix is used to indicate a TGA codon. 
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amino acid sequence makes the amino acid assignments which follow this position 
irrelevant and would initially suggest that the MTIL gene is non-functional, i.e. does 
not produce a protein. However, it is possible that a shortened, but still functional 
protein consisting of 25 instead of 62 amino acids is encoded by this gene. MT 
proteins consist of 2 domains and studies have shown that these are individually 
capable of binding heavy metals (Furey etal., 1986). A shortened MTIL protein 
consisting of 25 amino acids is an almost complete 0-domain and therefore may be 
functional in itself (see Figure 5.4). 
Alternatively, in several cases a TGA codon has been shown to encode an 
unusual amino acid residue, selenocysteine, rather than a termination signal (reviewed 
in Bock et al., 1991). This results in a functional selenoprotein being produced by the 
cotranslational insertion of a selenocysteine residue in the protein. All except one of 
the selenoproteins known are encoded by a gene with a single inframe TGA codon, 
like that ofMTIL, resulting in one selenocysteine residue in the protein chain. The 
best characterised of the mammalian selenoproteins is glutathione peroxidase and the 
selenol moiety is essential for the redox properties of this protein (Forstrom etal., 
1978). It has been proposed that the selenol moiety imparts increased reactivity 
compared with the thiol of a normal cysteine residue (Stadtman, 1996). 
In previous work by the author, MTIL (as well as the more highly 
characterised MT2A) was cloned into a eukaryotic expression vector, pSVL, and after 
transfection into the monkey kidney cell line, COS, were both shown to produce 
mRNA (A.F.Holloway, B.Sc. Honours Thesis). In addition the transfected genes 
conferred enhanced cadmium resistance (Figure 5.5), suggesting that MTIL, like 
MT2A encodes a functional MT protein. 
The aim of this work was to determine whether MTIL is expressed at the 
mRNA level in human tissues and cell lines, and to determine whether the MTIL gene 
encodes a functional protein, either a 61 amino acid selenoprotein or a truncated 25 
amino acid metallothionein protein. 
5.2 Results 
During the course of this work the entire sequence of the MTIL gene as 
shown in Figure 5.2, was rechecked, and the appearance of an inframe TGA codon in 
Figure 5.4 Models of the a- and 0- domains of the MT protein 
The separated a- and 13-domains of an MT protein are shown. The model is a ribbon 
representation of the MI' protein with the metal-cysteine clusters depicted as filled 
circles and thin lines. The a-domain consists of a 4 metal 11 cysteine cluster and the 
13-domain consists of a 3 metal 9 cysteine cluster (taken from Kagi, 1993). The 
position of cysteine residue 26 which is replaced with a TGA ("stop") codon in MT1L 
is indicated by an arrow. Note that this position is close to the end of the 13-domain of 
the protein. 
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Figure 5.5 Ability of MT1L to protect against cadmium toxicity 
The human MT1L gene and MT2A cDNA were cloned into the eukaryotic expression 
vector, pSVL to create the vectors SVL-1L and SVL-2A, respectively. COS cells 
were transfected with the vectors by Transfectam (Promega) mediated transfection 
• and treated with 301AM CdC12 for 24 hours. Untransfected cells and cells transfected 
with the pSVL vector alone represent negative controls. 
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exon 2 of this gene was reconfirmed from 2 separate clones, chMT-51 and X39.1, 
derived from 2 unrelated individuals (see West etal., 1990). 
A series of experiments were conducted to determine whether MT1L was 
expressed in human tissues or in human cultured cel lines. RT-PCR and northern 
bloting were used to detect MTIL mRNA. 
5.2.1 Detection of MT1L mRNA in human tissues by RT-PCR 
5.2.1.1 Specificity of human MT1L PCR primers 
PCR primers were designed to the 5' and 3' flanking regions of the MTIL 
gene. These regions are considerably less conserved than the coding regions and 
alowed primers to be designed which were specific for the MTIL gene. The location 
of the MTIL PCR primers within the gene sequence are indicated in Figure 5.2. 
These primers would be expected to amplify a gene fragment of 1164 bp or a cDNA 
fragment of 230 bp. In some instances primers specific for other MT genes, designed 
similarly to their 5' and 3' flanking regions were used for comparison. The folowing 
primer pairs were used to amplify DNA or cDNA by PCR: 
MT1L sense 	 5'-TCGCCTCTCCCGTCATTT-3' 
	
antisense 	 5'-AGCAGGGCTGTCCCCA-3'. 
MT2A sense 	 5'-GCAACCTGTCCCGACTCTAG-3' 
antisense 	 5'-ATCCAGGTTTGTGGAAGTCG-3' 
MTIH sense 	 5'-CGTGTTCCACTGCCTCTTCT-3' 
antisense 	 5'-CGTGTCATTCTGTTTTCATCTGAC-3' 
MTIX sense 	 5'-AACTCCTGCTTCTCCTTGCC-3' 
• antisense 	 5'-GCTCTATTTACATCTGAGAGCACA-3' 
13-actin sense 	 ,5'-CATCCTCACCCTGAAGTACC-3' 
antisense 	 5'-CACACTTCATGATGGAGTTGA-3' 
The RT-PCR protocol was as outlined in section 2.4 and an annealing 
temperature of 66°C was used in the PCR reaction. PCR products were 
electrophoresed through 1.4% agarose/1 X TBE, and visualised by ethidium bromide 
staining. 
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The specificity of the MT1L PCR primers was confirmed by PCR of cosmids 
chMT-51, chIVIT-5 and chMT-10 which contain all of the human MT-I and -II genes 
in the locus 16q13 (see Figure 5.6). This experiment demonstrated that the MT1L 
PCR primers were specific for the MT1L gene and were not able to amplify other 
MT-I or -II genes. As shown in Figure 5.6, addition of cosmid chMT-51 DNA 
(which contains the MT1L gene) to the PCR reaction resulted in amplification of a 
single DNA fragment. The size of this fragment (1164 bp) was as predicted for the 
amplification of the MT1L gene using these primers (see Figure 5.2). Amplification 
products were not detected when either cosmid chMT-5 or chMT-10 DNA (which do 
not contain the MT1L gene) were added to the PCR reaction, as demonstrated in 
Figure 5.6. 
5.2.1.2 Expression of MT1L mRNA in human tissues 
Total RNA was isolated from human autopsy samples (section 2.3.3) and 
subjected to RT-PCR using the various PCR primers described above at an annealing 
temperature of 66°C. RT-PCR of pancreas RNA using MT1L PCR primers amplified 
a fragment consistent with the expected size from MTIL cDNA of 230 bp (see Figure 
5.7A). MT1X (247 bp), MT2A (279 bp), and MT1H (286 bp) products were also 
amplified from pancreas RNA using the appropriate primers. Primers designed to 
amplify the ubiquitous 13-actin mRNA were used in each reaction as an internal 
control, and a product of 668 bp was amplified in all samples except when using the 
MT2A primers. This absence of a 13-actin product was frequently observed when 
using MT2A primers and has been observed elsewhere (F.A.Stennard, Ph.D. Thesis) 
and is probably due to a number of factors. The 13-actin product is larger than that of 
MT2A and the extension time required to form this product is likely to be longer. 
Since MT2A is also expressed at relatively high levels it is likely that reaction 
components are consumed in the amplification of the human MT2A cDNA at the 
expense of the 13-actin product. 
Using the MT1L PCR primers a PCR product of 230 bp was also amplified 
from thyroid, pineal gland and hypothalamus RNA by RT-PCR, but not from liver 
RNA (Figure 5.7B). As indicated in Table 5.1, MT1L cDNA was also not detected 
by RT-PCR in small intestine, large intestine, spleen, heart or thymus, although MT2A 
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Figure 5.6 Specificity of MT1L PCR primers 
The cosmid clones chMT-5, chMT-10 and chMT-51 which cover the entire functional 
MT-I and -II locus on human chromosome 16 were used to determine the specificity 
ofMTIL PCR primers. The location of the human MT-I and -II genes in the 
functional locus and their transcriptional orientations (arrows) are shown (A). 
Restriction maps for the endonucleases HindIII, Sad and EcoRI  (E) are indicated. 
The MT1L gene is highlighted (asterisk). Regions encompassed by  the cosmid 
genomic clones chMT51, chM=T-5 and chMT-10 are shown below the map (Adapted 
from West et al., 1990). Cosmid DNA was subjected to PCR and PCR products 
were electrophoresed through 1.4% agarose and visualised by  ethidium bromide 
staining (B). 
1:Molecular weight markers (sizes as marked) 
2:chMT-5, 1 ng 
3:chMT-10, 1 ng 
4:chMT-51, 1 ng 
5:chMT-5, 0.1 ng 
6:chMT-10, 0.1 ng 
7:chMT51, 0.1 ng 
8:Molecular weight markers 
A 	 1 2 3 4 5 	 1 2 3 4 5 6 7 8 
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Figure 5.7 Detection of MT1L in human tissues by RT-PCR 
A: RNA was isolated from human pancreas and subjected to RT-PCR using primers 
specific for human MT genes MTIX, MT2A, MTIH and MTIL. 13-actin primers were 
also included in each reaction. 
1:Molecular weight markers (sizes as marked) 
2:Pancreas RNA, MTIX primers, f3-actin primers 
3:Pancreas RNA, MT2A primers, I3-actin primers 
4:Pancreas RNA, MTIH primers, 13-actin primers 
5:Pancreas RNA, MTIL primers, (3-actin primers 
MTIL (230 bp, lane 5) and 0-actin (668 bp, al lanes) PCR products are indicated. 
B: RNA was isolated from human tissue samples or COS cels transfected with the 
human MTIL gene, and subjected to RT-PCR using primers specific for the human 
MT1L gene. 
1:Molecular weight markers (sizes as marked) 
2:no RNA 
3:RNA from COS cels transfected with the MTH, gene 
4:Liver RNA 
5:Thyroid RNA 
6:Pancreas RNA 
7:Pineal gland RNA 
8:Hypothalamus RNA 
The 230 bp MTIL PCR product is indicated. 
MT1L MT2A 
liver - + 
small intestine - 
large intestine - + 
pancreas + + 
thyroid + + 
spleen - + 
heart - + 
thymus - + 
pineal gland + + 
hypothalamus + + 
Table 5.1 Amplification of MT1L and MT2A transcripts by RT-PCR 
RNA was isolated from human tissues and subjected to RT-PCR using primers 
specific for the human MT1L and MT2A genes. The tissues in which products from 
the two genes were (+) and were not (-) amplified are indicated. 
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cDNA was detected in all of these tissues. All of these tissues were from a single 
individual (4 month old male, tissues obtained 48 hr postmortem). 
When MTIL PCR primers were used to amplify cDNA a second amplification 
product, slightly larger or smaller than that expected was often observed. This 
occurred particularly when using cDNA from the pancreas (see Figure 5.7A). The 
nature of these products are unknown, but are presumed not to be from another MT 
gene as the primers had been proved to be specific for the MTIL gene. However, the 
230 bp product obtained by RT-PCR using MTIL primers was confirmed to be 
amplification ofMTIL cDNA by several methods as outlined below. 
The MTIL gene and MT2A cDNA were previously cloned into the eukaryotic 
expression vector pSVL to create the constructs SVL-1L and SVL-2A 
(A.F.Holloway, B.Sc. Honours Thesis). The pSVL vector allows expression of 
cloned genes under the control of the SV40 promoter. RNA was isolated from COS 
cells, a monkey kidney cell line, transfected with these vectors: SVL, SVL-1L and 
SVL-2A (section 2.7.3). The RNA was subjected to RT-PCR using the MT1L PCR 
primers. A product of the same size as one of those amplified from human pancreas 
RNA (230 bp) was detected in cells transfected with the SVL-1L vector (MTIL 
gene), but not cells transfected with the SVL-2A vector (MT2A cDNA) or pSVL 
vector alone (Figure 5.8). 13-actin PCR primers were included in all reactions as an 
internal control and a product of 668 bp was amplified in each instance. Figure 5.7B 
demonstrates that the products amplified by RT-PCR from thyroid, pineal gland and 
hypothalamus RNA using MTIL primers were also the same size as that amplified 
from RNA isolated from SVL-1L (MT1L) transfected COS cells. 
As shown in Figure 5.2, MT1L contains a recognition site for the restriction 
endonuclease NcoI in the region encoding the third exon. This site should be present 
in the cognate PCR product from this gene. No other known human MT gene 
contains this Ncol site. Therefore, products of 230 bp amplified using MT1L primers 
from both the MT1L transfected COS cell RNA and human pancreas RNA were 
digested with the restriction endonuclease Ncol. Restriction fragments of 139 bp and 
91 bp were produced as expected (Figure 5.9A). These DNA fragments (both before 
and after digestion with Ncol) were electrophoresed through 1.4% agarose/1 X TBE, 
transferred to a nylon membrane by alkaline blotting (section 2.3.2) and hybridised 
1000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
.41MT1L gene (1164 bp) 
(3-actin (668 bp) 
MTIL (230 bp) 
1 2 3 4 5 6 
Figure 5.8 Detection of MT1L mRNA in transfected COS cells by RT-PCR 
COS cells were transfected with the eukaryotic expression vector SVL, the human MT2A 
cDNA (SVL-2A) and the human MTIL gene (SVL-1L). RNA isolated from these cells 
was subjected to RT-PCR using primers specific for the MT1L gene and also the human 
13-actin gene. 
1: Molecular weight markers (sizes as marked) 
2: no RNA 
3: RNA from SVL transfected COS cells 
4: RNA from SVL-2A transfected COS cells 
5: RNA from SVL-1L transfected COS cells 
6: RNA from human pancreas 
PCR products from amplification of the MTIL and f3-actin mRNA are indicated (arrows). 
A product is also detected in lane 5 from amplification of the MTIL gene from 
contaminating SVL-1L vector DNA. 
A 1234 5 
1000 bp 
750 bp 
500 bp 
300 bp 
150 bp 
50 bp 
230 bp 
139 bp 
91 bp 
1 2 3 4 5 
10- 
Figure 5.9 Confirmation of MTIL PCR product by restriction endonuclease 
digestion 
RNA was isolated from human pancreas and from COS cells transfected with the human 
MT1L gene in the eukaryotic expression vector SVL. RNA was subjected to RT-PCR 
using primers specific for MT1L, restricted with NcoI and electrophoresed through a 
1.4% agarose gel (A). The DNA fragments were transferred to nylon membrane by 
alkaline blotting and hybridised with a general MT-Jill radiolabelled probe, as described 
in the text. The resultant autoradiograph is shown (B). The 230  bp MT1L PCR product 
is indicated, as well as the 139 bp and 91 bp products of its restriction with NcoI. 
1: Molecular weight markers (sizes as marked) 
2: RNA from MT1L transfected COS cells 
3: RNA from MT1L transfected COS cells, NcoI restricted 
4: RNA from human pancreas 
5: RNA from human pancreas, NcoI restricted. 
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with a general MT probe. The probe used in this analysis was a MT2A RT-PCR 
product which hybridises to all human MT-I and -II genes including MTIL, under the 
conditions discussed later in this chapter (see Figure 5.12, below). This probe 
hybridised to the 230 bp RT-PCR product amplified from the human pancreas RNA 
and SVL-1L transfected COS cell RNA (Figure 5.9B). It also hybridised to the 139 
bp and 91 bp fragments produced by digestion of the products with the restriction 
endonuclease Ncol (Figure 5.9B). The Ncol digestion of the PCR products was 
incomplete and therefore hybridisation to the 230 bp product could still be detected 
after digestion. Hybridisation of the probe to the 91 bp fragment is partially masked 
by the signal from hybridisation to excess primers at the bottom of the blot. It should 
also be noted that although products of other sizes were often observed when using 
MTIL PCR primers, these products did not hybridise to the MT probe. However, 
RT-PCR of the RNA isolated from SVL-1L transfected COS cells resulted in 
amplification of a much larger fragment which hybridised to the MT probe (Figure 
5.9, Lanes 2 and 3). This product (of 1164 bp) is due to amplification of the Mill, 
gene from contaminating vector DNA in the RNA preparation. This contamination 
occurred because of the replication of SV40-based vectors to a high copy number in 
COS cells. 
The 230 bp PCR product obtained from amplification of human pancreas 
cDNA using MTIL PCR primers was excised from a 1.4% agarose gel and purified 
(section 2.2.1). The cDNA was blunt ended with mung bean nuclease and ligated into 
pUC19 (section 2.2). Sequence analysis of a purified clone confirmed that the RT-
PCR product was MTIL cDNA (Figure 5.10A). The clone was incomplete due to the 
removal of nucleotides at either end of the transcript by mung bean nuclease which 
has exonuclease activity. However, the sequence obtained corresponded to the entire 
second exon and most of the third exon of the gene, and importantly included the 
TGA codon at position 26 which is unique to MTI L. The clone was sequenced in 
both directions and the TGA codon is clearly evident in both cases, as demonstrated 
in Figure 5.10B and C. This experiment confirmed that the mRNA detected in human 
tissues by RT-PCR was derived from the MTIL gene, and that the TGA codon was 
indeed present in the mRNA. 
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GGCTCCTGCTCCTGTGCCAGCTCCTGCAAGTGCAAAGAGT 
GlySerCysSerCysAlaSerSerCysLysCysLysGluC 
GCAAATGAACCTCCTGCAAGAAGAGCTGCTGCTCCTGCTG 
ysLys***ThrSerCysLysLysSerCysCysSerCysCy 
CCCCATGGGCTGTGCCAAGTGTGCCCAGGGCTGCGTCTGC 
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Figure 5.10 Sequence of a partial clone amplified from human pancreas 
RNA was isolated from human pancreas and subjected to RT-PCR using primers 
specific for the human MTIL gene. The amplified transcript was blunt ended with 
mung bean nuclease, cloned into pUC19 and sequenced. Sequencing reactions were 
electrophoresed on a 6% acrylamide gel, the gel fixed and dried, and exposed to 
Hyperpaper (Amersham). The nucleotide sequence of the partial clone obtained (A) 
is identical to the MTIL gene, including an inframe TGA codon (***). The regions of 
the autoradiograph of the sequencing gel showing the TGA codon on both the sense 
(B) and antisense (C) strand are shown. Note that the TGA codon appears as the 
reverse compliment on the antisense strand ie TCA reading 5' to 3'. 
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5.2.1.3 Detection of MT1L mRNA in human cell lines by RT-PCR. 
The expression of the human MT1L gene at the RNA level was examined in a 
primary culture of human lymphocytes and also white blood cell lines by RT-PCR. 
RNA isolated from cultured human lymphocytes (prepared as outlined in 
Stennard et al., 1995), untreated and treated with 101.tM CdC12 or 10 AM ZnC12 for 6 
hr was supplied by F.A.Stennard. The RNA was subjected to RT-PCR using the 
MT1L PCR primers and a product consistent with the expected size from MT1L 
cDNA of 230 bp was amplified from cadmium and zinc treated samples (Figure 5.11). 
No product was detected using RNA from untreated lymphocytes. 
RNA was isolated from CEM and K562 cell lines (two lymphoid cell lines) 
maintained in culture as described in section 2.7.2. These cells were either untreated 
or treated with 101AM CdC12 for 16 hr. The RNA was subjected to RT-PCR using 
MT1L PCR primers and a product consistent with the expected size from MT1L 
cDNA of 230 bp was amplified from CEM cells (Figure 5.11). A product of the same 
size was amplified from RNA isolated from COS cells transfected with the SVL-1L 
vector, which contains the MT1L gene. This product (of 230 bp) was amplified from 
both the untreated and cadmium treated CEM cells however a product of this size 
was not amplified from K562 cells, even after cadmium treatment (see Figure 5.11). 
5.2.2 Detection of MT1L mRNA in human thyroid by northern analysis 
MT1L mRNA had been detected in human tissues by RT-PCR, however this 
technique is very sensitive and may detect transcripts at a level which is not 
necessarily physiologically relevant. Northern analysis is a less sensitive technique and 
detection of a message by this method is more likely to suggest physiological 
relevance. This technique can also be easily used to determine the relative amounts of 
a particular mRNA in different samples. The expression ofMTIL mRNA was 
therefore examined in thyroid samples by northern blotting (5.2.2.2). To do this, the 
construction of gene-specific probes for MT1L and several other genes was required 
and is described below (5.2.2.1). 
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Figure 5.11 Detection of MT1L mRNA in human white blood cels by RT-PCR 
RNA was isolated from primary cultures of human lymphocytes, CEM cels and K562 
cels, and subjected to RT-PCR using primers specific for MTIL. 	 • 
1:Molecular weight markers (sizes as marked) 
2:no RNA 
3:RNA from human lymphocytes, saline treated 
4:RNA from human lymphocytes, 10 ;AM CdC12, 6 hr 
5:RNA from human lymphocytes, 10 p.M ZnCl2, 6 hr 
6:RNA from CEM cels 
7:RNA from K562 cels 
8:RNA from CEM cels, 10 pM CdC12, 16 hr 
9:RNA from K562 cels, 10 plq CdC12, 16 hr 
10:mock extraction (see section 2.3.3) 
11:RNA from COS cels transfected with the MTIL gene 
The 230 bp MTIL PCR product is indicated (arow). 
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5.2.2.1 Specificity of a human MT1L oligonucleotide probe 
An antisense oligonucleotide (5'-AAATGACGGGAGAGGCGA-3') was 
designed to the 5' flanking region of the human MTIL gene. The oligonucleotide was 
complementary to the MTIL sense primer used in RT-PCR. The specificity of this 
oligonucleotide was determined using a cosmid blot prepared by F.A.Stennard (see 
Stennard etal., 1994) which contained the cosmid clones chMT-51, chMT-5 and 
chMT-10. These cosmids encompass the functional locus on chromosome 16q13 
containing al MT-I and -I genes (see Figure 5.12A). These were digested with the 
restriction endonuclease HindHI, producing DNA fragments which contained only a 
single MT gene. This was with the exception ofMTIH and MTH which are 
contained on the same HindII fragment and thus DNA from the cosmid CH-2 was 
digested with the restriction endonuclease SacI to separate these genes. The digested 
DNA was electrophoresed on an agarose gel (Figure 5.12B) and transfered to nylon 
membranes by alkaline bloting. The specificity of the MT gene specific probes was 
determined by their hybridisation to these blots. The MTIL oligonucleotide was 
radiolabeled with 732PATP using T4 polynucleotide kinase (section 2.3.10) and 
hybridised to the cosmid blot at 42°C in 20% formamide hybridisation bufer, for 16 
hr, then washed to a stringency of 0.2 X SSC, 1% SDS at 45°C. At this stringency 
the probe hybridised to only a single band on the cosmid blot, containing the human 
MT1L gene (Figure 5.12C). 
The specificity of oligonucleotides designed to other MT genes were 
determined similarly. Oligonucleotides used as gene specific probes and the 
stringency at which they were washed are as folows: 
MTIL 	 5'-AAATGACGGGAGAGGCGA-3' 
0.2 X SSC, 1% SDS at 45°C 
MT2A 	 5'-ATCCAGGTTTGTGGAAGTCG-3' 
0.2 X SSC, 1% SDS at 45°C 
MTIA 	 5'-ATGGGTCAGGGTTGTATGGA-3' 
0.2 X SSC, 1% SDS at 37°C 
MTIE 	 5'-CAAAGGGGATGCTGGAGCTC-3' 
0.2 X SSC, 1% SDS at room temperature 
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Figure 5.12 Specificity of MT probes 
A cosmid blot encompassing the functional MT-I and -I locus on chromosome 16 
was used to determine the specificity of MT probes. The location of  the MT-I and -II 
genes in the functional locus and their transcriptional orientation (arows) is shown 
(A). Restriction maps for the endonucleases HindII, Sad and EcoRI (E) are 
indicated. The HindII restriction fragments representing the genes MTIL and MT2A 
are shown (bracket and asterisk). Regions encompassed by the cosmid genomic clones 
chMT-51, chMT-5, chMT-10 and CH-2 are indicated (adapted from West et al., 
1990). 
Cosmid DNA was digested with restriction endonucleases, electrophoresed through 
an agarose gel and transfered to nylon membrane by alkaline bloting (Stennard et 
al., 1994). The ethidium bromide stained gel is shown (B); X: HindII restricted X. 
markers (sizes indicated), 1: HindII restricted chMT-51, 2: HindII restricted chMT-
5, 3: HindII restricted chMT-10, 4: Sad l restricted CH-2. A MTIL oligonucleotide 
was used as a specific probe for this gene. It hybridises to only the  MTIL gene (9.4 
kb) as indicated (arrow, C). A human MT2A PCR product was used  as a general 
probe as it hybridises to al MT-I and -I genes. Fragments representing MT2A (3.2 
kb) and MT1L (9.4 kb) are indicated (arows, D). 
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MTIF 	 5'-GAGAGACTGGACTTTCCAAG-3' 
0.2 X SSC, 1% SDS at room temperature 
MTIG 	 5 ' -GGTC ACTCTATTTGTACTTGG-3 ' 
0.2 X SSC, 1% SDS at 37°C 
MTL11 	 5 '-CGTGTCATTCTGTITTCATCTGAC-3' 
0.2 X SSC, 1% SDS at room temperature 
MTIX 	 5'-GCTCTATTTACATCTGAGAGCACA -3' 
0.2 X SSC, 1% SDS at room temperature 
13-actin 
	
	 5 '-C AC ACTTC ATGATGGAGTTGA-3 ' 
0.2 X SSC, 1% SDS at 37°C 
MT1B expression was determined using a HindII, BamHI fragment from the 
5' flanking region of the MT1B gene (A.K.West, Ph.D. Thesis). This was hybridised 
in 50% formamide hybridisation bufer at 42°C for 16 hr and washed to a stringency 
of 0.2 X SSC, 1% SDS at 65°C. 
A 279 bp human MT2A RT-PCR product amplified by RT-PCR of HeLa cel 
RNA using the MT2A PCR primers described earlier was cloned into the plasmid 
pSP64 by F.A.Stennard. This product was used as a general MT-I/II probe. The RT-
PCR product was radiolabeled with a-32PdCTP (section 2.3.8) and hybridised to the 
cosmid blot at 37°C in 50% formamide hybridisation bufer, for 16 hr. The blot was 
washed to a stringency of 0.2 X SSC, 1% SDS at 37°C and under these conditions 
this probe hybridises to al MT genes in the 16q13 locus as indicated in Figure 5.12D. 
It is evident from Figure 5.12D that this probe hybridises considerably more strongly 
to the MT2A gene from which it is derived, than other MT genes including MTIL, 
under these conditions. 
5.2.2.2 Expression of MT1L mRNA in the human thyroid 
The expression of MT1L mRNA in human thyroid samples was determined by 
northern bloting using the MT1L oligonucleotide described above as a probe. For 
comparison, expression of the other MT-I and -I genes was examined using the 
appropriate gene specific probes. 
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RNA was isolated from 3 human thyroid samples and subjected to northern 
analysis (section 2.3) using the MT gene specific oligonucleotide and cDNA probes 
under the conditions indicated above. MT1L mRNA was detected in 2 of the 3 human 
thyroid samples examined (Figure 5.13). MT2A (3 of 3), MT1H (2 of 3), MT1X (2 of 
3) and MT1G (1 of 3) mRNA were also detected in some of the thyroid samples, but 
MTIA,MTIB,MTIE and MTIF were not detected in any thyroid samples, even after 
long exposure of the autoradiographs. Hybridisation with the human 13-actin 
oligonucleotide probe under the conditions described above indicated that equal 
amounts of RNA were present in all lanes. 
5.2.3 Expression of MT/L under the control of the SV40 promoter 
Studies were undertaken to investigate the expression of MT1L protein. 
Although MTIL mRNA had been detected in human tissues by both RT-PCR and 
northern analysis the question remained as to whether the MTIL gene encoded a 
shortened MT protein of 25 amino acids, a selenoprotein of 62 amino acids, or 
whether the mRNA was translated into protein at all. The ability of the MTIL gene to 
produce protein was investigated using the SVL vector, in which a cloned gene or 
cDNA is expressed under the control of the SV40 promoter. 
Previously the MTIL gene and MT2A cDNA were cloned into the eukaryotic 
expression vector pSVL to create the constructs SVL-1L and SVL-2A, depicted in 
Figure 5.14 (A.F.Holloway, B.Sc. Honours Thesis). MTIL was shown to produce 
nilINA of the same size as that produced by MT2A after transfection into COS cells, a 
monkey kidney cell line, using the Transfectam reagent (Promega). 
This experiment was repeated in the present study, but the SVL-1L, SVL-2A 
and pSVL vectors were transfected into COS cells, by calcium phosphate-mediated 
transfection (see section 2.7.3). RNA was isolated after 48 hours and subjected to 
northern analysis. Hybridisation with a human MT2A RT-PCR product which 
hybridises to all human MT-I and -II genes including MTIL and MT2A (as described 
earlier, see Figure 5.12) confirmed previous experiments, demonstrating that both 
MT1L and MT2A produce full length mRNA of approximately 350 bp (Figure 5.15). 
The considerably weaker signal observed from the MTIL transfected cells compared 
with the MT2A transfected cells most likely reflects the relative hybridisation strength 
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Figure 5.13 Expression of MT mRNA in the human thyroid 
RNA was isolated from 3 human thyroids (lanes 1 to 3) and the expression of the 
various human MT-I and -II isogenes was examined by northern analysis. 
Radiolabeled oligonucleotide and cDNA probes specific for the human MT genes as 
specified in the text were used to examine the expression of the individual MT 
isogenes. A human 13-actin probe was used to confirm that equal amounts of RNA 
were present in each lane. 
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Figure 5.14 Diagrammatic representation of pSVL and the SVL-MT constructs 
pSVL is a 4.8 kb SV40-derived eukaryotic expression vector containing SV40 and 
pBR322 elements as indicated. The polylinker containing multiple cloning sites is 
shown. The SVL-1L construct was created by the insertion of a 1.6 kb Pvul 
fragment containing the MTIL gene into the SVL vector at the Smal site as indicated. 
The SVL-2A construct was created by insertion of a 0.3 kb MT2A cDNA into the 
SVL vector at the XbalSacI sites as indicated. 
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Figure 5.15 Expression  of MT mRNA in transfected COS cels 
COS cels were transfected  with the eukaryotic expression vector SVL, the human 
MTIL gene (SVL-1L) and the human MT2A cDNA (SVL-2A). As a positive control 
COS cels were also treated with CdC12. RNA was isolated from the cels and 
analysed for MT mRNA by northern analysis using a general MT probe (MT2A PCR 
product). RNA was from COS cels treated as folows: 
1:COS cels 
2:COS  cels, 10 1AM CdC12, 16 hr 
3:COS cels,  SVL transfected 
4:COS cels, SVL-1L transfected 
5:COS  cels, SVL-2A transfected 
AP-actin probe was  used to confirm that equal amounts of RNA were present in each 
lane. 
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of the probe to these 2 genes (see Figure 5.12D). Endogenous monkey MT mRNA 
induced by treatment of COS cells with 10 [tM CdC12 for 24 hr was also detected with 
this probe as a slightly smaller transcript (Figure 5.15). 
COS cells were then co-transfected with the same set of expression vectors 
(SVL, SVL-1L and SVL-2A) and a vector containing the 0-galactosidase gene under 
the control of the RSV promoter (RSV-0-gal, as described in Stennard etal., 1994). 
24 hr after transfection these cells were incubated with 35 S-cysteine (200 KO for 16 
hr. Protein was isolated from the cells, carboxymethylated and electrophoresed 
through a 15% polyacrylamide gel (as outlined in section 2.8). Autoradiography 
failed to detect an increased production of MT in the MTIL and MT2A transfected 
cells although the endogenous monkey MT was detectable, and a significant increase 
in MT levels was observed in COS cells which had been treated with 10 p.M CdC1 2 for 
24 hr (Figure 5.16). Assays for 0-galactosidase (section 2.8.4), produced by the 
cotransfected RSV-0-gal vector determined that the transfections had been successful 
(data not shown). 
A timecourse with cells transfected with the SVL-2A vector showed that the 
cells were viable and expressing MT2A mRNA up to 8 days after transfection (Figure 
5.17), with maximum MT2A mRNA levels after 4-6 days. On the basis of this result 
the radiolabelling experiment outlined above and in Figure 5.16 was repeated but cells 
were incubated with 35S-cysteine for 16 hr, 4 days after transfection. Again, no 
increases in MT protein were observed in the transfected cells, although endogenous 
monkey MT was detectable. There was a significant increases in the endogenous MT 
levels after treatment with cadmium (data not shown). As before 0-galactosidase 
assays confirmed the vectors had successfully been transfected into the cells. 
COS cells were again transfected with the expression vectors (SVL, SVL-1L 
and SVL-2A) but in the absence of 35 S-cysteine. Some COS cells were also treated 
with 10 jiM cadmium chloride for 24 hr to induce endogenous MT. The cells were 
harvested 4 days after transfection and the isolated proteins heat treated to remove 
heat unstable proteins. RIA assays performed by Dr C. Tohyama failed to detect 
increased MT levels in the transfected COS cells, although an approximately 20 fold 
increase was detected in the cadmium treated COS cells (Table 5.2). 
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Figure 5.16 Expression of MT protein in transfected COS cels 
COS cels were transfected with the eukaryotic expression vector SVL, the human 
MTIL gene (SVL-1L) and the human MT2A cDNA (SVL-2A). As a positive control 
COS cels were also treated with CdC12. Cels were incubated with "S-cysteine for 
16 hr. Protein was isolated from the cels and subjected to SDSPAGE. The protein 
gel was dried and exposed to Hyperfilm (Amersham). Proteins were from COS cels 
treated as folows: 
1:COS cels 
2:COS cels, 10 JAM CdC12, 16 hr 
3:COS cels, SVL transfected 
4:COS cels, SVL-1L transfected 
5:COS cels, SVL-2A transfected. 
The radiolabeled MT proteins are indicated (arow). The position of protein 
molecular weight markers (Pharmacia) electrophoresed on the  same gel are shown. 
The markers used were: phosphorylase b (94000), bovine serum albumin (67000), 
ovalbumin (43000), carbonic anhydrase (30000) soybean trypsin inhibitor (20100) and 
a-lactalbumin (14400). 
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Figure 5.17 Timecourse for expression of MT2A mRNA in transfected COS cels 
COS cels were transfected with the human MT2A cDNA cloned into the eukaryotic 
expression vector SVL. RNA was isolated from the cels and MT2A mRNA detected 
by northern analysis using a MT probe (MT2A PCR product). RNA was isolated 
from cels at the folowing timepoints after transfection: 2 days (lane 1), 4 days (lane 
2), 6 days (lane 3), 8 days (lane 4), 10 days (lane 5). RNA was also isolated from 
untransfected COS cels (lane 6). A [3-actin probe was used to demonstrate the 
relative levels of mRNA in each lane. 
• 
• 
MT (ng/ml) total protein 
(11g/m 1) 
MT (lig/pg total 
protein) 
COS cells 90.5 151 0.599 
COS cells, SVL 
transfected 
49.2 83.8 0.587 
COS cells, SVL-1L 
transfected 
51.5 124 0.415 
COS cells, SVL-2A 
transfected 
50.5 126 0.400 
COS cells, 10 I_LM 
CdC12,16 hrs 
2160 167 12.93 
Table 5.2 Detection of MT protein in transfected COS cells by 
radioimmunoassay 
COS cells were transfected with the eukaryotic expression vector SVL, the human 
MT1L gene (SVL-1L) and the human MT2A cDNA (SVL-2A). As a positive control 
COS cells were also treated with CdC12. Protein was isolated from the cells, and the 
concentration of MT protein determined by radioimmunoassay by Dr C.Tohyama. 
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Attempts were then made to look at the expression of MT1L protein in a cell 
line incapable of producing endogenous MT protein, thus avoiding the problem of 
trying to detect the protein produced by the vectors as an increased signal above the 
background endogenous MT protein. Embryonic fibroblasts were prepared from 
E12-14 foetal mice (section 2.7.4). The mice used were transgenic N4T-me- mice 
which fail to produce MT-I and -II proteins (Michalska and Choo, 1993). MT-I/II 4" 
fibroblasts were transfected with the expression vectors (SVL, SVL-1L and SVL-2A) 
by calcium phosphate-mediated transfection. The cells were harvested after 48 hr, 
RNA isolated and subjected to northern analysis with a general MT probe. The 
northern blot was hybridised with the MT2A RT-PCR probe in conditions described 
previously, under which the probe hybridises to all human MT-I and -II isogenes (see 
Figure 5.12). Although MTIL and MT2A mRNA was detected in COS cells 
transfected in parallel, significant levels of MT mRNA could not be detected in the 
transfected embryonic fibroblasts even after overexposure of the autoradiograph (see 
Figure 5.18). This may have been due to a combination of factors; firstly, transfection 
efficiencies are often reduced in primary cell lines and secondly, the SVL vectors are 
replicated in COS cells but not embryonic fibroblasts therefore reducing the amount 
of RNA produced by the vectors in the embryonic fibroblasts. 
5.2.4 Expression of MT1L under the control of the CMV promoter 
Attempts were made to observe protein produced by the MTIL gene using an 
alternate vector system, pBK-CMV (Stratagene). This vector contains the powerful 
cytomegalovirus (CMV) immediate early promoter and, unlike the SVL, vector does 
not rely on replication of the vector in host cells. The MTIL gene and MT2A cDNA 
were cloned into the pBK-CMV expression vector and transfected into embryonic 
mouse fibroblasts by calcium phosphate-mediated transfection. 
The pBK-CMV vector contains promoters for both eukaryotic and 
prokaryotic expression (as depicted in Figure 5.19). The lac Z promoter (244bp, 
necessary for prokaryotic expression only) was removed from the vector by digestion 
with the restriction endonucleases Nhel and Xbal. This digestion creates compatible 
ends allowing religation of the vector minus the lac Z promoter. The authenticity of 
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Figure 5.18 Expression of MT mFtNA in transfected cels 
COS cels and embryonic fibroblasts from MT-1/1-e- mice were transfected with the 
eukaryotic expression vector SVL, the human MTIL gene (SVL-1L) and the human 
MT2A cDNA (SVL-2A). As a positive control COS cels were also treated with 
CdC12. RNA was isolated from the cels and MT tnRNA was detected by northern 
analysis using a general MT probe (MT2A PCR product) and the resultant 
autoradiograph is shown. Overexposure of the autoradiograph is also shown (MT*). 
RNA was from cels treated as folows: 
1:COS cels 
2:COS cels, SVL transfected 
3:COS cels, SVL-1L transfected 
4:COS cels, SVL-2A transfected 
5:COS cels, 10 ptM CdC12, 16 hr 
6:MT-1/Hi" embryonic fibroblasts 
7:MT-U11-4 embryonic fibroblasts, SVL transfected 
8:MT-1/114 embryonic fibroblasts, SVL-1L transfected 
9:MT-I/Ie" embryonic fibroblasts, SVL-2A transfected 
A 0-actin probe was used to confirm that equal amounts of RNA were present in each 
lane. 
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Figure 5.19 pBK-CMV 	 0;1 
The pBK-CMV phagemid (from Stratagene) contains promoters for prokaryotic (LacZ) and eukaryotic (CMV) expression. It contains a multiple 
cloning site as shown below the phagemid map, and the neomycin/kanamycin resistance gene. The phagemid map is adapted from the 1994 
Stratagene catalogue. 
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this vector was checked by sequencing clones using the ABI PRISMTm Dye Primer 
Cycle Sequencing Ready Reaction Kit (section 2.5.2). 
The MT1L gene was removed from the pSVL-1L vector by digestion with the 
restriction endonucleases BamHI and Xbal. The 1.6 kb fragment containing the 
MT1L gene was bluntended with Pfu DNA polymerase and ligated into pBK-CMV at 
the Sma I restriction endonuclease site to create the vector pBK-CMV-1L (as 
outlined in Figure 5.20). The MT2A cDNA was removed from the vector pSP64-2A 
by digestion with the restriction endonucleases Xbal and Sad, bluntended with Pfu 
DNA polymerase and ligated into pBK-CMV to create the vector pBK-CMV-2A (as 
outlined in Figure 5.20). The authenticity of these constructs was confirmed by 
sequencing the regions where the gene or cDNA were ligated into the vector. The 
ABI PRISMTm Dye Terminator and Dye Primer Cycle Sequencing Ready Reaction 
Kits were used to sequence these clones. 
Embryonic fibroblasts from MT-I/Ie" mice prepared as outlined in section 
2.7.4, were transfected with the pBK-CMV-1L and -2A vectors by calcium 
phosphate-mediated transfections. The cells were harvested after 48 hr, RNA isolated 
and subjected to northern analysis with the MT2A RT-PCR clone which hybridises to 
all human MT-I and -II genes including MT1L and MT2A as a probe (as described 
earlier, see Figure 5.12). MT tnRNA was detected in both pBK-CMV-1L and pBK-
CMV-2A transfected cells, but not untransfected cells or cells transfected with vector 
alone (pBK-CMV). The pBK-CMV-1L vector produced mRNA of approximately 
350 bp as expected while the pBK-CMV-2A vector produced a mRNA of 
approximately 600 bp (Figure 5.21). The differences in sizes of the mRNA produced 
by the 2 vectors is because the MT2A cDNA uses the polyadenylation site provided by 
the vector adding about 250 bp to this mRNA, whereas the MT1L gene includes its 
own polyadenylation site. A faint MT transcript was detected in the untransfected 
cells and cells transfected with vector alone because the targetted mutation to the 
MT-I gene in these transgenic mice disrupts the translation but not transcription of 
this gene and therefore endogenous MT mRNA is observed (Michalska and Choo, 
1993). RNA was also isolated from HeLa cells treated with 10 1AM CdC12 for 16 hrs 
and examined on the northern blot described above. Significantly more MT mRNA 
was detected in the HeLa cells than the MT transfected embryonic fibroblasts. 
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Figure 5.20 Construction of pBK-CMV-1L and pBK-CMV-2A vectors 
The MT1L gene was removed from the SVL-IL vector and cloned into the pBK-
CMV eukaryotic expression vector by the strategy outlined above to create pBK-
CMV-IL. The MT2A cDNA was removed from the pSP64-2A vector and cloned 
into the pBK-CMV eukaryotic expression vector by the strategy outlined above to 
create pBK-CMV-2A. Constructs containing the gene or cDNA inserted in the 
required orientation were selected by digestion with a range of restriction 
endonucleases and confirmed by sequencing the constructs. 
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Figure 5.21 Expression of MT mRNA in transfected embryonic fibroblasts 
Embryonic fibroblasts prepared from MT-1/1I -/- mice were transfected with the 
eukaryotic expression vector pBK-CMV, the human MT1L gene (pBK-CMV-1L) and 
the human MT2A cDNA (pBK-CMV-2A). As a positive control HeLa cells were also 
treated with CdC12 . RNA was isolated from the cells and analysed for MT inRNA by 
northern analysis using a general MT probe (MT2A PCR product). RNA was from 
cells treated as follows: 
1: HeLa cells, 10 [LM CdC1 2 , 16 hr 
2: INAT-ulf- embryonic fibroblasts 
3: MT-I/114" embryonic fibroblasts, pBK-CMV-1L transfected 
4: MT-Ulf" embryonic fibroblasts, pBK-CMV-2A transfected 
5: MT-I/II -/- embryonic fibroblasts, pBK-CMV transfected 
Arrows indicate the MT2A transcript and MT1L transcript. A f3-actin probe was used 
to confirm that equal amounts of RNA were present in each lane. 
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However, since the pBK-CMV constructs were shown to be transfected into 
embryonic fibroblasts and MT mRNA could be detected in these cells, expression of 
MT1L protein was examined in this system. Embryonic MT-11114 fibroblasts were 
transfected with the MT containing vectors, pBK-CMV-1L and pBK-CMV-2A by 
calcium phosphate-mediated transfection. 48 hr after transfection cells were 
radiolabelled with 200 pCi 35S-cysteine for 16 hr. For comparison HeLa cells treated 
with 10 gM CdC1 2 were radiolabelled similarly. Protein was isolated from the cells, 
heat treated to remove heat unstable proteins, carboxymethylated and electrophoresed 
through a 15% polyacrylamide gel (as outlined in section 2.8). Autoradiography 
detected large amounts of the endogenous protein in cadmium treated HeLa cells, but 
failed to detect production of MT protein in the MTIL and MT2A transfected 
fibroblasts cells, i.e. a protein band could not be detected in the transfected cells that 
was absent in the untransfected cells (see Figure 5.22). 
5.3 Discussion 
Previously, a novel human MT gene, MT1L, from the functional locus on 
chromosome 16 was sequenced and found to contain an inframe TGA ("stop") codon 
midway through the coding region when compared to other MT genes. Earlier work 
had also indicated that this gene, when transfected into COS cells could confer 
resistance to cadmium, equivalent to the well characterised MT2A gene. Expression 
of the MTIL gene at the mRNA level was investigated in this study by RT-PCR and 
northern blotting. MT1L mRNA was detected in human pancreas, thyroid, pineal 
gland and hypothalamus by RT-PCR, using PCR primers specific for the human 
MTIL gene. The PCR product amplified from pancreatic tissue was confirmed to be 
MTIL cDNA by its size (230 bp), by comparison to products amplified from MTIL 
transfected COS cells, by its digestion with the restriction endonuclease Ncol, and its 
• hybridisation to an MT probe. Finally, sequence analysis of a partial clone of the RT-
PCR product confirmed it to be MT1L cDNA. The partial clone corresponded to the 
second exon and most of the third exon of the MTIL gene, and importantly included 
the unique inframe TGA codon in the second exon. Sequence analysis of this clone in 
both directions confirmed the presence of this TGA codon. Therefore, the MTIL 
gene was demonstrated to be expressed in some human tissues at the mRNA level. 
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Figure 5.22 Expression of MT protein in transfected embryonic fibroblasts 
Embryonic fibroblasts prepared from MT-I/I4" mice were transfected with the 
eukaryotic expression vector pBK-CMV, the human MTIL gene (pBK-CMV-1L) and 
the human MT2A cDNA (pBK-CMV-2A). As a positive control HeLa cels were also 
treated with CdC12. Cels were incubated with 35S-cysteine for 16 hr. Protein was 
isolated from the cels and subjected to SDSPAGE. The protein gel was dried and 
exposed to Hyperfilm (Amersham). Proteins were from cels treated as folows: 
1:HeLa cels 
2:MT-1/1I-/- embryonic fibroblasts, pBK-CMV-2A transfected 
3:MT-1/11-/- embryonic fibroblasts, pBK-CMV-1L transfected 
4:MT-I/Irl" embryonic fibroblasts, pBK-CMV transfected 
5:MT-Iflr embryonic fibroblasts 
The radiolabeled MT proteins are indicated (arow). The position of protein 
Molecular weight markers (Pharmacia) electrophoresed on the same gel are shown. 
The markers used were: phosphorylase b (94000), bovine serum albumin (67000), 
ovalbumin (43000), carbonic anhydrase (30000), soybean trypsin inhibitor (20100) 
and a-lactalbumin (14400). 
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Furthermore, the existence of the TGA codon was thus confirmed in samples obtained 
from a third unrelated individual. 
The human MT2A gene appears to be expressed at the RNA level in most 
tissues (Richards etal., 1984), while differential expression patterns have been 
demonstrated for various MT-I isogenes (Varshney etal., 1986; Jahroudi etal., 1990; 
Heguy etal., 1986). Similarly, the MTIL gene appears to be expressed in a tissue-
specific manner, at least at the mRNA level. Interestingly, MTIL was detected by 
RT-PCR in those endocrine tissues indicated above, but was not detected in tissues 
such as the liver and intestine from the same individual. These latter tissues generally 
have high levels of MT expression (see Kagi and Kojima, 1987), and it is interesting 
that MTIL mRNA was not detected in the liver by RT-PCR. 
MTIL mRNA was also detected by RT-PCR in cultured human lymphocytes 
after treatment with cadmium or zinc, but not in untreated human lymphocytes. This 
suggests that like other MT genes, MTIL may be inducible by the heavy metals 
cadmium and zinc. Furthermore, MTIL mRNA was detected in the human T-
lymphoid cell line, CEM, by RT-PCR, but not in the human myeloid leukemia cell 
line, K562. This further demonstrates the differential expression of the human MT 
gene, MTIL. 
MTIL mRNA was detected by northern analysis in 2 of 3 human thyroid 
samples using an oligonucleotide probe which was specific for the MTIL gene. 
Expression of other human MT genes (MTIG, MTIH, MT IX and MT2A) were also 
detected in the thyroid samples, and the thyroid sample in which MTIL mRNA was 
not detectable also contained lower levels of the other MT isoforms. Northern 
analysis is a considerably less sensitive technique than RT-PCR for detecting mRNA 
transcripts, and detection of MTIL by this technique is significant. It has been 
suggested that RT-PCR is sensitive enough to detect only a few copies of a mRNA 
transcript in a cell (Chelly et al., 1989) and therefore can detect expression of a gene 
at levels which are not physiologically relevant. However, detection ofMTIL in 
thyroid tissues by northern analysis suggests that this gene contributes significantly to 
the larger pool of MT expression in the thyroid gland. Although the expression levels 
of the different isogenes can not be directly compared by northern analysis, the fact 
that MT IL mRNA was detected by this method and inRNA from other MT genes 
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(MTIA,MT1B,MTIE and MTIF) which have been shown to be expressed in other 
tissues or cell lines were not, adds weight to the proposal that this gene is an 
important component of the repertoire of MT mRNA expression in the thyroid. 
The detection ofMTIL mRNA by RT-PCR and northern blotting does not 
necessarily infer that this gene expresses a protein, i.e. the mRNA observed may not 
necessarily be translated. It is possible that the mRNA produced by the MTIL gene, 
which contains a TGA ("stop") codon midway through the transcribed region, is 
unstable and rapidly degraded within the cell, although the fact that significant levels 
ofMTIL mRNA were detected by northern blotting suggests that this is not the case. 
Alternatively, the inRNA may be translated into a shortened 25 amino acid protein 
which may be unstable and rapidly degraded by the cell. Also, it is possible that the 
TGA codon is from a mutated copy of a functional gene, however the fact that this 
sequence was confirmed from three different sources, i.e. two gene sequences and a 
cDNA sequence from three unrelated individuals, makes this unlikely. 
Interestingly, a recent report documents the cloning of a novel human MT 
cDNA, MDR by RT-PCR from human reticulocytes (Lambert et al., 1996). This 
novel cDNA is almost identical to that determined for MTIL, the most striking 
differences in the coding region being that the TGA codon at position 26 ofMT1L is a 
TGT (cysteine) codon in MTIR (see Figure 5.23). Also, the serine residue at position 
6 is encoded by a TCC codon in MT1L but a TCG codon in MTIR. There are several 
differences between the MTIR cDNA 3' untranslated region and the corresponding 
region of the MTIL gene (see Figure 5.23), however the number of differences is 
significantly less than is usually seen between two different human MT isogenes (e.g. 
between MTIL and MTIE, see Figure 5.23). In all there are 15 mismatches between 
MTIL and MTIR, but 40 mismatches between MTIL and the most closely related of 
the other MT-I genes on chromosome 16, MTIE. Considering the similarities 
between MTIL and MTIR, particularly in the coding regions, the possibility exists 
that MTIL cDNA and MTIR cDNA in fact arise from the same gene, and the 
differences are due to sequencing errors, errors incorporated during RT-PCR, or 
allelic differences. To reconcile this situation, the MTIL gene was resequenced and 
the presence of the inframe TGA codon in the second exon of the MTIL gene was 
reconfirmed. The paper describing MTIR cDNA states that it was amplified on two 
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CysLysGluCysLys * ThrSerCysLysLysSerCysCysSerCysCysProMetGly 
TGCAAAGAGTGCAAATGAACCTCCTGCAAGAAGAGCTGCTGCTCCTGCTGCCCCATGGGC 
121 CysAlaLysCysAlaGlnGlyCysValCysLysGlyAlaSerGluLysCysSerCysCys TGTGCCAAGTGTGCCCAGGGCTGCGTCTGCAAAGGGGCGTCGGAGAAGTGCAGCTGCTGT 
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GCCTGATGTGGGGACAGCCCTGCTCCCAGATGTAAACAGAGCAACCTGCACAAACCTGGA 
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Figure 5.23 Comparison of MT1L,MTIR and MT1E nucleotide sequences 
The nucleotide sequence of the MTIL cDNA is shown with the predicted amino acid 
sequence above (three leter code). This sequence is compared with the nucleotide 
sequences of the MT1R cDNA depicted immediately below in bold (Lambert etal., 
1996) and the MT1E cDNA (Schmidt et al., 1985). Mismatches are indicated; an 
alternative nucleotide by its leter code and a deletion as -. Dots indicate where the 
sequences are identical. There are 15 mismatches between the MTIL and MTIR 
nucleotide sequences and 40 mismatches between the MT1L and MTIE nucleotide 
sequences. 
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separate occasions, but it is unclear whether this was from two individuals. Obviously 
the possibility exists that MTH? and MTIL are 2 separate genes, but such a gene has 
not been found in the functional locus mapped to chromosome 16q13. It is possible 
however, that the MTH? gene is a distinct gene situated in another position in the 
genome, although there is some evidence against this, since Karin et al. (1984a) 
showed that all human MT genes capable of conferring cadmium resistance are on 
chromosome 16, and most likely in the one locus. 
Several lines of evidence have demonstrated that the MTIL gene produces 
mRNA, the question remains as to whether this is translated into a functional MT 
protein. The MT1L gene was cloned into eukaryotic expression vectors and 
transfected into mammalian cells in an attempt to express MT1L protein. The MT1L 
gene was demonstrated to produce a full length mRNA when transfected into the 
COS cell line under the control of the SV40 promoter. The mRNA produced by this 
gene was of the same size as that produced by MT2A. Although northern analysis of 
transfected cells with a general MT-Jill probe showed lower levels of expression of 
MTIL mRNA than MT2A mRNA, this is at least partly due to the hybridisation 
strength of the probe, which was shown to hybridise considerably more strongly to 
the MT2A gene than the MTIL gene. 
Previous preliminary data suggested that the MTIL gene encodes a functional 
MT protein as the transfected gene, like MT2A, under the control of the SV40 
promoter was capable of protecting transfected COS cells from cadmium toxicity 
(A.F.Holloway, B.Sc. Honours Thesis). An attempt was made to determine the size 
of the encoded MT1L protein by expressing it in COS cells under the control of the 
SV40 promoter and incubating the cells with 35 S-cysteine, thereby radiolabelling 
expressed MT proteins. However, neither MT1L nor MT2A protein (investigated in 
parallel) was detectable under these conditions, although endogenous MT was 
observed as well as significant increases in endogenous MT levels after cadmium 
treatment. Since MT is expressed in many cells at relatively high levels, and 
endogenous monkey MT mRNA and protein were easily detected in the COS cells, it 
is likely that the endogenous monkey MT protein masked any human MT IL and 
MT2A protein expressed in these cells after transfection. This suggests that 
significant amounts of protein were not produced by the transfected constructs and 
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this was in fact confirmed by the failure to detect increased MT levels by the sensitive 
radioimmunoassay. Notably, this assay detected an approximately 20 fold increase in 
the endogenous MT protein after treatment with cadmium. 
To overcome this problem attempts were made to examine the MT1L protein 
in a cell line which does not produce endogenous MT protein. Embryonic fibroblasts 
from MT-I/Ie" transgenic mice which are incapable of expressing MT-I and -II 
protein (Michalska and Choo, 1993) were transfected with the MTIL gene and MT2A 
cDNA under the control of the SV40 promoter. However, significant levels ofMT2A 
or MT1L mRNA were not detected by northern analysis following transfection. This 
vector may have been unsatisfactory in the mouse fibroblast system because of a 
combination of factors. Much of the effectiveness of the SVL vector relies on the fact 
that it is able to replicate in COS cells (Kaufman, 1990), however such replication 
does not occur in embryonic fibroblasts reducing the expression levels in this cell type. 
Furthermore, primary cell lines, such as the mouse embryonic fibroblasts prepared in 
this instance, usually are transfected with much lower efficiencies than established cell 
lines such as COS cells and therefore only a very small percentage of cells may have 
been transfected with the MT genes (e.g. Hawley-Nelson et al., 1993). 
Finally, the expression ofMT1L and MT2A was examined in the MT-UIe" 
embryonic fibroblasts using the expression vector pBK-CMV. The CMV promoter 
produces transcription at levels much higher than the SV40 promoter of the SVL 
vector, and the pBK-CMV vector does not rely on replication of the vector for high 
expression levels (Kaufman, 1990). Again, MT1L or MT2A protein was not detected 
in transfected cells, although the cadmium induced endogenous MT in HeLa cells was 
easily detected. It is likely that the failure to see protein in this case was due to the 
inherent problem of low transfection efficiencies in such primary cell cultures. 
Thus a model system has not yet been found in which any protein produced by 
the human MTIL gene could be observed. Transfection of the gene into a eukaryotic 
cell line appears the best approach to examine this question, although alternative 
approaches exist. One alternative would be to purify the protein from human tissues 
or cell lines, but this method has inherent problems in that although upregulation of 
the gene may be achieved in an expressing cell line like CEM using cadmium or zinc, 
any MT isolated from these cells would no doubt contain many of the MT isoforms 
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with MT2A being the predominant MT protein. A second alternative would be to 
produce the protein by in vitro translation, although this method is somewhat artificial 
and expression of a protein in this way may not necessarily imply that the protein is 
likely to be produced in vivo. However, it should be noted that mammalian 
selenoproteins have been investigated by in vitro translation (Berry etal., 1991a). 
Thirdly, the protein could be expressed in a bacterial system, however this approach 
would not cover the possibility that the MTIL gene encodes a selenoprotein, as 
prokaryotic and eukaryotic cells possess different systems for the incorporation of 
selenocysteine residues (Rocher etal., 1991), and a mammalian selenoprotein can 
therefore not be expressed in a bacterial system. 
Although the transfection of the MT IL gene into a cell line appears the best 
method for detection of MT1L protein, there are complications involved with the 
detection of an MT protein by this approach. Most problematic is the masking of the 
expressed protein by the cell's endogenous protein. This arises primarily because 
most cells express MT proteins at relatively high levels, but also because endogenous 
MTs are induced by physiological stresses and insults and possibly also by calcium 
phosphate-mediated transfections (Foster et al., 1989). An alternative is to use cell 
lines which do not express endogenous MT protein such as MT-I/II 4- embryonic 
mouse fibroblasts, however such primary cell lines have, as stated above, the 
complication of notoriously low transfection efficiencies. A worthwhile further study 
may be to use the CHO (chinese hamster ovary) cell line for transfecting the pBK-
CMV-MT constructs. This cell line has the advantage that it does not generally 
express MT protein, and furthermore since it is an established cell line, transfection 
efficiencies are usually relatively high. 
It remains to be determined whether the MT IL gene encodes a functional MT 
protein, but it should be noted that difficulties encountered in expressing the MT IL 
protein in this study were not due to the gene itself since MT2A was also never 
successfully detected. 
The fact that MT IL mRNA is expressed in a highly tissue specific manner 
suggests that this gene is likely to produce a functional protein and the detection of 
MTIL mRNA in the thyroid and other endocrine tissues may be relevant to the 
possible production of a selenoprotein. The thyroid is the site of expression of several 
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mammalian selenoproteins, including type 1 iodothyronine de-iodinase. Furthermore, 
studies suggest that selenoproteins may have particular importance in the brain and in 
endocrine and reproductive organs (Behne etal., 1988). Thus, the possibility that a 
MT selenoprotein is expressed in this tissue is quite conceivable. 
There are now a number of well investigated mammalian selenoproteins and 
more examples are regularly being discovered. The manner in which a TGA codon is 
translated into a selenocysteine residue is becoming clearer, although the mechanisms 
involved are still not completely known (Stadtman, 1996). Many studies have 
investigated the factors involved in the recognition of a TGA codon as a 
selenocysteine rather than a termination signal. Unique sequence motifs termed 
selenocysteine-insertion sequences (SECIS) have now been identified in the 3' 
untranslated region (3'UTR) of the mRNA of selenoproteins and have been shown to 
be essential in the translation of selenoproteins (Berry etal., 1991b; Shen etal., 
1993). Conserved 3-4 nucleotide sequences have been identified in the SECIS 
elements of several selenoproteins and have been shown to be necessary for the 
insertion of a selenocysteine residue (e.g. the sequences `UAAA' and `UGAU', as 
indicated in Figure 5.24). Furthermore, although the primary nucleotide structure of 
the 3'UTRs are not conserved, the SECIS elements are predicted to form stem-loop 
secondary structures (see Figure 5.24) which appear highly conserved (Berry et al., 
1993). There are differences in the efficiencies with which the predicted stem-loops 
of different mRNAs allow the insertion of a selenocysteine residue and this appears to 
mirror the order of appearance of these proteins after selenium-repletion of selenium-
deficient animals (Berry et al., 1993). The MT1L 3'UTR was investigated for the 
presence of stem-loop structures which may be necessary for the translation of a 
MT1L selenoprotein. Predicted secondary structure of the MT1L 3'UTR was 
generated using the University of Wisconsin Genetics Computer Group Fold program 
and is shown in Figure 5.24. The predicted secondary structure of the 3'UTR of the 
MT1L tnRNA does not contain a stem-loop structure with a high degree of homology 
to those identified in the 3'UTRs of known selenoproteins. However, the major loop 
contains a "UAAA" sequence which has been found to be an element essential for 
selenocysteine insertion (Low and Berry, 1996). 
Human MT1L 
-18.6 kcal 
Rat GPX 
-82.1 kcal 
Human 5'DI 
-68.6 kcal 
Rat 5'DI 
-44.3 kcal 
Figure 5.24 Predicted secondary structure in the 3'UTR of selected 
selenocysteine-encoding mRNAs and the MT1L mRNA. 
The predicted secondary structure of the MTIL rriRNA 3'UTR is shown. The 
selenocysteine encoding triRNAs are rat type I iodothyronine 5' deiodinase (5'DI), 
human 5'DI and rat glutathione peroxidase (GPX), taken from Berry etal., 199 lb. 
The MTIL mRNA was analysed using the FOLD program of the University of 
Wisconsin Genetics Computer Group software. The conserved sequences "UAAA" 
and "UGAU" are indicated with arrows. 
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Studies also suggest that the nucleotide following the TGA codon has an 
affect on whether termination or selenocysteine incorporation occurs. Although 
selenoproteins have been identified with all possible bases in this fourth position (Low 
and Berry, 1996), studies suggest that in eukaryotes termination rather than 
selenocysteine insertion is favoured when the base following the TGA codon is a 
purine (McCaughan etal., 1995), as is the case with the internal TGA codon in MTIL 
(see Figure 5.2, nucleotide 994). Finally, most of the eukaryotic selenoprotein 
mRNAs have a TGA codon specifying a selenocysteine residue but have a codon 
other than TGA specifying termination of translation (Low and Berry, 1996). A 
MT1L selenoprotein would therefore be relatively unusual since both the 
selenocysteine residue and termination would be specified by a TGA codon (see 
Figure 5.2). Analysis of the 3'UTR and context of the internal TGA codon of the 
MTIL triRNA therefore suggests there is a low probability that this gene encodes a 
selenoprotein. However, such analysis only suggests the likelihood that a 
selenocysteine residue is specified and can not be taken as proof of whether a 
selenoprotein is or is not encoded. 
Almost all of the known selenoproteins are involved in redox reactions, and 
the best studied of the mammalian selenoproteins, glutathione peroxidase, is involved 
in the scavenging of hydroxyl radicals. The selenol moiety has been shown to be the 
active centre of this enzyme (Forstrom etal., 1978), and it is suggested that under 
normal physiological conditions a selenol moiety is more reactive than the 
corresponding thiol moiety (Stadtman, 1996). It is intriguing that MTs have also been 
implicated in the scavenging of free radicals, and it is conceivable that a MT-
selenoprotein may be a more efficient free radical scavenger. Oikawa et al. (1991) 
synthesized a selenium analogue of metallothionein in which all 7 of the cysteine 
residues of Neurospora crassa metallothionein were replaced with selenocysteine 
residues. This protein had reduced metal binding properties, binding 3 rather than the 
usual 6 copper ions probably as a result of constraints on the protein structure due to 
the ionic radius of selenium compared with sulfur. However, it is difficult to draw 
inferences with respect to the metal binding properties of a mammalian 
metallothionein with a single selenocysteine substitution. 
( 
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This study has further characterised the human MT1L gene at the mRNA level 
and demonstrated its differential expression which is possibly restricted to endocrine 
tissues and lymphocytes. In addition previous studies suggest that MT IL has the 
capacity to protect against cadmium toxicity. Therefore, the MT1L gene is now as 
well characterised as many of the human MT genes located on chromosome 16. It is 
likely that a MT IL protein, either a selenoprotein or a truncated MT protein would 
have novel properties. Such properties may be required or advantageous in endocrine 
tissues. Further investigation of such a protein may provide insight into its 
physiological role and the function of MTs as a whole. 
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CHAPTER 6: CONCLUDING REMARKS 
Metallothioneins (MTs) are highly conserved cysteine rich proteins found 
throughout the animal kingdom. The regulation, protein structure and metal binding 
properties of MTs are well understood. However, the primary physiological role of 
these proteins remains to be determined. Suggested roles include heavy metal 
detoxification, metal transport and homeostasis and free radical scavenging. The 
primary aim of this study was to investigate the expression profiles and structures of 
MTs in two mammalian species, and to integrate this information with current ideas 
on MT action. MTs were examined in the sheep and in the human, both of which have 
complex multigene families encoding multiple MT isoforms. Firstly, the expression of 
MT-I and -II isoforms was investigated in the developing sheep brain. The aim was 
to examine MT expression at the regional and cellular level in the developing brain in 
order to gain insight into the factors which regulate MT expression during neural 
development. Secondly the cDNA encoding the brain-specific MT isoform, MT-III, 
was cloned from the sheep and its expression examined with respect to MT-I and -II 
isoforms. Thirdly, a novel human MT gene, MTIL, was characterised. The aim was 
to investigate the contribution of this isogene to MT expression in the human. The 
theme of this study was to correlate MT expression with its physiological role, and 
particular attention was paid to the function of MT in the brain. The role of MT in 
the brain is topical due to the recent finding of a novel brain-specific isoform, MT-III, 
with growth inhibitory properties. This finding also has drawn renewed attention to 
another enigmatic feature of MTs; the apparent requirement for the expression of 
multiple isoforms in higher eukaryotes. 
The expression of MT-I and -II mRNA and protein in the developing sheep 
brain was investigated by immunocytochemistry and northern blotting, as detailed in 
Chapter 3. Changes in both the regional and cell type expression of MT was observed 
during the development of the sheep brain. The appearance of MT mRNA and 
protein in the foetal sheep brain was found to coincide with the migration of glial cells 
into the cortex and the maturation of this cell type. Furthermore, expression of MT 
protein was found to be confined to glial cells as it was detected in oligodendrocytes, 
astrocytes and radial glial cells but not in neurons. Interestingly, the expression of 
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MT protein in oligodendrocytes was confined to the foetal brain. Further 
investigation of MT protein at the cellular level determined that under normal 
physiological conditions MT protein was present in only a subset of glial cells at any 
one time. The pattern of MT expression suggested that at least under basal conditions 
MT regulation may be more dependent on cell-specific or localised factors than on 
cell location, subclass of glial cell or blood-borne factors. MT expression in the 
normal brain may then be dependent on the physiological state of individual cells, and 
factors such as the proliferative state, internal zinc concentration or redox state of the 
cell may be important. Although MT was found to be expressed in some dividing 
cells, and was localised to proliferative regions in the developing brain, MT was found 
not to be intrinsic to cell division. Further studies may, however, be able to correlate 
MT expression with the internal environment of the cell and factors such as changes in 
zinc status or redox state. MT protein was often expressed in glial cells forming the 
glial limiting membrane and in cells surrounding blood vessels raising the possibility it 
has a protective role in the brain. However, MT was also found in many other 
regions of the sheep brain, and its expression in the glial limiting membrane or around 
blood vessels was not always complete, suggesting that MT has other roles in the 
brain. This study documents in detail the expression patterns of MT during the 
development of the sheep brain. The sheep brain may now be used as a convenient 
model system to examine changes in MT expression during physiological stresses or 
insults. Investigation of MT under such conditions may provide a wider 
understanding of MT physiology in the brain. 
Discovery of the brain specific MT-III isoform has generated much interest 
since it is structurally unique and has been found to display novel growth inhibitory 
properties in vitro. Expression of the MT-III isoform is restricted almost entirely to 
neural tissue and is suggested to be deficient in the Alzheimer's disease brain. 
Chapter 4 documents the cloning of a MT-III cDNA from the sheep brain. The 
putative MT-III isoform predicted by this cDNA is unique in that it contains a 
structural deletion of 3 amino acids which have been shown to be conserved in all MT 
isoforms from mammals so far examined. Furthermore, the sheep MT-III protein is 
missing 3 cysteine residues which are normally conserved in MT proteins. The 
putative sheep MT-III protein is therefore likely to have altered metal binding 
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properties. However, the sheep MT-III protein retains the CPCP amino acid 
sequence unique to MT-III isoforms to which the growth inhibitory function of these 
proteins has been assigned. This novel sheep MT-III isoform may then provide a 
valuable tool for determining the relevance of its growth inhibitory and metal binding 
properties in vivo and ultimately in determining the physiological role of MT-III in the 
brain. Interestingly, the work in Chapter 4 demonstrated that the expression of sheep 
MT-III mRNA mirrors that of MT-I and -II in the developing brain, i.e. MT-HI 
mRNA is first detected at the same time as significant levels of MT-I and -H mRNA 
are observed. Furthermore, the differential expression pattern of MT-III mRNA in 
different regions of the adult brain closely mimics that of MT-I and -II mRNA. This 
is particularly interesting since it has been suggested that the MT-III isoform has a 
distinctly different role in the brain to MT-I and -II isoforms. The cell type expression 
of the MT-III isoform is particularly controversial as it has been shown to be co-
expressed in glial cells with MT-I and -II in the human, but expressed in neurons in 
the mouse. The cellular localisation of MT-III may then be species specific and 
investigation of MT-III expression in a further species may shed light on this matter. 
The cellular localisation of MT-III in the sheep brain may be determined by a detailed 
in situ hybridisation study and suitable oligonucleotides for such a study have been 
identified here. Determination of the localisation of MT-III protein will require 
production of a MT-III specific antibody and the novel sheep MT-III protein may be 
ideally suited to the production of such an antibody. Future work will focus on 
confirming the structure of the MT-III protein and investigating its metal binding and 
growth inhibitory properties. 
The requirement for multiple functional MT genes in higher eukaryotes is still 
unknown. One possibility is that their function is to provide the immediate production 
of large amounts of protein in times of stress or insult. Alternatively, the various 
isoforms may function in different tissues or cell types or in response to different 
stimuli. However, the discovery of a MT-III isoform with novel properties adds 
weight to the theory that the various MT isoforms may provide functional diversity. 
Investigation of the individual MT genes, their regulation, expression patterns and any 
unique features or properties is important in order to understand the function of MTs 
as a whole. Chapter 5 examines a novel human MT gene, MT1L located in the 
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functional MT locus on chromosome 16. This gene is particularly interesting due to 
the presence of an inframe TGA ("stop") codon in the middle of the second exon. 
Despite this, the MTIL gene was shown to produce a full length mRNA and 
furthermore previous work by the author suggested that the MT1L gene encoded a 
protein capable of protecting cells from cadmium toxicity. Expression ofMTIL 
mRNA was examined by RT-PCR and found to be tissue specific. The data presented 
in Chapter 5 suggests that the expression of this gene may be confined to endocrine 
tissues and blood cells as MTIL mRNA was detected in pineal gland, pancreas, 
thyroid, hypothalamus and lymphocytes, but not in the human liver. A novel human 
MT cDNA, MT1R, recently cloned by Lambert et al. (1996) has high sequence 
homology with MTIL, however, the TGA codon in MTIL is a TGT (cysteine) codon 
in MT1R. The sequence ofMTIL presented here has been confirmed in clones from 
three individuals. The similarities ofMT1L cDNA to MT1R cDNA are intriguing and 
further investigation is necessary to determine whether they arise from the same gene, 
the differences being due to polymorphisms, or they arise from completely different 
genes. However, a gene encoding the MTIR cDNA has not been identified in the 
functional locus on chromosome 16q13. The possibility exists that the MTIL gene 
encodes a shortened but functional MT protein truncated at the TGA codon in the 
second exon. Such a protein would be almost equivalent to a normal 0-domain of 
MT proteins. Alternatively, the MTIL gene may encode a selenoprotein with a single 
selenocysteine residue encoded by the TGA codon in the second exon. Either of 
these possibilities would result in a MT protein with novel properties and possibly a 
novel function which is particularly relevant in endocrine tissues and this requires 
further examination. Importantly though, the data presented in Chapter 5 indicates 
that the MTIL gene contributes to the repertoire of human MT mRNA expression, 
particularly in endocrine tissues and is now as well characterised as many of the 
human MT genes. 
The data presented in this thesis then has provided a detailed study of the 
expression of MT in the developing and adult sheep brain, correlating MT expression 
with glial cell type but more importantly providing insight into the regulation of MT 
expression at the cellular level. The gene encoding a MT-III isoform with novel 
structural properties was cloned from the sheep brain. This novel MT isoform may 
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provide a useful tool in examining the physiological role of MT-III isoforms and their 
relationship to other MT proteins. Finally, a novel human MT gene, MT1L, with 
unique features was characterised at the mRNA level and found to be expressed in 
endocrine tissues. The expression of any protein encoded by this gene is likely to 
have novel properties and warrants further investigation. 
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ADDENDUM 
Page Vi, line 2 	 Replace "Chatacterisation" with "Characterisation" 
Page x, line 4 	 Replace "MT-II and -II nul mice" with "MT-I and -II nul mice" - 
Page 2, line 19 	 Replace "subtisilin" with "subtilisin" 
Page 3, line 4 	 Replace "were" with "where" 
Page 3, line 5 	 To the phrase "..MT-III and MT-IV were discovered only recently" Add 
",although MT-IV expression has not been confirmed at the protein level." 
Page 11, line 3 	 Replace "Bremner et at, 1984" with "Mehra and Bremner, 1984" 
Page 13, line 13 	 Replace "MT-I/I1-/- "with "MT-I/II4." 
Page 15, line 26 	 Replace "ilicit" with "elicit" 
Page 15, line 28 	 Replace ".related to the role of these proteins.." with "..related to the role of 
MT proteins.." 
Page 17, line 20 	 Replace "..Elisa assay, and a silver saturation method." with "..Elisa assay, a 
silver saturation method and a Cadmium haem assay" 
Page 20, line 8 	 Replace "where" with "were" 
Page 44, line 3 	 To the phrase "Embryonic mouse fibroblasts were prepared.." add ", from 
transgenic mouse (Michalska and Choo, 1993).." 
Page 46, line 6 	 Replace "167 ml" with "167 p.1" 
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Page 55, line 27 
Figure 3.10, line 9 
Add" 2.10.5 Collection of tissues 
Fetal sheep tissues were collected by Dr K. Dziegielewska from ewes of 
known gestation according to NH&MRC guidelines. Details of the procedure 
are outlined in Reynolds and Mollgard, 1985. Immediately after dissection 
tissues were either frozen in liquid nitrogen and stored at -80°C for RNA 
isolation, or fixed in Bouin's or paraformaldehyde fixative. 
Replace "(E120-E133)" with "(E120-E133, where E denotes the gestational 
age in days)" 
Replace "...(eg arrow in C) but there is no cross reactivity with 
,.FITC (eg arrow in D)." with "...(eg arrow in D) but there is no cross 
reactivity with FITC (eg arrow in C)." 
Page 82, line 31 
Page 88, line 10 
Remove "the probe was specific for the MT-III isoform" 
Replace "expression is restricted to the brain" with "expression is probably 
restricted to the brain" 
Page 101, line 3 
Add References 
To the phrase "MT1L mRNA was detected in 2 of the 3 human thyroid 
samples examined (Figure 5.13)." Add "..., which is more evident on the 
original autoradiograph." 
Holloway, A.F. (1992) Human metallothionein genes, MT1J and MT1L. B.Sc. 
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Reynolds, M.L. and Mollgard, K. (1985) The distribution of plasma proteins 
in the neocortex and early allocortex of the developing sheep brain. Anat. 
Embryo!. 171, 41-60. 
